Skin neglected tropical diseases in Cameroon : the need for integrated control and elimination by Tabah, Earnest Njih
  
 
Earnest Njih Tabah  Skin NTDs in Cameroon: the need for integrated control and elimination 
  
Skin Neglected Tropical Diseases in Cameroon: the need 
for integrated control and elimination. 
edoc.unibas.ch 
 
 
 
Inauguraldissertation 
Zur 
Erlangung der Würde eines Doktors der Philosophie 
Vorgelegt der 
Philosophisch-Naturwissenschaftlichen Fakultät 
der Universität Basel 
 
von 
 
 
Earnest Njih Tabah 
 
von 
 
Kamerun 
 
Basel, 2019 
 
Originaldokument gespeichert auf dem Dokumentenserver der Universität Basel 
edoc.unibas.ch 
i 
 
Earnest Njih Tabah  Skin NTDs in Cameroon: the need for integrated control and elimination 
  
 
Genehmigt von der Philosophisch-Naturwissenschaftlichen Fakultät der Universität Basel  
auf Antrag von Prof. Dr. Gerd Pluschke und PD. Dr. Markus Hilty. 
 
 
 
 
 
Basel, den 22 Mei 2018 
 
 
 
 
 
 
 
 
 
Prof. Dr. Martin Spiess 
Dekan der Philosophisch-
Naturwissenschaftlichen Fakultät 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ii 
 
Earnest Njih Tabah  Skin NTDs in Cameroon: the need for integrated control and elimination 
  
Thesis Supervisors 
 
Prof. Gerd Pluschke, PhD 
Professor of Molecular Immunology, 
Swiss Tropical and Public Health Institute, 
Faculty of Science, The University of Basel, Switzerland. 
 
 
 
Prof. Alfred Kongnyu Njamnshi, MD, MA, DMS, FMH 
Professor of Neurology and Clinical Neurophysiology,  
Faculty of Medicine and Biomedical Sciences, The 
University of Yaounde I, Cameroon. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
iii 
 
Earnest Njih Tabah  Skin NTDs in Cameroon: the need for integrated control and elimination 
  
Dedication  
 
 
 
 
 
 
Dedicated to: 
My mother, Mama Anna Nkini Tabah; 
My wife, Mrs Njih Irine Ngani Nformi; 
My kids: Njih Beri Nkini, Njih Asonyu Senge 
and Njih Earnest Njih Junior. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
iv 
 
Earnest Njih Tabah  Skin NTDs in Cameroon: the need for integrated control and elimination 
  
Table of Contents 
Thesis Supervisors............................................................................................................................. ii 
Dedication ........................................................................................................................................ iii 
Table of Contents ............................................................................................................................. iv 
Acknowledgements ......................................................................................................................... viii 
Summary. .......................................................................................................................................... x 
Zusammenfassung. ........................................................................................................................... xii 
Résumé. .......................................................................................................................................... xiv 
Chapter 1 : Introduction .................................................................................................................... 1 
1.1 Rationale ............................................................................................................................ 1 
1.2 Leprosy .............................................................................................................................. 3 
1.2.1 Definition ................................................................................................................... 3 
1.2.2 History of leprosy ....................................................................................................... 3 
1.2.3 Epidemiology ............................................................................................................. 5 
1.2.4 Causative agent and reservoir ..................................................................................... 6 
1.2.5 Transmission .............................................................................................................. 8 
1.2.6 Pathogenesis ............................................................................................................... 9 
1.2.7 Classification of clinical forms of leprosy ................................................................. 10 
1.2.8 Clinical Manifestations of leprosy............................................................................. 12 
1.2.9 Clinical manifestation of leprosy reactions. ............................................................... 17 
1.2.10 Diagnosis of leprosy ................................................................................................. 18 
1.2.11 Treatment ................................................................................................................. 20 
1.2.12 Leprosy elimination .................................................................................................. 23 
1.3 Buruli ulcer ...................................................................................................................... 24 
1.3.1 History and Epidemiology ........................................................................................ 24 
1.3.2 Causative agent ........................................................................................................ 26 
1.3.3 Reservoir, vector and transmission ............................................................................ 27 
1.3.4 Pathogenesis ............................................................................................................. 29 
1.3.5 Diagnosis ................................................................................................................. 31 
1.3.6 Treatment of Buruli ulcer ......................................................................................... 34 
1.3.7 Control ..................................................................................................................... 35 
1.4 Yaws ................................................................................................................................ 36 
1.5 Goal ................................................................................................................................. 40 
1.6 Objectives ........................................................................................................................ 40 
1.7 References ....................................................................................................................... 41 
v 
 
Earnest Njih Tabah  Skin NTDs in Cameroon: the need for integrated control and elimination 
  
Chapter 2 : The burden of leprosy in Cameroon ............................................................................... 49 
2.1 Abstract ........................................................................................................................... 50 
2.2 Author summary .............................................................................................................. 51 
2.3 Introduction ..................................................................................................................... 51 
2.4 Materials and Methods ..................................................................................................... 53 
2.5 Results ............................................................................................................................. 56 
2.6 Discussion........................................................................................................................ 63 
2.7 Conclusions: .................................................................................................................... 68 
2.8 Acknowledgments ............................................................................................................ 68 
2.9 References ....................................................................................................................... 69 
2.10 Supporting information .................................................................................................... 71 
Chapter 3 : Community knowledge, perceptions and attitudes regarding leprosy in rural Cameroon . 72 
3.1 Abstract ........................................................................................................................... 73 
3.2 Author summary .............................................................................................................. 74 
3.3 Introduction ..................................................................................................................... 75 
3.4 Methods ........................................................................................................................... 76 
3.5 Results ............................................................................................................................. 82 
3.6 Discussion........................................................................................................................ 93 
3.7 Supporting information .................................................................................................... 97 
3.8 References ....................................................................................................................... 97 
Chapter 4 : Buruli ulcer in Cameroon ............................................................................................ 100 
4.1 Abstract ......................................................................................................................... 101 
4.2 Author Summary ............................................................................................................ 102 
4.3 Introduction ................................................................................................................... 102 
4.4 Methods ......................................................................................................................... 105 
4.5 Results and discussions .................................................................................................. 106 
4.6 Challenges in BU control ............................................................................................... 116 
4.7 The way forward ............................................................................................................ 117 
4.8 Conclusion ..................................................................................................................... 117 
4.9 Acknowledgments .......................................................................................................... 118 
4.10 Supporting information .................................................................................................. 118 
4.11 References ..................................................................................................................... 119 
Chapter 5 : A case of cutaneous TB in a BU endemic area ............................................................. 122 
5.1 Presentation of Case ....................................................................................................... 123 
5.2 Case Discussion ............................................................................................................. 124 
5.3 Learning points .............................................................................................................. 127 
vi 
 
Earnest Njih Tabah  Skin NTDs in Cameroon: the need for integrated control and elimination 
  
5.4 Acknowledgement ......................................................................................................... 127 
5.5 References ..................................................................................................................... 127 
Chapter 6 : Yaws in the Lomie Health District, East Region of Cameroon ..................................... 129 
6.1 Introduction ................................................................................................................... 130 
6.2 Objectives and Methods ................................................................................................. 130 
6.3 Results ........................................................................................................................... 131 
6.4 Follow-up ...................................................................................................................... 131 
6.5 Challenges ..................................................................................................................... 131 
6.6 In perspective ................................................................................................................. 132 
6.7 Reference ....................................................................................................................... 132 
Chapter 7 : Yaws ........................................................................................................................... 133 
7.1 Abstract ......................................................................................................................... 134 
7.2 Introduction: .................................................................................................................. 134 
7.3 Clinical features of yaws ................................................................................................ 135 
7.4 Diagnosis of yaws .......................................................................................................... 144 
7.5 Differential diagnoses of yaws........................................................................................ 146 
7.6 Treatment of yaws .......................................................................................................... 146 
7.7 Importance of yaws ........................................................................................................ 147 
7.8 Epidemiology of yaws .................................................................................................... 148 
7.9 Public health importance of yaws ................................................................................... 151 
7.10 Should yaws be controlled, eliminated or eradicated? ..................................................... 152 
7.11 References ..................................................................................................................... 155 
Chapter 8 : Stigma in neurological diseases in the tropics .............................................................. 158 
8.1 Abstract: ........................................................................................................................ 159 
8.2 Introduction ................................................................................................................... 160 
8.3 Neurological diseases associated with stigma in the Tropics ........................................... 168 
8.4 Measurement of stigma .................................................................................................. 173 
8.5 Determinants of stigma .................................................................................................. 176 
8.6 Consequences and challenges of stigma reduction .......................................................... 177 
8.7 Conclusions and perspectives ......................................................................................... 181 
8.8 References ..................................................................................................................... 181 
Chapter 9 : General Discussion and Conclusion ............................................................................. 188 
9.1 General remarks ............................................................................................................. 188 
9.2 Epidemiology ................................................................................................................. 190 
9.2.1 The burden of skin-NTDs in Cameroon .................................................................. 190 
9.2.2 Geo-ecological zones of Cameroon ......................................................................... 196 
vii 
 
Earnest Njih Tabah  Skin NTDs in Cameroon: the need for integrated control and elimination 
  
9.2.3 Geographical distribution ....................................................................................... 198 
9.2.4 Co-endemicity ........................................................................................................ 201 
9.3 Surveillance of Skin-NTDs in Cameroon ........................................................................ 203 
9.3.1 The current surveillance strategy for Skin-NTDs in Cameroon ................................ 203 
9.3.2 Skin-NTDs surveillance tools in Cameroon ............................................................ 205 
9.3.3 Gaps in Skin-NTD surveillance in Cameroon.......................................................... 207 
9.3.4 Suggestions for improvement of Skin-NTDs surveillance in Cameroon................... 208 
9.4 Diagnosis ....................................................................................................................... 209 
9.4.1 Clinical diagnosis at primary health care level ........................................................ 209 
9.4.2 Laboratory diagnosis for Skin-NTDs control........................................................... 213 
9.5 Treatment ....................................................................................................................... 219 
9.5.1 Leprosy: ................................................................................................................. 219 
9.5.2 Buruli ulcer: ........................................................................................................... 223 
9.5.3 Yaws ...................................................................................................................... 224 
9.6 Prevention ...................................................................................................................... 226 
9.6.1 Leprosy prevention ................................................................................................. 226 
9.6.2 Buruli ulcer prevention ........................................................................................... 230 
9.6.3 Yaws prevention ..................................................................................................... 232 
9.7 Control-elimination-eradication of NTDs in Cameroon................................................... 233 
9.7.1 The need for an integrated strategy ......................................................................... 233 
9.7.2 The current situation of the control of NTDs in Cameroon ...................................... 235 
9.7.3 Why integrated control of Skin-NTDs is the best option for Cameroon ................... 236 
9.7.4 Suggested intervention packages for an integrated control strategy of Skin-NTDs in 
Cameroon .............................................................................................................................. 240 
9.7.5 Proposed model for collaboration of CNLP2LUB with other national control 
programmes ........................................................................................................................... 243 
9.8 What changes can we expect in skin-NTDs control in the near future in Cameroon ......... 245 
9.9 Conclusions ................................................................................................................... 248 
9.10 Major recommendations for improvement of skin-NTDs control .................................... 250 
9.10.1 To the National Control Programme ....................................................................... 250 
9.10.2 To the scientific community ................................................................................... 251 
9.10.3 To the World Health Organization .......................................................................... 251 
9.11 References ..................................................................................................................... 252 
 
 
 
viii 
 
Earnest Njih Tabah  Skin NTDs in Cameroon: the need for integrated control and elimination 
  
Acknowledgements  
In the first place, I thank Prof. Dr. Gerd Pluschke for the supervision of my PhD 
thesis. His great insights into Neglected Tropical Diseases has been a treasure, from which I 
will continue to tap for future projects in the domain. Prof. Pluschke has not only supervised 
the work but has sponsored all the activities of the thesis project that were based at the Swiss 
TPH in Basel Switzerland. I will forever be indebted to him. 
Secondly, I give great thanks to Prof. Dr. Alfred K. Njamnshi of the Faculty of 
Medicine and Biomedical Science of The University of Yaoundé I, Yaoundé, Cameroon, for 
co-supervising the work. Beyond supervising the science of this work on skin-NTDs, which 
also affect the nervous system (his primary interest), he has always found the right words of 
encouragement to get me back on track at moments when I felt like abandoning the project. 
He played the mentor and the “Big brother” role. 
I am also very grateful to PD. Dr. Hilty Markus of the University of Bern for being 
the co-referee of my PhD thesis and for taking time to read and understand my work. 
At Swiss TPH, I am thankful to Christine Mensch for her administrative and moral 
support. I am thankful to Dr. Martin W Bratschi for working together with me on a number of 
my projects and for his sense of scientific discuss and assiduity. I am also thankful to Dr. 
Marie-Thérèse Ruf and Zsuzsanna Györffy for their assistance.  
In Cameroon, I am grateful to Prof. Anne-Cécile Zoung-Kanyi Bissek of the Faculty 
of Medicine and Biomedical Sciences and the Ministry of Public Health for her support in 
several of my projects, proof-reading the manuscripts and discussion about the Science and 
other related issues. The same goes to Prof. Dickson Shey Nsagha of the Faculty of Health 
Sciences, University of Buea. I pay gratitude to Mrs. Njih Irine Ngani Nformi for her support 
in my work by helping to collect data in the field, data entry and proof-reading of manuscript. 
ix 
 
Earnest Njih Tabah  Skin NTDs in Cameroon: the need for integrated control and elimination 
  
My thanks equally go to Mr Theophilus Ngeh Njamnshi of the Department of Medical 
Laboratory Sciences, School of Health and Medical Sciences, Catholic University of 
Cameroon, Bamenda for his support in some of my projects, and proof-reading the 
manuscripts. 
Furthermore, in Cameroon, I will like to say “a big thank you” to the regional 
supervisors of the leprosy and Buruli ulcer Control Programme for helping with collating 
surveillance data on leprosy, Buruli ulcer and yaws in their respective regions and 
transmitting them to the National Control Programme office in Yaounde. I will also thank the 
Buruli ulcer diagnostic and treatment centres of Akonolinga, Ayos, Bankim, Mbonge, and 
Ngoantet for their work in keeping BU patient records as well as the health districts that were 
assiduous in keeping district leprosy registers that served as information source for this PhD 
project. I say “thank you” to Mr Kouayep Watat Christian Elvis, Mr Mbock Mbock Denis 
Ghislain, Mr Tizi Zourmba, and Mr Nfor Kevin Ntani all staff of the National Yaws, 
Leishmaniasis, Leprosy and Buruli ulcer Control Programme office in Yaounde for their 
selfless support to my work. 
Finally, I thank the World Health Organisation for technical support and donation of 
specific antibiotics for leprosy, Buruli ulcer and yaws treatment in Cameroon. Great thanks 
also go to the FAIRMED Foundation and Médecins Sans Frontières Suisse who have 
supported leprosy and Buruli ulcer control in Cameroon for several decades. Thanks equally 
goes to Centre Pasteur du Cameroon and again Swiss TPH for supporting the National 
Control Programme with PCR confirmation of Buruli ulcer diagnosis. 
 
 
 
 
x 
 
Earnest Njih Tabah  Skin NTDs in Cameroon: the need for integrated control and elimination 
  
Summary. 
Among the updated WHO list of 20 Neglected Tropical Diseases, about six manifests on 
the skin and are now known as Skin-NTDs. NTDs have not received equal attention from the 
international community compared to HIV/AIDS, malaria and tuberculosis although their 
burdens in terms of disability adjusted life years (DALYs) are comparable. Following 
advocacy for over a decade and half, NTDs are now being prioritized on the global health 
agenda, and the WHO has set a 2020 roadmap for accelerating work to overcome the global 
impact of NTDs.  
For this PhD thesis, we aimed at determining the current burden of major skin-NTDs in 
Cameroon and make recommendations for proper control strategies. The basis was 
surveillance data from 2000 to 2014 for leprosy and Buruli ulcer available at the National 
Control Programme office, community-based surveys and a literature review. 
We confirmed that Cameroon attained elimination of leprosy as a public health problem 
in 2000. Between 2000 and 2014, the leprosy prevalence and the detection dropped 
significantly, with the steepest reductions occurring between 2000 and 2005, followed by a 
stagnation from 2006 to 2014. We also showed a persistent but moderate transmission of 
leprosy, with an increasing trend between 2007 and 2014. Ten health districts had not 
achieved leprosy elimination, and eighteen were high leprosy-burdened according to the 
Leprosy Burden Score at the end of 2014. The increasing trend in leprosy transmission and 
the persistence of high-burdened districts were attributed to reduction in key leprosy control 
activities secondary to waning of resource allocation by the government and support partners. 
Some 3700 Buruli ulcer (BU) cases, with an annual average of 264 cases were treated from 
2001 to 2014 in Cameroon. Control activities began in two endemic foci of Ayos and 
Akonolinga in the centre region and were later expanded to Ngoantet-Mbalmayo in the 
centre, Bankim in the Adamawa and Mbonge in the southwest regions following a national 
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survey in 2004. Analysis of data from treatment centres created at these foci, further revealed 
presence of BU in 64 health districts mainly from the southern part of the country. BU case-
detection increased between 2001 and 2005, and then declined progressively until 2014 and 
beyond. Analysis of key BU control indicators showed deterioration from 2010 to 2014 and 
beyond. We also highlighted the importance of differential diagnosis in a context of co-
endemicity of mycobacterial diseases, through a case-report of cutaneous tuberculosis 
misdiagnosed for BU. BU activities in Cameroon were supported by two partners, who from 
2010, reduce their support significantly to complete withdrawal of one of them in 2014. 
Currently there is little funding from the government budget, which is insignificant compared 
to the expressed needs. We also confirmed the resurgence of yaws in Cameroon through a 
survey among the pygmy population in the east region, and building on this, we have 
determined the status of yaws in 53 of 189 health districts and confirmed 37 of them as 
endemic for yaws.  
Research conducted within the framework of this thesis, has increased our understanding 
of skin-NTDs, the efforts made in their control, and the challenges faced by the control 
activities in Cameroon. Based on these, we have recommended an integrated surveillance and 
control strategy of skin-NTDs to the National Control Programme. To the scientific 
community we recommend, accelerated research and development activities for point-of-care 
diagnostic tests, shorter treatment courses, and vaccines for reinforcement of prevention of 
these NTDs.   
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Zusammenfassung. 
 Unter den gegenwärtig von der WHO aufgelisteten 20 vernachlässigten 
Tropenkrankheiten (neglected tropical diseases, NTDs), manifestieren sich sechs 
hauptsächlich auf der Haut und diese werden daher als Haut-NTDs bezeichnet. NTDs haben 
in der Vergangenheit nicht die gleiche Aufmerksamkeit von der internationalen Gemeinschaft 
und von Geldgebern erhalten wie HIV / AIDS, Malaria und Tuberkulose, obwohl ihre 
Bedeutung in Bezug auf den Verlust an behinderungsbereinigten Lebensjahren (DALYs) 
vergleichbar ist.  Nach mehr als eineinhalb Jahrzehnten verstärkter Interessenvertretung wird 
den NTDs jetzt in der globalen Gesundheitsagenda eine höhere Priorität eingeräumt, und die 
WHO hat einen Fahrplan für 2020 festgelegt, um die Arbeit zur Überwindung der globalen 
Auswirkungen von NTDs zu beschleunigen. 
 Ziel dieser Doktorarbeit war, die aktuelle Belastung durch wichtige Haut-NTDs in 
Kamerun zu untersuchen und Empfehlungen für geeignete integrierte Kontrollstrategien zu 
entwickeln. Als Grundlage dienten Überwachungsdaten aus den Jahren 2000 bis 2014 für 
Lepra und Buruli Ulcer, die vom Nationalen Kontrollprogramm Kamaruns gesammelt 
worden sind, sowie gemeinschaftsbasierte Erhebungen und einer Literaturübersicht. 
 Wir konnten bestätigen, dass Kamerun im Jahr 2000 die Schwelle zur Lepra-
Elimination überschritten hat. Zwischen 2000 und 2014 ist die Lepraprävalenz und die 
Erkennung neuer Fälle deutlich zurückgegangen, wobei die stärksten Rückgänge zwischen 
2000 und 2005 zu verzeichnen waren. Von 2006 bis 2014 war ein eher stagnierender Trends 
zu beobachten. Wir haben auch gezeigt, dass es eine moderate, aber anhaltende 
Neuinfektionsrate mit Lepra mit steigender Tendenz zwischen 2007 und 2014 gibt. Zehn 
Gesundheitsbezirke hatten Ende 2014 das Ziel einer Lepra-Elimination nicht erreicht, und 
achtzehn waren laut Lepra-Belastungs-Score hoch Lepra-belastet. Die weiterbestehende 
Übertragung der Lepra und das Fortbestehen stark belasteter Bezirke können einer Reduktion 
der Aktivitäten zur Leprabekämpfung zugeschrieben werden, nachdem die Zuteilung von 
Ressourcen durch die Regierung und die Unterstützung durch Partnerinstitutionen 
abgenommen hat.  
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Im Zeitraum von 2001 bis 2014 wurden in Kamerun etwa 3700 Fälle von Buruli Ulkus (BU), 
mit einem jährlichen Durchschnitt von 264 Fällen, behandelt. Die Kontrollaktivitäten 
begannen in den beiden endemischen Gebieten von Ayos und Akonolinga in der 
Zentralregion und wurden später nach einer nationalen Erhebung im Jahr 2004 auf Ngoantet-
Mbalmayo im Zentrum, Bankim in Adamawa und Mbonge im Südwesten ausgeweitet. Eine 
Analyse der Daten der Behandlungszentren in diesen Brennpunkten, deckte das Auftreten 
von BU in 64 Gesundheitsbezirken auf. Diese liegen hauptsächlich im südlichen Teil 
Kameruns. Die Zahl der erfassten BU-Fälle nahm zwischen 2001 und 2005 zu und ging 
danach schrittweise zurück; wichtige Kontrollindikatoren haben sich allerdings ab 2010 
verschlechtert. Im Rahmen dieser Arbeit weisen wir anhand eines Fallberichts einer als BU 
falsch diagnostizierten Hauttuberkulose auf die Bedeutung der Differentialdiagnose im 
Zusammenhang mit der Co-Endemizität von mycobakteriellen Erkrankungen hin. BU-
Kontrollaktivitäten wurden in Kamerun von zwei Partnern unterstützt, die aber ab 2010 ihre 
Unterstützung erheblich reduzierten. Eine der Organisationen stellte im Jahr 2014 ihre 
Unterstützung völlig ein. Gegenwärtig erhält das Kontrollprogramm nur geringe Mittel aus 
dem Staatshaushalt, die gemessen am Bedarf völlig unzureichend sind.  
Mit eine Untersuchung unter der Pygmäenpopulation in der Ostregion bestätigten wir ferner 
das Wiederaufleben der Frambösie in Kamerun. Darauf aufbauend haben wir den Status der 
Frambösie in 53 von 189 Gesundheitsbezirken bestimmt und 37 von ihnen als endemisch für 
Frambösie bestätigt. 
 Die Studien, die im Rahmen dieser Arbeit durchgeführt wurden, haben unser 
Kenntnisse über die Bedeutung der Haut-NTDs in Kamerun verstärkt. Wir konnten die 
Entwicklung der Kontroll-Aktivitäten erfassen und die aktuellen Herausforderungen bei der 
Kontrolle der Haut-NTDs benennen. Auf der Grundlage dieser Untersuchungen empfehlen 
wir dem Nationalen Kontrollprogramm eine integrierte Überwachungs- und Kontrollstrategie 
von Haut-NTDs. Im Bereich der internationalen Forschung sehen wir Prioritäten bei der 
Entwicklung von dezentral durchführbaren diagnostischen Tests, kürzeren 
Behandlungszyklen und Impfstoffen zur Verstärkung der Prävention dieser NTDs. 
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Résumé. 
 Parmi la liste mise à jour de l'OMS de 20 maladies tropicales négligées, environ six 
se manifestent sur la peau et sont maintenant connus comme MTN-cutanées. Les MTN n'ont 
pas bénéficiées d'une attention égale de la part de la communauté internationale par rapport 
au VIH / SIDA, au paludisme et à la tuberculose, bien que leurs fardeaux en termes d'années 
de vie corrigées de l'incapacité (AVCI) soient comparables. Après plus de dix ans de 
plaidoyer, les MTN sont désormais prioritaires dans l’agenda mondial de santé, et l'OMS a 
établi une feuille de route 2020 pour accélérer les travaux visant à surmonter l'impact 
mondial des MTN. 
 Pour cette thèse de doctorat, nous avons cherché à déterminer le fardeau actuel des 
principales MTN-cutanées au Cameroun et à faire des recommandations pour des stratégies 
de contrôle appropriées. Les données de surveillance de la lèpre et de l'ulcère de Buruli de 
2000 à 2014, disponibles au bureau du Programme national de contrôle, des enquêtes 
communautaires et une revue de la littérature ont servi de base des travaux. 
 Nous avons confirmé que le Cameroun avait éliminé la lèpre en tant que problème 
de santé publique en 2000. Entre 2000 et 2014, la prévalence de la lèpre et la détection ont 
chutés, les réductions les plus fortes étant survenues entre 2000 et 2005, puis stagnant de 
2006 à 2014. Nous avons également montré une transmission persistante mais modérée de la 
lèpre, avec une tendance à la hausse entre 2007 et 2014. Dix districts sanitaires n'avaient pas 
atteint l'élimination de la lèpre et dix-huit avaient un fardeau élevé de la lèpre selon le 
Leprosy Burden Score à la fin de 2014. La persistance de la transmission et des districts à 
forte charge de la lèpre a été attribuées à la réduction des principales activités de lutte contre 
la lèpre suite à la diminution de l'allocation des ressources par le gouvernement et les 
partenaires d’appuis. Quelque 3700, avec une moyenne annuelle de 264 cas d'ulcère de 
Buruli (UB) ont été traités de 2001 à 2014 au Cameroun. Les activités de lutte ont débuté 
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dans deux foyers endémiques d'Ayos et d'Akonolinga dans la région centre et ont ensuite été 
étendues à Ngoantet-Mbalmayo au centre, à Bankim dans l'Adamaoua et à Mbonge dans le 
sud-ouest après une enquête nationale en 2004. L’analyse des données des centres de 
traitement créés dans ces foyers, a révélé la présence d’UB dans 64 districts de santé 
principalement de la partie sud du pays. La détection des cas d'UB a augmentée entre 2001 et 
2005, puis a progressivement diminuée jusqu'en 2014 et au-delà. L'analyse des indicateurs 
clés de la lutte contre l'UB a montrée une détérioration entre 2010 et 2014 et au-delà. Nous 
avons également souligné l'importance du diagnostic différentiel dans un contexte de co-
endémicité des maladies mycobactériennes, à travers un rapport de cas de tuberculose 
cutanée mal diagnostiquée pour l’UB. Les activités d’UB au Cameroun ont été soutenues par 
deux partenaires qui, à partir de 2010, réduisent significativement leurs appuis au retrait 
complet par l'un d'entre eux en 2014. Actuellement, le budget gouvernemental est maigre, et 
insignifiant par rapport aux besoins exprimés. Nous avons également confirmé la résurgence 
du pian au Cameroun à travers une enquête auprès de la population pygmée de la région de 
l'est. Suit à cette confirmation, nous avons déterminé le statut du pian dans 53 des 189 
districts sanitaires et confirmé l’endémicité du pian dans 37 d'entre eux. 
 Les recherches menées dans le cadre de cette thèse ont permis d'approfondir notre 
compréhension des MTN-cutanées, des efforts consentis dans leur contrôle et les défis 
rencontrés dans la mise en œuvre des activités de lutte au Cameroun. Sur la base de ceux-ci, 
nous avons recommandé une stratégie intégrée de surveillance et de lutte contre les MTN-
cutanées dans le cadre du programme national de lutte. A la communauté scientifique, nous 
recommandons une accélération des activités de recherches et de développement de tests 
diagnostiques utilisables sur le lieu des soins, des protocoles de traitements plus courts et de 
vaccins pour le renforcement de la prévention de ces MTN. 
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Chapter 1 
Chapter 1 : Introduction 
Introduction 
 
1.1 Rationale 
Leprosy, Buruli ulcer and yaws (endemic treponematosis) belong to the group of 17 
conditions classified by the World Health Organization (WHO) as Neglected Tropical 
Diseases (NTD) [1]. They affect about two and half billion people worldwide [2], and occur 
especially in remote areas of the tropical countries of Africa, Asia and the Americas, among 
the very poor and the voiceless populations [3]. These conditions are also referred to as 
diseases of poverty [1, 2], not only because the affect mostly poor people of remote 
communities, but also because the victims and affected families are rendered poorer [4] thus 
leaving them in a spiral of poverty.  
At the beginning of the 21st century the United Nations 55th General Assembly 
adopted the UN Millennium Declaration to reduce poverty [5], and established the 
Millennium Development Goals (MDG) [6] to measure progress. In a bid the achieve the 6th 
MDG to combat HIV/AID and other diseases, a lot of international momentum was throbbed 
culminating in the creation of the Global Fund against HIV/AID, Tuberculosis and Malaria 
(GFATM) in 2000 [7]. The interest of GFATM was on the three major killer diseases at the 
time namely HIV/AIDS, malaria and tuberculosis, and so neglecting “the other diseases” that 
were also stipulated in the 6th MDG. However, a whole lot of diseases put together, that 
continue to plague close to half of the world’s population were not given equal attention. 
With this situation, some committed members of the scientific community and the WHO 
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gathered evidence for close to a decade, to prove to the world that most of the “other 
diseases” could be dealt with, in an integrated manner, and could be eliminated or even 
eradicated within a few years of intervention [8, 9, 10] . Then in April 2007, the WHO 
convened a global meeting on Neglected Tropical Diseases, that marked a turning point for 
these conditions as they were repositioned on the priority list of the global health agenda [11]. 
In the 2030 United Nations Agenda for Sustainable Development adopted by the 70th UN 
General Assembly in 2015, and in its 3rd Goal to ensure healthy lives and promote well-being 
for all, Neglected Tropical Diseases stand out clearly in the 3rd point of the health goal [12]. 
The Republic of Cameroon is endemic for at least 10 of the NTDs in the WHO list of 
including leprosy, Buruli ulcer, yaws, leishmaniasis, human African trypanosomiasis, 
onchocerciasis, lymphatic filariasis, soil-transmitted helminthiasis, schistosomiasis, and 
blinding trachoma [13]. Subscribing to all the global efforts to combat NTDs, the government 
of Cameroon has created five different national programmes to fight against the NTDs. One 
of them is the National Programme for Yaws, Leishmaniasis, Leprosy and Buruli ulcer 
Control, which formerly was a single-disease (leprosy) programme but was reorganized in 
2009 to integrated the control of three other skin-NTDs [14].   
Taking advantage of the existence of an integrated national control programme for 
four case-management NTDs, and backing on the 66th World Health Assembly resolution No, 
WHA66.12 on NTDs [15], calling for integration of interventions and activities in order to 
achieve efficient use of resources, we aimed within the framework of this PhD thesis project, 
to carry out a situational analysis of the control of leprosy, Buruli ulcer and yaws in 
Cameroon, establish their current burden and make recommendations for proper integrated 
control strategies. 
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1.2 Leprosy 
1.2.1 Definition 
Leprosy, also known as Hansen’s disease is a chronic infectious disease that affects the 
skin and peripheral nerves. It is caused by Mycobacterium leprae. Patients not diagnosed or 
diagnosed late in the evolution of the disease will develop physical deformities. These 
deformities impact the patients’ ability to perform normal life activities but most importantly 
expose the individual patient to stigma and social exclusion (16). 
1.2.2 History of leprosy 
Leprosy is an age-old disease known from biblical times, with records describing its 
clinical manifestation dating as far back as 600BC to 1400 BC in India where it was referred 
to as Kushta (17; 18). Results of recent genomic studies of Mycobacterium leprae trace it 
back to over 100 000 years [19, 20]. Although leprosy was known to humanity for a very 
long time, it was only in 1873 that the causative agent, Mycobacterium leprae, was isolated 
by the Norwegian physician, Gerhard Armauers Hansen  (21; 18). The first treatments for 
leprosy were chaulmoogra and hydnocarpus oils and their derivatives, first given orally and 
then parenterally (22; 23). This treatment led to improvement but not cure of leprosy. The 
hope of a real treatment for leprosy came in 1942 when Faget from Carville, USA, reported 
remarkable results with the use of the diamino-diphenylsulfone derivative, Promin, in 
lepromatous leprosy patients (22; 18). The Promin treatment subsequently underwent 
refinement in order to reduce its toxicity, with the outcome being dapson, which became the 
universally accepted treatment of leprosy for over 25 years [22]. Following issues with 
dapson related to requirement of prolonged treatment, high occurrence of lepromatous 
reactions in patients, adverse drug effects like hemolytic anemia and mild disturbance of 
hepatic function and finally development of resistance (22; 23), research continued to sought 
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for better leprosy treatment. The new effective candidate drugs discovered were clofazimine 
(lamprene) [24] and rifampicin [25]. Both drugs showed bactericidal properties against M 
leprae and in addition, clofazimine could reduce inflammation in patients with lepromatous 
reactions [26]. With these new developments, the WHO established a study group for the 
development of an effective leprosy treatment and in 1982, the group recommended 
multidrug therapy (MDT), a combination of dapson, rifampicin and clofazimine as the new 
treatment for leprosy (27). By 1985, the WHO fully adopted the MDT and recommended it to 
all member countries. Furthermore, new leprosy control tools were developed, including a 
simplified classification of clinical forms into two classes: Paucibacillary (PB) and 
Multibacillary (MB), from the Ridley-Jopling spectrum of five clinical forms. MDT 
treatment regimens for each of the two forms were also defined (27). The implementation of 
MDT yielded remarkable results between 1985 and 1990, with a 42% drop in the number of 
registered leprosy cases (5 368 282  ➔ 3 737 375)  (28). Encouraged by these results, the 44th 
World Health Assembly holding in Geneva in 1991, adopted a resolution (WHA44.9) to 
eliminate leprosy as a public health problem by the year 2000 [29]. In 1985, Cameroon was 
among the 122 leprosy endemic countries. By the end of 2000, 107 countries including 
Cameroon had attained the leprosy elimination threshold of less than 1 case per 10000 
population at the national level (30). Although eliminated at the national level, Cameroon, 
like many other countries continues to harbour leprosy hotspots at subnational levels. With 
the advent of elimination, resources allocated to leprosy control in Cameroon have dwindled 
from the year 2000 to very low levels, making the challenge for further reduction of the 
current leprosy burden a huge task. This issue and more have been discussed in greater detail 
in chapter 2 of this thesis. 
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1.2.3 Epidemiology  
At the end of 2016, the WHO received reports on leprosy from 143 countries. Some 171 
948 leprosy cases were registered at the end of 2016, giving a global prevalence of 0.23 per 
10 000 population. About 214 783 new leprosy cases were detected, giving a detection rate of 
2.9 per 100 000 population in 2016. Among the new cases, 60% were MB cases, 6% had 
grade-2 disabilities and 39% were female. Twenty-two countries including 12 from Africa, 
accounted for 96% of all the new cases reported in 2016 [31]. Figure 1 shows the global map 
of the distribution of new leprosy cases in 2016. 
 
Fig1.1. Map of global distribution of new leprosy cases in 2016. Source : 
http://www.searo.who.int/entity/global_leprosy_programme/epidemiology/en/ 
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Fig 1.2. 5-year trend in global leprosy new case detection. Panel A shows the proportion of case load, and Panel B 
the absolute numbers of new case detection by WHO region. Adapted from WHO data presented in the WER 2017; 92(35) 
[32] 
 
From 2012 to 2016, 217581 new leprosy cases on the average were reported annually, 
with South-East Asia contributing the greatest proportion followed by the Americas and 
Africa (Fig 1.2A) [32]. The trends in the number of new cases showed stagnation between 
2013 and 2016 (Fig 1.2B). Within the framework of our thesis project, we were able to 
describe similar trends in Cameroon. Details are shown in Chapter 2 of this document. 
1.2.4 Causative agent and reservoir 
i. Causative agent 
Leprosy is caused by Mycobacterium leprae. The microbe was identified by Gerhard 
Armauer Hansen in 1873 [21]. Consequently, the microbe is also known as Hansen’s 
bacillus. 
In the scientific classification, M. leprae belongs to the Schizomycetes class, 
Actinomycetales order, Mycobacteriaceae family and of the genus Mycobacterium (16). M. 
leprae is rod-like in shape, and measures 1.5-8 μm x 0.2-0.5μm (16). It is an acid-fast 
bacillus, identified in smears or biopsy tissues after the application of Ziehl-Neelsen staining 
technique [33]. They usually appear in red clusters called globi inside the macrophages or 
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Schwann cells for which they have high affinity (16) or as single red rods when viewed under 
the microscope (Figure 1.3).  
On microscopy, M. leprae cannot be differentiated from other mycobacteria like M. 
tuberculosis and M. ulcerans. Genomic studies have however shown a great variation in the 
number of genes contained in the genomes of these mycobacteria [19]. It is believed that in 
the course of adaptation from a free-living bacterium into an obligate intracellular bacterium, 
M. leprae gave away non-essential genes, to remain only with 1604 genes in its genome 
unlike the free-living M. ulcerans that has 4160 genes in its genome [19]. 
 
Fig 1.3. Bacterial index (BI):  Panel A is a photomicrograph depicting an acid-fast stain of M. leprae bacteria. Source : 
www.ppdictionary.com/bacteria/gpbac/leprae.htm. Panel B shows the bacterial index interpretation.  
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Table 1.1: Comparison of genome features of three Mycobacterium species.  
Genome features* M. leprae M. tuberculosis M. ulcerans M. marinum 
Number of genes 1604 3974 4160 5424 
Number of pseudogenes 1116 17 771 65 
Mega-base pairs 3.37 4.41 5.63 6.64 
Guanine + cytosine 
(G+C) content 
57.8% 65.6% 65.5% 65.7% 
Living style Human parasite Human parasite Free-living Free-living 
Cultivation in media No Yes Moderate Low 
Pathogenicity Moderate High Moderate Low  
Main infection sites Skin, nerves Lungs, bone Skin (limbs) Skin  
*Adapted from Han XY et al., [19].  doi:10.1371/journal.pntd.0002544.t001. 
 
ii. Reservoir 
Humans beings especially patients with the lepromatous form of leprosy [34] are the 
main reservoir for M. leprae, where it thrives in the skin, the peripheral nerves and the upper 
respiratory pathways, which are relatively colder parts of the body with temperatures between 
27oC and 30oC [35].  However, secondary natural reservoirs have been reported in animals 
like the 9-banded armadillos in Central and Southeastern America [36, 37], and the red 
squirrels in Scotland [38]. 
1.2.5 Transmission 
Leprosy is thought to be transmitted by close and prolonged contact between a leprosy-
free person and an untreated leprosy patient, through direct skin contact or inhalation of 
bacilli from nasal droplets or secretions (16; 34). No study to date, has demonstrated in 
unequivocal terms the mechanism by which leprosy transmission occurs (39; 40). The 
pathway of transmission mostly suggested is through the nasal mucosa (41; 42; 39), and to a 
lesser extend through the skin (42; 43; 39). Infected persons, including those not manifesting 
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signs of the disease (healthy carriers) also release bacilli from their nostrils and could 
therefore transmit the disease (42). 
Erroneous beliefs related to hereditary as a mode of transmission has been lingering 
since time immemorial. However, leprologists and scientists interested in leprosy research 
have always refuted this as shown in the following 1911 quote by Sandes TL: “It is 
exceedingly improbable that an ovum, still less a sperm cell, could contain so relatively large 
an intruder as a lepra bacillus and yet suffer so little derangement of its great but excessively 
delicate potentialities as to render successful fertilization and development possible” [44]. 
Within the framework of this thesis project, we have explored Community knowledge, 
perceptions and attitudes regarding leprosy in two rural health districts of Cameroon (see 
Chapter 3). We have also contributed to a book chapter on stigma in neurological diseases in 
the tropics, that has dwelled elaborately on leprosy related stigma (see chapter 8). 
1.2.6 Pathogenesis 
Two structural elements of M. leprae: the capsule and the cell wall, give it the 
propensity to survive within a tight ecological niche [35]. The lipid capsule is the target for 
humoral immune response mediated by immunoglobulin M [45]. The lipoarabinomannan, a 
component of the cell wall is an antigen for macrophage. The Schwann cell which coats the 
peripheral nerves has a specific binding site - the laminin-α2 chain on the basal lamina, which 
provides high attraction to the M. leprae [35, 46]. Once in the Schwann cell, the 
mycobacteria replicate slowly until a threshold is reached when its antigens are recognized by 
the T lymphocytes and this sets the stage for a chronic inflammatory reaction [46]. 
Not all individuals who get infected with M. leprae develop leprosy [34]. The infected 
individual’s immune status determines the development of clinical manifestations. The 
mannose receptor in the macrophage surface facilitates phagocytosis [35]. The human 
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leukocyte antigen vitamin D receptor (HLA-DR2 and HLA-DR3) genes have been associated 
with the development of tuberculoid leprosy, meanwhile the HLA-DQ1 has been associated 
with the lepromatous form of leprosy (16; 35). Many other components of the immune 
system have been linked with the clinical forms and evolution of the disease. For instance, a 
strong cellular response is observed with the tuberculoid form whereas it is absent in the 
lepromatous form of leprosy [35]. 
The immune response to M. leprae is variable. This variability may spontaneously lead 
to changing clinical manifestation in the form of type 1 or 2 leprosy reactions. A type 1 (or 
reversal) reaction involves type IV hypersensitivity, in which levels of cytokines (interferon-γ 
and tumor necrosis factor) in the blood rise and T-cells are activated [47]. The type 2 (or 
erythema nodosum leprosum) reaction involves a type III hypersensitivity reaction, 
secondary to deposits of immune complexes that are associated with systemic toxicity and 
high levels of tumour necrosis factor as well as neutrophilic infiltration and complement 
deposition in the skin [35]. The type 2 reaction is common in lepromatous forms of leprosy. 
1.2.7 Classification of clinical forms of leprosy 
The International Leprosy Congress of 1953 holding in Madrid established the first 
classification of leprosy into four classes namely tuberculoid (T) and lepromatous (L) on two 
poles and indeterminate (I) and borderline (B) in-between the two poles. This was based on 
clinical state of the patients and the results of skin smears (16). 
 Ridley and Jopling in 1966, proposed another classification of leprosy based on the 
patient’s immune status and clinical state. A spectrum of five clinical forms with two poles 
and three intermediate but dynamic forms were suggested [48]. Accordingly, there were the 
lepromatous (LL) and the tuberculoid (TT) poles and three borderline states which were 
borderline lepromatous (BL), borderline borderline (BB) or borderline tuberculoid (BT) 
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depending on which of the poles they tilted to. At the initial state of the disease, the 
expression is not usually clear and therefore cases are identified as indeterminate. However, 
as the disease evolves, they eventually progress to one of the poles [35]. If a patient is 
detected and put on treatment and follow-up at this stage, disease evolution is halted and the 
patient is cured. 
For the purposes of MDT implementation and expansion of its access as wide as 
possible, the WHO Study Group recommended a simplified classification of leprosy into two 
clinical forms: Paucibacillary (PB) and Multibacillary (MB) in 1982 based on the bacterial 
index (BI) (27). Patients with BI <2+ were classified as PB and those with BI ≥ 2+ as MB 
(16; 27). According to this recommendation, the L and B forms of the Madrid classification; 
and the LL, BL, and BB forms of the Ridley-Jopling classification became classified as MB, 
whereas the I and the T forms of the Madrid classification; and the TT and BT forms of the 
Ridley-Jopling classification were now classified as PB (27). In 1987, a slight modification 
was made to the classification so that all smear positive cases were from henceforth to be 
considered as MB cases. Consequently, MB leprosy cases included all BB, BL, LL (Ridley-
Jopling classification), and B, L (Madrid classification), as well as any other smear positive 
type. PB cases included only smear negative I, TT, BT (Ridley Jopling classification), and I 
or T (Madrid classification) cases [49]. Based on the argument that laboratory facilities for 
bacteriological examination of skin smears were not always available especially in the remote 
leprosy endemic areas, a further simplification in the classification was operated in 1998 
during the seventh meeting of WHO Expert Committee on leprosy. They decided to base the 
classification of leprosy purely on clinical presentation, whereby PB cases were patients with 
0-5 skin lesions/or only one nerve trunk involvement; and MB cases patients with 6 or more 
skin lesions/ or more than one nerve trunk involvement (50; 16). 
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1.2.8 Clinical Manifestations of leprosy 
i. Tuberculoid (TT) leprosy:  
The typical lesion of tuberculoid leprosy is a large erythematous plaque with raised outer 
borders and a flattened centre which is dry, rough, without hair and scaly (Fig 1.4A). It also 
has loss of sensitivity. However, when the lesion is on the face, sensory loss is not very 
pronounced [48]. Lesions of tuberculoid leprosy are few, often not exceeding five in number, 
because the patient is immune-competent [35]. Sometimes, the lesion may be macular and 
hypochromic with a well-defined outer border (Fig 1.4B) and a dry, hairless and insensitive 
centre. The lesions may appear anywhere on the body except the perineum, groins, axillae 
and scalp [48]. 
Sometimes, the clinical manifestation of tuberculoid leprosy may be purely neural, with 
involvement of one or at most two peripheral nerves (Fig 1.4C). The nerve trunk becomes 
enlarged and painful, and may lead to sensory loss, muscle weakness and muscle atrophy of 
the extremities served by the nerve in question [48].   
 
Fig 9.10.4. Clinical presentations of tuberculoid leprosy. A: Hypochromic annular plaque on the right arm with well-
defined and raised borders, and flattened centre with apparent hair loss. B: Hypochromic macular lesion with well -defined 
borders on the back. C. Enlarged left auricular nerve. (Pictures courtesy of EN Tabah). 
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ii. Borderline tuberculoid (BT) leprosy 
Lesions of BT leprosy resemble those of TT leprosy in appearance and sensory loss. 
However, the difference lies in that, the BT leprosy lesions are smaller in size and tend to be 
more numerous. Their outer edges are clear-cut and their surfaces are less dry and with little 
hair loss (Fig 1.5A). Close to the periphery of larger lesions, small satellite lesions are 
sometimes present (Fig 1.5B&C). Nerve enlargement though more numerous in BT leprosy, 
is not as exaggerated in TT leprosy. The immune status of BT leprosy patients is low as they 
will show a weak positivity to the lepromin test compared to TT leprosy patients [48]. 
 
Fig 1.5. Clinical presentation of borderline tuberculoid leprosy. A: Smaller hypochromic annular plaques with well-
defined and raised borders, and flattened centre with apparent hair loss. B: A larger hypochromic plaque with clear-cut 
borders, and satellite lesions (arrows) on the periphery. C: A larger hypochromic macular lesion with clear-cut borders, and 
satellite lesions (arrows) on the periphery (Pictures courtesy of EN Tabah) 
 
iii. Borderline borderline (BB) leprosy 
BB leprosy lesions and intermediate between those of tuberculoid and lepromatous 
leprosy in size and number. They are typically punched-out in appearance and have moderate 
sensory loss. They are irregularly shaped erythematous plaques vague outer borders and an 
oval hypo-pigmented and punched-out centre (Fig 1.6 A & B). The lesions may also appear 
as circular band with clear-cut outer and inner borders (Fig 1.6C). Small satellites lesions 
may also be present like in BT leprosy [48]. 
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Fig 1.6. Clinical presentation of Borderline borderline leprosy. A: Irregularly shaped erythematous plagues with 
blurred borders and apparently punched-out centres. B: numerous and more or less oval hypochromic lesions. C: Circular 
bands with well-defined outer and inner borders. (Pictures courtesy of EN Tabah) 
 
iv. Borderline lepromatous (BL) leprosy 
Borderline lepromatous leprosy lesions are numerous and diversified in the same patient 
and may include macules, plaques, papules and nodules. Some characteristics distinguish BL 
from LL lesions. The BL lesions do not have a real bilaterally symmetric distribution over all 
the affected areas; some plaques are too large with definite loss of sensitivity in some parts, 
have punched-out centres, and are not shiny (Fig 1.7A); some nodules are umbilicated in the 
centre (Fig 1.7 B&C). Finally, typical features of lepromatous leprosy like madarosis, nasal 
secretions, keratitis, leonine facies are absent in BL leprosy [48]. 
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Fig 1.7. Clinical presentation of Borderline lepromatous leprosy. A: Numerous small plaques with bilateral and 
symmetric distribution. Some the lesions have the characteristic “punched-out” appearance of borderline leprosy. B: 
Disseminated papules and nodules with bilateral and symmetric distribution. The skin in-between lesions is normal. C: 
Papules and nodules on the face with dimples on some of the nodules. The skin in-between the lesions is normal; the eye 
brows are intact. (Pictures courtesy of EN Tabah). 
v. Lepromatous (LL) leprosy 
Here, the skin lesions are multiple and characterized by hypo-pigmented, erythematous 
and shiny spots with blurred edges. Sensory loss is not pronounced on the spots. There are 
numerous peripheral nerves involved but with no enlargement unless the patient evolved 
from the borderline form of leprosy. The lesions become infiltrated, forming plaques and 
nodules as the disease progresses (Fig 1.8 A&B). Other common symptoms are oedema in 
the legs and feet and reduced sensitivity in the limbs (Fig 1.8D). In the advanced stages, 
lepromatous leprosy patients develop diffuse infiltration of the face, giving it a peculiar 
appearance, known as leonine facies (Fig 1.8C). Eyelash loss (madarosis) is also present at 
this stage (Fig 1.8C). The eyes, mucous membranes of the upper respiratory pathway, the 
teeth, lymph nodes and some internal organs may also be affected (16; 48). 
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Fig 1.8. Clinical presentations of lepromatous leprosy. A: Infiltrated macules superimposed by papules and plaques 
with bilateral and symmetrical distribution. B: Generalized erythematous and shiny macules with confluent edges. Presence 
of nodules on the posterior left thigh. C: Leonine facies and madarosis. D: Oedema of feet. Note nodules on right foot. 
(Pictures courtesy of EN Tabah). 
vi. Indeterminate (I) leprosy 
Indeterminate leprosy presents purely with macular lesions (never plaques and 
nodules). The macules are faintly hypochromic, with blurred borders and few in number (Fig 
1.9). Sensory loss may be present [48]. 
 
Fig 1.9. Clinical presentation of indeterminate (I) leprosy. Macular lesions that are faintly hypochromic, with poorly 
defined borders. (Pictures courtesy of EN Tabah). 
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1.2.9 Clinical manifestation of leprosy reactions. 
i. Type 1 (or reversal reaction) 
As mentioned earlier, Type 1 (or reversal reaction) is a cell-mediated type IV 
hypersensitivity, in which high levels of cytokines are produced into the blood circulation. 
This may occur few months after commencement of treatment or after the end of treatment 
[35].  Clinically, type 1 reaction manifest as erythematous macules (Fig 1.10A&B) which are 
painful and may evolve into blisters, and ulcers. Nerve trunks are often the target of this 
reaction, leading to inflammation, enlargement and sometimes abscess formation. This is a 
very important aspect of type I reaction which should be watched for in leprosy patients in 
order to offer them timely and effective treatment before irreversible damage occurs to the 
nerve(s) (16; 35).  
 
Fig 1.10. Clinical manifestation of Type 1 leprosy reaction. Marked erythematous macules on the faces. Note the 
inflamed and swollen upper lip in 1.10A. (Pictures courtesy of EN Tabah) 
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ii. Type 2 reaction (Erythema nodosum leprosum (ENL))  
Type 2 reaction occurs in 60% of lepromatous leprosy patients and may happen 
repeatedly in the course of the disease. ENL manifests as painful nodules, occurring on the 
limbs most frequently, but occasionally on the trunk also. It is associated with systemic 
symptoms including fever, joint pains, fatigue, weakness and weight loss. ENL develops as a 
result of immune complex deposition [35]. 
 
Fig 1.11. Clinical manifestation of ENL. Erythematous and tender nodules or lumps under the skin, usually on the arms 
and legs (Panel A) but occasionally on the trunk (Panel B). 
1.2.10 Diagnosis of leprosy 
The diagnosis of leprosy is largely clinical and relatively easy to make for trained health 
workers, especially those at the primary health care level where laboratory or microscopy 
services are not always available [50]. The major challenge now is the low suspicion index of 
leprosy among health workers at every level, in the current tropical context where the disease 
incidence has reduced remarkably, or in western countries where it has almost disappeared.  
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Although not required for decision to treat, paraclinical (bacteriological and 
histological) tests can help to confirm clinical diagnosis, when the health practitioner is in 
doubt and has the possibility to carry out the tests [51]. 
i. Clinical diagnosis 
The first clue is in the patient’s medical history, especially when the patient is from an 
endemic area or has lived there for some time [51]. A thorough clinical examination of the 
skin lesions and verification of peripheral nerve involvement, will determine the diagnosis 
based on the 3 cardinal signs laid down by the WHO Expert committee on Leprosy in 1997 
[50, 35, 52]. The diagnosis is made in an individual who has not taken MDT treatment, when 
1 or more of the following 3 cardinal signs is/are present: 
- A hypo-pigmented or erythematous skin lesion with sensory loss 
- An enlarged peripheral nerve 
- A positive slit skin smear or bacilli observed in biopsy. 
Table 1.2: Cardinal signs for diagnosis and classification for treatment of leprosy 
Cardinal signs* Classification for treatment 
- Hypopigmented or slightly erythematous 
macules with sensory loss 
- Enlarged peripheral nerves 
- Positive acid-alcohol-fast smear or skin 
biopsy 
- Paucibacillary (PB): 1 – 5 skin lesions 
- Multibacillary (MB): 6 or more skin 
lesions or positive smear/biopsy 
regardless of the number of skin lesions 
*Any single cardinal sign is diagnostic and indicates clinical classification for guiding treatment according to 
WHO [50, 52, 35].  
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ii. Paraclinical diagnosis 
Smear test: Smears are usually obtained from skin slits of the ear lobe, and/or skin 
lesion; and nasal swabs. Ziehl-Neelsen stain is done and slides are observed under the 
microscope. Bacillary index (BI) is used to interpret the results [33] (Fig 1.3). 
Skin biopsy: Biopsy is taken from a skin lesion and stained using the modified Fite-
Faraco technique [53]. Bacilli are not seen at the tuberculoid pole. Instead, granulomas made 
up of epithelioid cells, giant Langerhans cells and lymphocytes, are most commonly found, 
with nerve involvement. At the lepromatous pole, common features are: foamy macrophages 
filled with bacilli, inflammatory infiltrates and loss of adnexal structures [35]. 
Serology test: Serology diagnosis is based on the detection of antibodies against 
phenolic glycolipid 1 (PLG-1), an M. leprae antigen [54, 55], but also on polymerase chain 
reaction (PCR), using as targets M. leprae genes, the genes coding for 36-kDA, 18-kDA, 65-
kDA, antigens; the complex 16S rDNA [56] 
1.2.11 Treatment 
Through the MDT donation programme, the WHO and partners have rendered leprosy 
treatment free-of-charge to all endemic countries. The drugs are supplied in packs that 
contain the regimens for adult and child PB, and adult and child MB leprosy cases 
respectively [57]. 
i. Treatment of patients 15 years of age or older: 
PB leprosy treatment: The treatment course is six MDT PB adult blister packs (Fig 
1.12), with dosage as on Table 1.3. The monthly dose is taken at the start (Day 1) of the 
treatment and then every 28 days for six months. The daily dose is taken every day for six 
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months. For an adequate treatment, the full course of PB leprosy treatment should be taken 
ideally for a period of six months but must be completed within 9 months [57]. 
Table 1.3: Dosages of MDT treatment for adults by regimen (adapted from ILEP [57]) 
 MDT for PB leprosy MDT for MB leprosy 
Monthly dose - Rifampicin 600mg - Rifampicin 600mg 
- Dapson 100mg - Dapson 100mg 
 - Clofazimine 300mg 
Daily dose - Dapson 100mg - Dapson 100mg 
 - Clofazimine 50mg 
 
MB leprosy treatment: The treatment course is 12 MDT MB adult blister packs (Fig 
1.12), with dosage as on Table 1.3. The monthly dose is taken at the start (Day 1) of the 
treatment and then every 28 days for 12 months. The daily dose is taken every day for 12 
months.  For an adequate treatment, the full course of PB leprosy treatment should be taken 
ideally for a period of 12 months but must be completed within 18 months [57]. 
ii. Leprosy treatment for children 
Table 1.4: Dosages of MDT treatment for children by age and regimen (adapted from ILEP [57]) 
  Below 10 years 10 -14 years  
PB leprosy Monthly dose Rifampicin 300mg Rifampicin 450mg 
Dapson 25mg Dapson 50mg 
Daily dose Dapson 25mg Dapson 50mg 
MB leprosy Monthly dose Rifampicin 300mg Rifampicin 450mg 
Clofazimine 100mg Clofazimine 150mg 
Dapson 25mg Dapson 50mg 
Daily dose Clofazimine 50mg 
twice weekly 
Clofazimine 50mg 
every other day 
Dapson 25mg Dapson 50mg 
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The duration of treatment for children is the same as for adults, that is: 6 – 9 months for PB 
leprosy and 12 – 18 months for MB leprosy. However, the dosage varies by age (see Table 
1.4). In children, clofazimine is only given for MB leprosy cases. The treatment for children 
10-14 years is also available in blister packs (Fig 1.12). 
 
Fig 1.12. Presentation of MDT blister packs by regimen. (a) paucibacillary treatment for adults, and (b) multibacillary 
treatment for adults; (c) paucibacillary treatment for children, and (d) multibacillary treatment for children (adapted from ILEP 
[57]). 
The MDT treatment for leprosy has been very effective since institution in the early 
1980s. Less than 2% relapse rates have been reported [58, 59]. Resistance of M. leprae to 
MDT is rare, however some recent studies have demonstrated mutations in the Drug 
Resistance Determining Region (DRDR) of the rpoB and folP1 genes, isolated from some 
leprosy relapse patients [60]. 
iii. Treatment of leprosy reactions 
Leprosy reaction be it type 1 or type 2, accelerates nerve damage, with attendant and 
irreversible physical deformities. Given that they can occur within two months from the start 
of treatment, during treatment and even years after treatment, it is important that leprosy 
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patients, especially those at high risk (MB leprosy patients) are monitored throughout in the 
course of their treatment and up to two years after the end of their treatment for leprosy 
reactions [52]. 
Type 1 reaction with neuritis, is treated with prednisone at a starting dose of 40-60mg 
per day, and then decreasing the daily dose by 5mg every 2-4 weeks depending on clinical 
improvement of the patient [35, 52].  The treatment may last from 12 to 16 weeks in patients 
with tuberculoid leprosy [52].  
Type 2 reaction (ENL) is best treated with thalidomide at a daily dose of 100 to 200mg, 
for a period of 3-4 weeks [35]. Prednisone or clofazimine can also be used in ENL. 
Clofazimine is indicated here for its anti-inflammatory properties and is the preferred 
alternative for women of child-bearing-age and those who cannot tolerate thalidomide. When 
prescribed, clofazimine is given at a daily dose of 300mg [35], and prednisone at 40 – 60mg, 
and decreasing by 5mg every 2-4 weeks. The treatment of ENL can last for 6 months [52]. 
1.2.12 Leprosy elimination  
The leprosy elimination programme has been going on in the world for several decades 
following the introduction of multi-drug therapy in the early 1980s (27), and the call for its 
elimination as a public health problem by the 44th World Health Assembly of 1991 [29]. The 
WHO roadmap for Neglected Tropical Diseases still targets leprosy for elimination by 2020 
(61). A global leprosy strategy 2016 – 2020 is currently being implemented with the goal of 
further reducing the leprosy burden and global and local levels, and as main targets to stop 
leprosy transmission, and to stop disability and stigma related to leprosy [62]. 
In Chapter 2 of this thesis, we evaluate the burden of leprosy in Cameroon in the post 
elimination era from 2000 to 2014, using a novel concept of “Leprosy Burden Score 
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(LBS)”, which is a composite indicator, integrating nine different indicators recommended 
by WHO and ILEP in 2001 for monitoring different aspects of leprosy elimination [63]. 
 
1.3 Buruli ulcer 
1.3.1 History and Epidemiology 
Buruli ulcer (BU) also called M. ulcerans disease, is the 3rd human mycobacterial 
disease after tuberculosis and leprosy. Ulcers consistent with BU were first described in 1897 
by Sir Dr. Albert Cook, working at the Mengo Hospital in Uganda [64]. However, it was 
MacCallum and colleagues who published a definitive description of M. ulcerans disease in 
1948 in Australia, after isolating a mycobacterium from six patients with large atypical ulcers 
[65]. In the 1960s and 70s, huge number of cases were report from the Buruli county in 
Uganda hence the name Buruli ulcer [66, 67]. During the same period, cases were also 
reported in other African countries namely Congo [68], Ghana [69], Nigeria [70], Cameroon 
[71]. There has been an upsurge in BU incidence since the 1980s particularly in West Africa, 
with Cote d’Ivoire, Ghana and Benin registering the highest incidences [72], but also 
including Togo, Liberia, Guinee Conakry, Nigeria and Sierra Leone [67]. Central African 
countries too, including Cameroon, Democratic Republic of Congo, Congo Brazzaville and 
Gabon have also reported increasing number of cases [67].  Outside Africa, the disease is also 
endemic in Southeast Asia, Western Pacific and the Americas [72]. In 1998, the WHO put in 
place the Global BU Initiative to create awareness, mobilize resources, and coordinate control 
and research efforts regarding the disease. Today, about 32 countries worldwide are endemic 
for Buruli ulcer, but only 16 are actively reporting cases currently (Fig 1.13) [73]. 
Buruli ulcer has a focal distribution, occurring in specific foci within endemic countries, 
most often close to marshy areas, stagnant or slow flowing water bodies [67]. BU affects 
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individuals of both sexes almost equally, but with an age predominance in children below 
15years although a study in Cameroon has shown that children below 4 years are 
underrepresented [74], and close to 60% of lesions occurring on the lower limbs [74, 75].  
A cumulative number of 58 814 BU case have been registered worldwide since 2002. 
From an annual average of about 5000 cases between 2002 and 2010, the number has been 
declining steadily to reach 1 864 in 2016 (Fig 1.14) [76]. 
 
Fig 1.13. Global distribution of Buruli ulcer in 2015. Source: WHO website. 
http://gamapserver.who.int/mapLibrary/Files/Maps/Buruli_2015.png?ua=1  
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Fig 1.14. Trend in global number of BU cases reported. The number of cases is on a downward trend since 2010. 
Data is from World health organization, accessed at: http://apps.who.int/gho/data/node.main.A1631  
 
In Cameroon, after the first report of Buruli ulcer by Ravisse and colleagues in 1969 
[71], it took another 32 years for a trigger for effective control to be given, when  Noeske and 
colleagues rediscovered BU in the Nyong valley in the Centre Region of Cameroon in 2001 
[77].  
In Chapter 4 of this thesis, we describe the National Buruli ulcer Control Programme 
(NBUCP) in Cameroon from creation in 2002 and its evolution through to 2014, based on 
reports and data from 2001 to 2014. We also highlight the challenges faced by the NBUCP 
and then make recommendations for the way forward.  
1.3.2 Causative agent 
Buruli ulcer is caused by M. ulcerans, first isolated in 1948 by MacCallum [65]. It is a 
free-living mycobacterial found in specific niches within an aquatic ecosystem in tropical 
countries [78]. The taxonomy is: Class: Actinobacteria; Order: Corynebacteriales; Family: 
Mycobactericeae; Genus: Mycobacterium; Species: Mycobacterium ulcerans [79]. 
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Genomic studies have shown that M. ulcerans evolved from its ancestral M. marinum 
which is a ubiquitous aquatic species, by acquiring the pMUM plasmid that contains genes 
for mycolactone production, that confers its virulent nature, followed by a reductive evolution 
[80]. In the course of the evolution, about 1364 genes were lost or converted pseudogenes so 
that the resulting M. ulcerans retained 4160 genes and 771 (15.64%) pseudogenes (Table 1.1) 
[19, 81]. The pseudogene formation is illustrated in the presence of multiple copies of the 
insertion sequences IS2404 and IS2406 on the M. ulcerans chromosome [80]. The ability of 
M. ulcerans to produce the mycolactone exotoxin, confers to it a selective advantage in 
colonizing various ecological niches including aquatic insects, aquatic biofilms and mammals 
successfully [78]. This has implications for BU pathogenesis as discussed late in this chapter.  
After evolution from the ancestral M. marinum, M. ulcerans is said to have 
subsequently diverged into two major mycolactone-producing lineages. The classical lineage 
associated with Buruli ulcer in Africa and Australia; and the ancestral lineage associated with 
BU in Japan, China and Mexico, as well as ulcerations in fish and frogs [81, 82]. These 
different lineage strains produce mycolactone potencies [83].  
1.3.3 Reservoir, vector and transmission 
From epidemiological studies by the Uganda Buruli Group in the 1970s, Buruli ulcer 
was already described as a slowly developing disease, with an incubation period of about 3 
months, and with no evidence of human to human transmission [66]. It is generally believed 
that the M. ulcerans occurs naturally in the environment, but the mode of transmission to 
hosts remains a myth, although a handful of hypotheses have been proposed [84].  
Since the 1960s and 70s, an association between the occurrence of Buruli ulcer and 
water bodies was described by the Uganda Buruli Group in a report of an extensive 
epidemiological study of Rwandan refugees settled near the Nile river in Central Uganda 
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[66]. Many other reports linking Buruli ulcer to stagnant or slow flowing water bodies and 
marsh lands have been made since then in West and Central Africa [85, 86, 87, 88] and in 
Australia [89]. In addition to proximity to water bodies, it has also been shown that man-
made changes to the environment like building dams, deforestation, mining activities, and 
some agricultural practices like the cultivation of lowland rice, are associated with risk of 
increase BU incidence [87, 90, 86]. At the individual level, failure to wear long-sleeve shirts 
and trousers, and to sleep under insecticide treated nets, and poor wound care have also been 
suggested as risk factors [91].  
Environmental studies to determine the reservoir within the aquatic environment have 
detected M. ulcerans in niches including water bugs [85], water columns and under water 
detritus soil [92], water snails and biofilms on water plants [78] through PCR, targeting the 
insertion sequence IS2404 of the M. ulcerans DNA. Such detections have not been enough to 
confirm the various aquatic niches as reservoirs given that M. ulcerans is a free-living 
mycobacterium and therefore could just be ubiquitously present in those milieus [84]. In 
Australia, possums have been demonstrated to develop Buruli ulcer and to harbor M. 
ulcerans in their excrement [93]. Equally, a number of wild and domestic animals including 
koalas, cats and dogs have been detected with M. ulcerans [94]. Mosquitoes as well have 
been detected with M. ulcerans in their salivary glands [95]. Several attempts to culture M. 
ulcerans from environmental samples have not yielded good results except for one successful 
isolation from an aquatic insect in Benin [96]. Research efforts to confirm environmental 
reservoirs have therefore proven futile so far [84]. 
With M. ulcerans detected in water, detritus soil, insects and animals, one would think 
that transmission would occur either through thorough inoculation of the bacteria via 
abrasions on the skin, via insect of water bugs or mosquitoes playing a vector role [95] or 
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through contacts with affected animals (zoonotic transmission) [93]. All of these suggested 
modes of transmission remain hypothetical to date [84]. 
It is important to acquire and gain new knowledge on the reservoir for M. ulcerans and 
understand its mode of transmission, in order to develop primary prevention strategies for 
Buruli ulcer. Despite considerable research efforts, no convincing explanation of infection 
with the disease has been defined, leading to the assumption of existence of multiple modes 
of transmission [84]. This leaves control programmes only with the option of secondary 
prevention that relies on early case detection and prompt and adequate treatment with 
recommended antibiotics.  
1.3.4 Pathogenesis 
There is abundant literature as to the fact that mycolactone, a macrolide polyketide 
produced by M. ulcerans is responsible for its virulence [97, 78, 98]. At the point of 
infection, M. ulcerans produces an extracellular matrix (ECM) composed of proteins, 
carbohydrate, lipids as well as the polyketide toxin, mycolactone. It is this ECM that helps 
the M. ulcerans to adapt and then colonize its new location be it in the environment or in the 
infected individual [78]. Of all the elements of the ECM, mycolactone has been identified as 
the sole element responsible for Buruli ulcer pathogenesis [97].  
Mycolactone has immunosuppressive and cytotoxic properties and uses these to subdue 
its environment and cause disease [99]. Torrado and colleagues had indicated that 
mycolactone inhibited the production of Tumor Necrosis Factor (TNF) in macrophages [98].  
Hall and colleagues have shown the mechanism by which this happen. Mycolactone actually 
inhibits the production of lipopolysaccharide (LPS)-dependent proinflammatory mediators 
and the translation of (TNF), Interleukin 6 (IL6) and Cox-2 mRNA; as well as inhibits the 
translocation of inflammatory proteins through the endothelial reticulum (ER) in 
macrophages [100]. As a result, M. ulcerans is not phagocytosed by the macrophage. The 
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mechanism of mycolactone-mediated cytotoxicity begins with an increase in intracellular 
calcium, and then an arrest of the G0/G1 phase of the cell cycle and eventually cell death 
[99]. The cytotoxic activity of mycolactone is not cell-specific, and this is why all tissue cells 
around the point of infection of M. ulcerans become necrotic and eventually slough off. This 
also explains the painlessness of the Buruli ulcer lesion, as the Schwann cells forming the 
myelin sheath of nerve fibers are also damaged around the BU lesion [101]. The painless 
nature of the initial BU lesion has been responsible for delay in seeking treatment in some 
patients [72]. 
Each of the two M. ulcerans lineages: that is the classical lineage (the African and the 
Australian strains); and the ancestral lineage, (the Chinese, the fish and the frog strains) [82, 
81], produces a different variant of mycolactone with variable potencies (See Table 1.5) [83]. 
Table 1.5: variants and potency of mycolactone produced by M. ulcerans strains. 
M. ulcerans lineage Strain Mycolactone 
variant 
*Potency 
Classical African A/B ++++ 
Australian A/B ++++ 
C + 
Ancestral Chinese D + 
Fish E + 
Frog F ++ 
*adapted from study published by Scherr et al [83]. 
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1.3.5 Diagnosis 
i. Clinical features: 
Clinically, Buruli ulcer has two main clinical forms: the non-ulcerative and the ulcerative 
forms. A detailed description of the clinical forms is given in Chapter 4 of this thesis. 
The non-ulcerative forms may either be papules, nodules, plaques or oedematous 
lesions. Papules are painless and raised lesions less than 1cm in diameter. A nodule is a 
painless, palpable but firm lesion measuring 1-2 cm in diameter, situated in the subcutaneous 
tissue and attached to the skin. The skin over the lesion may be itchy and hypo-pigmented. A 
plaque is a painless, indurated, elevated and well-demarcated lesion of more than 2cm in 
diameter. The skin over the lesion is often hypo-pigmented. The Oedematous lesion is a 
diffuse, firm and non-pitting swelling, with poorly defined borders, which may be painful, 
and may exhibit colour change of the affected skin, involving part of or an entire limb, or 
other parts of the trunk [67]. Each of the non-ulcerative forms will eventually open up to 
form an ulcer (Fig 1.15). 
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Fig 1.15. Clinical forms of Buruli ulcer 
 
Ulcerative forms: are initially painless skin lesions characterized by necrotic centres 
with cotton wool-like fibrin tissue, undermined edges, and indurated/oedematous skin. The 
ulcers may become painful in case of secondary infection with other bacteria.  
ii. Clinical diagnosis 
Medical history and physical examination of the patient presenting with a suspected BU 
lesion are very important, and when carried out by a well-trained health worker, is often 
sufficient to make the diagnosis. However, some epidemiological considerations are essential 
to bear in mind: If the patient lives in a BU endemic area or has visited such an area, it will be 
important to suspect every indolent papule, nodule, plaque, oedema or ulcer as Buruli ulcer 
until proven otherwise [67]. About 60% of cases occur in children below 15 years of age, 
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with no marked sex difference. About 90% of lesions occur on the limbs with 60% on the 
lower limbs. Ulcers are peculiar in that their edges are undermined, with a cotton wool-like 
necrotic tissue at the base.  
iii. Laboratory diagnosis 
Laboratory diagnosis of Buruli ulcer actually employ four methods namely microscopy 
after a Ziehl-Neelsen stain for evidence of acid-fast-bacilli (AFB), histopathological method 
where biopsy tissue cuts are stained for evidence of AFB and characteristic tissue changes, 
PCR to detect the M. ulcerans specific insertion sequence IS2404, and culture of M. ulcerans 
from clinical samples [102, 103]. 
Of the four diagnostic methods, only one, microscopy following a Ziehl-Neelsen stain 
can be practiced at the peripheral health care level. The other three tests are usually available 
only at the reference laboratory. Despite the advantage of being the closest to point of care 
test for BU at the moment, the ZN technique has a sensitivity of <60% and cannot 
differentiate between the pathogenic mycobacteria that cause disease in man namely M. 
tuberculosis, M. leprae, and M. ulcerans [103]. This situation poses a problem in areas where 
there is co-endemicity for more than one mycobacterial disease. In Chapter 5 of this thesis, 
we present a case of cutaneous tuberculosis that was mistaken for Buruli ulcer in Bankim 
Cameroon because of clinical resemblance and local laboratory confirmation by ZN, but later 
discovered to be negative by PCR months later. 
The other 3 diagnostic methods require sophisticated laboratory with highly skilled 
personnel and expensive equipment. For this reason, they reserved for the reference 
laboratory. PCR is the gold-standard in the diagnosis of Buruli ulcer [102] because of its high 
sensitivity and specificity, and can be performed with samples from swabs, fine needle 
aspiration or biopsy, and results rendered relatively rapidly [103].  Despite the usefulness of 
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PCR as a diagnostic test, it is limited in that it cannot determine the viability of M. ulcerans 
and therefore is not suitable for monitoring of treatment success [102]. Cultures are 
considered the only valid test for confirmation as they detect viable bacteria. However, 
cultures are not a suitable diagnostic test because they take long (6-12 weeks) for the results 
to be rendered, and the sensitivity is low [102, 103]. Histopathological methods have high 
sensitivity and can be used for establishment of differential diagnosis but require an invasive 
procedure [103].  
For BU control, the microscopy following ZN staining is recommended for use at the 
local peripheral health care level, while PCR is recommended for confirmation of diagnosis. 
The World Health Organization requires that at least 70% of clinical BU cases are confirmed 
by PCR [104]. 
1.3.6 Treatment of Buruli ulcer 
Before 2004, the treatment of Buruli ulcer was mainly surgical, entailing large excisions 
of skin around the lesion. The surgical treatment lead to lengthy hospital stay and high cost 
[105] but also registered high relapse rates of between 16% to 28% [106]. Following 
encouraging results from clinical trials on drug treatment of Buruli ulcer, the World Health 
Organization in 2004, gave recommendations for antibiotic treatment of Buruli ulcer [107]. 
According to these guidelines, Buruli ulcer patients were to be treated with a combination of 
rifampicin and streptomycin for a period of 8 weeks. This specific antibiotic treatment was to 
be associated with surgery, only after the antibiotics had been given for a specified period of 
time depending on the clinical form of the disease [107]. The implementation of these 
guidelines in the endemic countries gave very satisfactory results as the relapse rates dropped 
to 0-2% and the need for surgery was reduced by 50% [108, 109]. Issues with the rifampicin 
and streptomycin combination therapy related to daily painful injections of streptomycin for 8 
weeks and the need for skilled personnel to administer the treatment, pushed for continued 
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search for an all oral drug treatment. Successful outcomes of trials and observational studies 
with the use of all oral combinations of rifampicin and clarithromycin in Africa [110, 111], 
rifampicin and clarithromycin, and rifampicin and fluoroquinolones in Australia [112, 113] 
were registered. 
 Based on these evidences and in anticipating the conclusive outcome of a large scale 
randomized control trial of rifampicin-streptomycin versus rifampicin-clarithromycin that 
was in progress in Ghana and Benin, the World Health Organization put forth a revised 
treatment guidelines of Mycobacterium ulcerans disease (Buruli ulcer) for health workers in 
2012 [114]. According to these new guidelines, while maintaining the standard treatment of 
rifampicin-streptomycin combination, an all-oral treatment of rifampicin at 10mg/kg body 
weight daily by mouth for 8 weeks combined with clarithromycin at 7.5mg/kg body weight 
by mouth twice daily for 8 weeks was instituted. At the time, the recommended oral 
treatment was limited to pregnant women and for BU patients in Australia and French 
Guiana, but today it has been generalized to all BU patients. The drug treatment could be 
associated with surgery if required, and in this case only after 8 weeks of antibiotic treatment 
[114]. 
1.3.7 Control 
The control of Buruli ulcer is carried out by national control programmes, with the 
support of development partners, based on the recommendations of the World Health 
Organization as contained in the 57th World Health Assembly resolution WHA57.1 on the 
surveillance and control of Buruli ulcer [115], and in the Cotonou Declaration on Buruli ulcer 
[116], adapted to country levels.  
The major objective of BU control is to reduce suffering, disability and socioeconomic 
burden. The major strategies include early case detection and adequate treatment. The key 
components of the control strategy are: 
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− Early case detection; information, education and communication: training of 
community volunteers at the community level 
− Health system strengthening: including infrastructure, equipment and logistics: 
training of health workers, standardized recording and reporting using BU 01 and BU 
02 forms. 
− Standardized case management: including laboratory confirmation (ZN and PCR), 
specific antibiotic (rifampicin and clarithromycin or streptomycin) treatment; surgery; 
prevention of disability (POD)/physical rehabilitation 
− Cross-cutting component: supervision, monitoring and evaluation, advocacy, social 
mobilization, resource mobilisation, partnerships, and research. 
As indicated earlier, we describe the National Buruli ulcer Control Programme 
(NBUCP) in Cameroon from creation in 2002 and its evolution through to 2014, based on 
reports and data from 2001 to 2014 in Chapter 4 of this thesis. We also highlight the 
challenges faced by the NBUCP and then make recommendations for the way forward.  
 
1.4 Yaws 
Yaws belongs to a small group of chromic bacterial infections known as endemic 
treponematosis, all caused by the sub species of Treponema pallidum. Members of the group 
include yaws caused by Treponema pallidum pertenue, endemic syphilis (bejel) caused by 
Treponema pallidum endemicum, and pinta caused by Treponema pallidum carateum [117, 
118].  
In 1948 when the World Health Organization was created, the incidence of 
treponematoses was estimated at about 50 million cases of yaws, 20 million cases of venereal 
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syphilis, 1 million cases of endemic non-venereal syphilis and a smaller number of pinta 
[119]. It had a worldwide distribution, mainly along the tropics cutting from the Americas 
through Africa to Asia; but also, in parts of Eastern Europe and the Middle-East, involving 
over 71 countries (Fig 1.16) [117, 119] 
 
Fig 1.16. Global distribution of endemic treponematosis in the early 1950s [117]. 
 
Following the discovery of penicillin in the 1940s and its proven effectiveness in the 
treatment of treponematoses, and most importantly its availability after the second world war 
[119], the World Health Organization and UNICEF jointly led a yaws eradication campaign 
between 1950 and 1970 [120, 117]. Some 45 countries were supported by WHO and 
UNICEF, and by 1965, 152 million people had been examined, of whom 46 million clinical 
yaws cases and contacts, as well as latent yaws cases were treated with penicillin [120]. At 
the end of the campaign, the global burden of yaws was reduced by 95% to about 2.5million 
cases [118]. Only few foci remained in Africa, Latin America and Asia (Fig 1.17). 
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Fig 1.17. Global distribution of the endemic treponematoses in the early 1980s. [121]. 
During the yaws eradication campaign, primary health care systems were being 
established and/or strengthened in endemic areas. At the end of the campaign, the 
responsibility of completing the job, that is clear the remaining 5% was shifted to the 
established primary health care system [118]. At the same time, the vertical 
programmes/structures that achieved the massive reduction in the incidence were dismantled 
[122, 118]. This resulted in discontinued surveillance, waning of commitment and resources, 
with an obvious consequence of yaws resurgence in the late 1970s in West Africa, Asia and 
the Pacific [117]. 
The yaws resurgence was also confirmed in Cameroon in 1970 among the pygmies in the 
South and the East regions of the country [123]. Despite this confirmation, and the call by the 
31st World Health Assembly resolution, WHA31.58, on countries to implement integrated 
treponematoses control programmes with focus on active surveillance [124], surveillance was 
never reinforced in Cameroon until after 2009, when the National Yaws, Leishmaniasis, 
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Leprosy and Buruli ulcer Control Committee was created. Prior to the creation of the control 
committee, two yaws outbreaks had been reported in 2007 and 2008 among the pygmies in 
the East Region of the country.  
Within the framework of establishing the Yaws programme activities, we set out to 
confirm yaws endemicity in the Lomié Health District in the East Region of the country in 
late 2009. The outcome of this survey is presented in Chapter 6 of this thesis. A rapid 
assessment of the capacity of health personnel at the primary health care level to clinically 
diagnose yaws and treat it revealed total ignorance of this condition among them. This was 
further explained by the fact that yaws was absent from the training curricular of the 
professional schools for health personnel, as well as that of medical schools in Cameroon. To 
fill this gap and in addition to organizing training workshops for health personnel working in 
endemic areas, we have also written a book chapter on yaws, which should serve as training 
material for medical students and other health personnel, which is presented in Chapter 7 of 
this thesis. 
 
 
 
 
 
 
 
 
40 
 
Earnest Njih Tabah  Skin NTDs in Cameroon: the need for integrated control and elimination 
  
1.5 Goal  
For the PhD project, we set out primarily to evaluate the burden of Neglected Tropical 
Diseases of cutaneous expression in Cameroon, establishing their trends in recent years and 
determining challenges facing their control or elimination. Based on the results, the 
secondary goal was to make recommendations for improvement of the control of these 
diseases. 
 
1.6 Objectives 
i. To evaluate the burden of leprosy in Cameroon from 2000 to 2014, and the 
challenges facing the National Leprosy Programme. 
ii. To assess community knowledge, perceptions and attitudes regarding leprosy in high 
endemic rural health districts. 
iii. To evaluate the burden of Buruli ulcer in Cameroon from 2001 to 2014, the impact 
of the National Buruli Ulcer Programme and the challenges facing the programme. 
iv. To raise awareness on issues related to differential diagnosis of some mycobacterial 
diseases in co-endemic areas. 
v. To confirm the resurgence of Yaws in Cameroon after its eradication in the 1970s. 
vi. To conduct a review of the literature on stigma in neglected tropical diseases 
affecting the skin (and the nervous system). 
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2.1 Abstract 
Background: Cameroon achieved the elimination target of leprosy in 2000 and has 
maintained this status ever since. However, a number of health districts in the country 
continue to report significant numbers of leprosy cases. The aim of this study was to assess 
the burden of leprosy in Cameroon from 2000 to 2014. 
Methods: We obtained and analyzed using the new leprosy burden concept of analysis, 
leprosy surveillance data collected between 2000 and 2014 from the National Leprosy 
Control Programme.  
Principal findings: Cameroon achieved leprosy elimination in 2000, registering a prevalence 
rate of 0.94/10,000 population. The prevalence rate dropped further to reach 0.20/10,000 
population (78% reduction) in 2014. Similarly, the new case detection rate dropped from 
4.88/100,000 population in 2000 to 1.46/100,000 population (85.3% reduction) in 2014.  All 
10 regions of the country achieved leprosy elimination between 2000 and 2014; however, 10 
health districts were still to do so by 2014. The number of high-leprosy-burden regions 
decreased from 8 in 2000 to 1 in 2014. Seven and two regions were respectively medium and 
low-burdened at the end of 2014. At the health districts level, 18 remained at the high-
leprosy-burdened level in 2014. 
Conclusion: The leprosy prevalence and detection rates as well as the overall leprosy burden 
in Cameroon have dropped significantly between 2000 and 2014. However, a good number 
of health districts remain high-leprosy-burdened. The National Leprosy Control Programme 
should focus efforts on these health districts in the next coming years in order to further 
reduce the burden of leprosy in the country. 
Key words: 15-year; leprosy burden in Cameroon 
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2.2  Author summary 
Cameroon achieved the elimination of leprosy in 2000, however, a number of areas in 
the country continue to report high numbers of cases. We conducted this study to assess the 
burden of leprosy in Cameroon from 2000 to 2014. We obtained and analysed leprosy data 
for this period from the National Control Programme. After elimination in 2000, the leprosy 
prevalence rate continued dropping, to reach 0.20/10,000 population (78% reduction) in 
2014. Similarly, the new case detection rate dropped to 1.46/100,000 population (85.3% 
reduction) in 2014.  All 10 regions of Cameroon achieved leprosy elimination by 2014; 
however, 10 health districts were still to do so. Using the new leprosy burden concept of 
analysis, the number of high-leprosy-burden regions decreased from 8 in 2000 to 1 in 2014, 
meanwhile 18 health districts remained high-leprosy-burdened at the end of 2014. In 
conclusion, leprosy prevalence and detection rates as well as the overall leprosy burden in 
Cameroon have dropped significantly between 2000 and 2014. However, a good number of 
health districts remain high-leprosy-burdened. The National Leprosy Control Programme 
should focus efforts on these health districts in the next coming years in order to further 
reduce the disease burden in the country. 
2.3 Introduction 
Leprosy is the oldest disease known to humanity, as recent genomic studies have 
traced Mycobacterium leprae, its causative agent, along human dispersal in the past 100,000 
years [1]. It affects peripheral nerves, the skin and mucosa of the upper respiratory pathways 
[2]. Transmission is believed to be through nasal droplets or prolonged skin contact with an 
untreated patient, however, the exact mode of transmission is still unclear [3; 4]. Untreated 
patients or those diagnosed late would develop irreversible disabilities and disfiguring 
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complications. These physical complications associated with socio-cultural construction of 
leprosy are responsible for stigma and social exclusion of victims [5; 6].  
 Effective control of leprosy only began in the 1940s with the discovery of dapson [6; 
7]. The dapson mono-therapy was replaced by multi-drug therapy (MDT) in the early 1980s 
[8; 7]. Furthermore, a simplified classification as well as treatment regimens for each class was 
established, so that patients with 1-5 lesions were classified as paucibacillary (PB) leprosy and 
were treated for six months. Those with 6 or more lesions were classified as multibacillary 
(MB) and treated for 12-24 months, and subsequently for 12 months [9; 10; 11].  
The results of MDT implementation were very encouraging, with a relapse rate of <1% 
and a remarkable drop in global leprosy prevalence from 5.37 million registered cases in 1985 
to 3.74 million in 1990 [12]. These developments led the World Health Assembly (WHA) to 
adopt a resolution (WHA 44.9) in 1991, to eliminate leprosy as a public health problem by the 
year 2000, defining elimination as a leprosy prevalence rate of <1 case per 10,000 population 
[13].  
At the end of 2000, leprosy elimination was achieved globally and in107 countries 
(including Cameroon) out of 122 countries that were considered endemic in 1985 [14; 15].  
After achievement of leprosy elimination in Cameroon in 2000, the objectives of the 
National Leprosy Control Programme (NLCP) were focused on consolidating the status at the 
national level and to further eliminate the disease at sub-national levels. However, some health 
regions and health districts (HD) have continued to report significant numbers of cases [16]. 
Furthermore, the declaration of elimination has led to significant reduction in resource 
allocation for leprosy control activities in the country. 
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The objective of this study was to assess the leprosy burden in Cameroon in the post-
elimination era from 2000-2014, using data from routine reporting available at the NLCP, and 
to make recommendations for acceleration of its elimination at sub-national levels.  
2.4 Materials and Methods 
We obtained and analysed routine leprosy surveillance data of 2000 to 2014 from the 
NLCP. Throughout the period, patients suspected of leprosy were confirmed by establishing 
the presence of one or more of the following three cardinal signs: hypo-pigmented or reddish 
skin patch with definite loss of sensation; an enlarged peripheral nerve trunk, with loss of 
sensation and/or weakness of muscles supplied by that nerve; and the presence of acid-fast 
bacilli in a slit skin smear on microscopy [11].  A patient case record file (CRF) was opened 
for each patient and information was also registered in a local facility treatment register 
(FTR). Patients were classified and treated based of the number of skin lesions as specified 
above [11]. A positive skin smear classified the patient as MB regardless of the number of 
skin lesions.  
Routinely, data were compiled from FTRs and aggregated into the HD leprosy 
register (DLR) from which a statistical report was drawn using a standard reporting form and 
transmitted to the regional level. Each region in turn transmitted on a quarterly basis an 
aggregate of district reports to the NLCP. Reports from the regions were captured at the 
national level electronically using Microsoft Excel spread sheets.  
For the purpose of this review, annual statistical reports of the ten regions and 181 HD 
of Cameroon, available at the NLCP were reviewed. The annual statistical reports were 
summaries of leprosy cases registered each year per HD, providing information for the 
calculation of the different leprosy elimination indicators [17]. Each regional annual 
statistical report was cross-checked with HD statistical reports transmitted to the regions. 
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Furthermore, for each region, statistical reports from a sample of HD were compared with 
data in their respective DLR for quality assurance.  
The national leprosy burden analysis was based on the leprosy elimination indicators 
published by The International Federation of Anti-Leprosy Associations (ILEP) [17]. 
Accordingly, for each year, the point prevalence and point prevalence rate at the end of the 
year per 10,000 population, the number of cases detected and new case detection rate 
(NCDR) per 100,000 population were calculated. Among new cases detected, the MB 
proportion; the child (0-14 years of age) proportion; the grade 2 disability (G2D) proportion; 
the G2D rate per 100,000 population; the female proportion; and the point prevalence/new 
case detection (P/D) ratio were also calculated. Population estimates of regions and HD used 
for the calculation of indicators were based on the 2005 general population and housing 
census report of Cameroon [18]. Trend analyses of the key indicators for the period 2000-
2014 were done using Microsoft Excel. A linear regression analysis of each indicator curve 
was performed using the Statistical Package for Social Sciences (SPSS) version 20, and the 
regression coefficient for each curve was tested for statistical significance in the variation of 
the curve. 
 The WHO Regional Office for Africa (Afro) recently developed a new indicator 
called the “Leprosy Burden Score (LBS)” for assessing leprosy burden at national and sub-
national levels (Table 2.1) [19].  
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Table 2.1: Scale for the leprosy burden score (LBS) assessment. 
 
The LBS is a composite indicator, involving nine leprosy elimination indicators [17]. 
Depending on the cut-off points (see Table 2.1), each individual indicator is graded into High 
= Red (score =2), Medium = Yellow (score =1), and Low = Green (score =0). The sum total 
of the individual indicator scores, the LBS, is in turn graded into three levels of: High = Red 
(score =2) when LBS equal 5 or more, Medium = Yellow (score =1) when LBS is between 3 
and 4, and Low = Green (score =0) when LBS is 2 and below.  
LBS were determined for each region and HD of Cameroon at five-year intervals 
from the year 2000 (2000, 2005, 2010, and 2014) and used to categorize them into high, 
medium or low-leprosy-burdened. Regional and HD leprosy burden trend maps from 2000 to 
2014 were then established using the ArcGIS software (Environmental Systems Research 
Institute, Redlands, USA). 
Ethics statement 
This study was instructed by the Cameroon Ministry of Public Health Decision No 
0486/D/MINSANTE/CAB and was approved the National Ethics Committee of Cameroon 
through the authorization No 172/CNE/SE/2011. All data were anonymized and 
confidentiality was strictly respected in the data handling and analysis. 
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Limitations 
There were missing data in some HDs for some of the years under review. A number 
of report files were damaged and some reports were incompletely filled. However, the 
proportion of missing data was not significant (about 3%) and did not influence the quality of 
the review. 
2.5 Results 
Leprosy trend in Cameroon from 2000 to2014: 
Data was available for all the years from 2000 to 2014 except for information on 
females among new cases, which was available only from 2005.  We confirmed that 
Cameroon achieved leprosy elimination at the end of 2000, recording a point prevalence rate 
of 0.94/10,000 population.  
The point prevalence rate declined from 0.94/10,000 in 2000 to 0.20/10,000 
population in 2014 (P<0.001) (Table2.2 and Fig 2.1). This decline accounted for 78% 
reduction in the prevalence rate, with the largest reduction, 64.9%, occurring between 2000 
and 2005.  From 2006 to 2014, the annual leprosy prevalence rate was rather stagnant. A 
similar pattern was followed by the leprosy NCDR, with a decline from 4.88/100,000 
population in 2000 to 1.46/100,000 population in 2014 (P = 0.018) (Table 2.2 and Fig 2.1), 
accounting for an 85.3% reduction. The largest reduction occurred between 2002 and 2007, 
followed by a relative stagnation in the NCDR from 2008 to 2014.Two peaks in annual 
NCDR were however noticed in 2002 and 2006 with annual NCDR of 9.96/100,000 and 
4.29/100,000 population respectively.  
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Fig 2.1: Trends in the leprosy point prevalence rate and NCDR from 2000 – 2014. The point prevalence rate declined 
from 0.94/10,000 in 2000 to 0.20/10,000 population in 2014 (P<0.001) accounting for a 78% reduction. Similarly, the annual 
NCDR declined from 4.88/100.000 population in 2000 to 1.46/100.000 population in 2014 (P = 0.018) accounting for an 
85.3% reduction.  However, two peaks in annual NCDR were noticed in 2002 and 2006 with annual NCDR of 9.96/100,000 
and 4.29/100,000 population respectively 
 
Among the new cases of leprosy detected, the proportion of MB cases was relatively 
high throughout the 15-year period investigated, with an increasing trend from 62% in 2000 
to 87% in 2014 (P = 0.035). The proportion of child cases generally remained low between 
10% and 20% except for the year 2011 when a peak of 25% was observed (P = 0.054). The 
proportion of new cases with G2D was stable at an average of 6% (P = 0.156). The female 
proportion was fluctuating, with an overall increasing trend from 26% in 2005 to 43% in 
2014 (P = 0.244) (Table 2.2 and Fig 2.2).  
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Fig 2.2: Trends in leprosy detection indicators in Cameroon from 2000 to 2014. The MB proportion was high ranging 
from 62% to 87%. The G2D proportion remained below 10% throughout the 15-year period. Although the child proportion 
generally ranged between 10% and 20%, there was a rising tendency from 2008. The Female proportion was fluctuating 
though with a general rising tendency to reach an acceptable level of 40%.  
 
Between 2000 and 2014, six regions witnessed more than 50% reduction in registered 
prevalence with the Far-north and the North-west leading with 96% and 86% reduction 
respectively (Table 2.3). From 2000 to 2005, six regions namely the Adamawa, East, Far-
north, North, North-west and South-west accounted for over 70% of new leprosy case 
detection in the country. After 2005, four of these regions excluding the Far-north and North-
west reported over 70% of new case detection and also registered some of the highest 
proportions of child and G2D cases in the country (Table 2.3).  
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Table 2.3: 5-year trend in selected leprosy elimination indicators by region from 2000 to 2014. 
 
Progress towards the elimination of leprosy at regional and health district levels: 
Out of the 10 regions in Cameroon, the number of leprosy endemic regions, with 
point prevalence rates of 1 or more per 10,000 population, decreased from 5 in 2000 to 0 in 
2014 (Fig 2.3A) meanwhile the number of endemic HDs decreased from 53 to 10 over the 
same period (Fig 2.3B). Table 2.4 lists the remaining 10 leprosy endemic HDs in Cameroon. 
 
Fig 2.3: Trends in the number of leprosy endemic regions and health districts in Cameroon from 2000 to 
2014. Panel A shows the trend in the number of regions of Cameroon, out of a total of 10 regions, with a point 
prevalence rate per 10,000 population of more than 1. Panel B shows the trend in the number of HDs of 
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Cameroon, out of a total of 181 HDs, with a point prevalence rate per 10,000 population of more than 1. At the 
end of 2014, leprosy elimination was achieved in all 10 regions; and is still to be achieved in 10 HDs. 
 
Table 2.4: Health Districts which remained hyper endemic for leprosy at the end of 2014. 
Region Health District Point prevalence rate per 
10.000 population 
Adamawa Ngaoundere Rural 2.29 
East Abong Mbang 2.21 
Garoua Boulai 1.05 
North Poli 9.40 
North-west  Benakuma 2.38 
South-west  Nguti 3.65 
Mundemba 3.25 
Ekondo Titi 1.36 
Akwaya 1.25 
West Galim 1.21 
 
Progress towards the target of the “Enhanced global strategy for further reduction of 
leprosy burden (2011 – 2015)” in Cameroon: 
At the national level the trend in G2D rate decreased slightly from 0.133/100.000 
population in 2010 to 0.105/100.000 population in 2014 (P = 0.747) (Fig 2.4), constituting a 
drop of 21%.  
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Fig 2.4: Trend in G2D rate per 100.000 population. The G2D rate decreased slightly from 0.133/100.000 
population in 2010 to 0.105/100.000 population in 2014, constituting a 21% reduction.  
  
 
Trend in leprosy burden with-respect-to the new Leprosy Burden Score: 
A 5-year-interval trend analysis of leprosy burden by region (Fig 2.5), revealed that in 
the year 2000, eight regions were high-leprosy-burdened and one medium-burdened. By 2005 
the number of high-burdened regions decreased to 6 and then to 5 in 2010, and further to 1 in 
2014.   
 
Fig 2.5. Five-year-interval trend in leprosy burden map of Cameroon by region from 2000 to 2014. In 
2000, 8 out of 10 regions in Cameroon were high-leprosy-burdened and one medium-burdened. By 2005 this 
number decreased to 6 and then to 5 in 2010, and further to 1 in 2014. 
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At the HD level, (Fig 2.6) the number of high-leprosy-burdened districts stagnated at 
68 and 69 between 2000 and 2005, and then dropped to 49 in 2010 and further to 18 in 2014. 
During the same period, the number of medium-burdened districts also witnessed a drop from 
31 in 2000, to 20 in 2014. The decrease in the number of both high and medium-burdened 
districts was gained by low-leprosy-burdened districts that rose from 82 in 2000 to 143 in 
2014. 
 
Fig 2.6. Five-year-interval trend in leprosy burden map of Cameroon by health district from 2000 to 
2014. The number of high-leprosy-burdened districts dropped from 68 in 2000 to 18 in 2014. During the same 
period, the number of medium-burdened districts also witnessed a drop from 31 to 20. The reduction in the 
number of both high and medium-burdened health districts was gained by low-leprosy-burdened districts that 
rose from 82 in 2000 to 143 in 2014. 
 
 
2.6 Discussion 
In 1991, The WHA passed a resolution to eliminate leprosy as a public health 
problem by the year 2000. The yard stick for measuring elimination was the attainment by 
countries of a leprosy prevalence rate below 1 per 10 000 population [13]. At the end of 
2000, the WHO announced the elimination of leprosy as a public health problem globally and 
in 107 out of 122 countries that were considered endemic in 1985 [14]. Despite elimination at 
the national level, leprosy has remained a public health problem at sub-national levels in 
many countries [7; 20], and many other concerns were unresolved [21; 22]. 
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 Cameroon achieved leprosy elimination at the end of 2000 [23]at the national level 
and has maintained this status to date. The results of our analyses show trends in the 
prevalence and detection rates. These declined sharply between 2000 and 2007 and then 
became rather stagnant from 2008 to 2014. These trends match with those of the WHO 
African Region, where the stagnation was explained by significant increase in case detection 
in six countries. [19]. The stagnation in the prevalence and new case detection in Cameroon 
is attributed to high numbers of new leprosy cases being detected in four regions namely the 
Adamawa, East, North, and South-west (Table 2.3). 
 Generally, leprosy transmission in Cameroon between 2000 and 2014 has been 
moderate considering that the proportion of children among new cases ranged from 10% to 
20% over this period. However, high transmission occurred in the Adamawa, East and South-
west regions where child proportions above 20% were often registered (Table 2.3). The 
proportion of G2D among new leprosy cases was as desired, below 10% throughout the 
period under review. This places Cameroon in the low-disability-burdened countries [19]. 
The proportion of females among new leprosy cases has gradually risen to attain an 
acceptable level of more than 40% implying that more and more affected women are getting 
access to leprosy care [19]. The high and rising proportion of MB among new leprosy cases 
could be perpetuating transmission of the disease in the population, as MB cases constitute 
the main source of infection [24; 25; 26] (Fig 2.2). The reduced number of skilled personnel 
in leprosy diagnosis at the primary health care level, and the passive mode of leprosy case 
detection in Cameroon may explain the delayed diagnosis and consequently, high MB 
proportion. There is need for training of operational level staff, as well as the reinforcement 
of leprosy courses in the curricular of training schools for health personnel and faculties of 
medicine in the country. 
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After the achievement of leprosy elimination at national level in 2000 efforts were 
focused towards eliminating at sub-national levels. Five out of 10 regions were still endemic 
with a prevalence rate above 1 per 10.000 population in 2000 (Fig 2.3A). This number 
dropped to one in 2010, with the Southwest being the only region with a prevalence of 1 per 
10.000 population. By 2014 all the regions achieved elimination. With regards to HDs (Fig 
2.3B), those that were still to eliminate leprosy, the number dropped from 53 in 2000 to 10 in 
2014. The remaining high endemic HDs at the end of 2014 were concentrated in the 
Southwest, East, Adamawa, North and West regions (Table 2.4). Poli HD in the North region 
was the most endemic in the whole country, with a prevalence rate of 9.40 per 10.000 
population in 2014, followed by Mundemba and Nguti in the South-west, with 3.25 and 3.65 
per 10.000 population respectively.  
The pattern in leprosy prevalence reduction between 2000 and 2014 varied across the 
regions, sometimes with adjacent regions witnessing totally different patterns. For instance, 
the Far-north region had a 6-fold reduction in leprosy prevalence compared to the adjacent 
North region, and the North-west a 2-fold reduction compared to the Southwest region (Table 
2.3). These disparities could be attributed to two major reasons: first, the update of leprosy 
registers in all ten regions following recommendations of the third meeting of the Technical 
Advisory Group on Leprosy Elimination [27], allowed the removal of patients unduly 
maintained in leprosy registers between 2001 and 2004. The highest numbers of such patients 
were removed from registers in the Far-north and North-west regions.  Secondly, geo-cultural 
reasons could be responsible for patterns in the North and the South-west region. An active 
leprosy case finding by the NLCP in Poli HD, detected most of the cases from among the 
Koma people [28] who reside in the enclaves of the Atlantika Mountains on the border 
between Cameroon and Nigeria. These are indigenous people with a peculiar lifestyle (little 
or no proper clothing, poor personal skin hygiene, and probably overcrowding) that may be 
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favourable for the transmission of leprosy. In the South-west region, most of the reported 
cases come from Akwaya, Ekondotiti, Mundemba, Mbonge, Nguti HDs which are very 
enclaved HD and where some tribal people believe leprosy is a spell and can only be handled 
by traditional healers. These beliefs may affect health-seeking behaviours and consequently 
contribute to the high burdens recorded in these areas. 
In launching the “Enhanced Global Strategy for Further Reducing the Disease Burden 
due to Leprosy (2011-2015)” [29], a new indicator, the G2D rate per 100.000 population, was 
introduced for monitoring progress in the implementation of the strategy. A targeted 35% 
reduction in G2D rate by 2015 was set, taking as baseline the rate in 2010 [29]. Between 
2010 and 2014, Cameroon achieved a 21% reduction in the G2D rate (Fig 3) below the 
desired level.  
With the achievement of leprosy elimination by all countries, the WHO recently 
developed a new method for the assessment of leprosy burden [19], and its use for 
categorising countries and sub national levels as high, medium or low leprosy burdened. The 
new leprosy burden assessment takes into account not only the prevalence rate but also eight 
other indicators (Table 2.1). Using this concept to categorise regions and HDs and to evaluate 
the leprosy burden trend from 2000 to 2014, we concluded that a lot of progress has been 
made in reducing leprosy burden at both regional and HD levels in Cameroon (Fig 2.5 and 
2.6). In 2000, despite elimination of leprosy at national level, eight regions were still highly 
burdened with leprosy. The situation improved significantly, as by 2014 only one region 
remained high-leprosy-burdened. Three regions namely East, North-west and South were 
unstable in their progression from high towards low-leprosy burden. This is probably 
explained by the degradation of leprosy services in these regions, following the attrition of 
resources for leprosy elimination activities (Fig 2.5). Despite the apparent improvement in the 
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reduction of leprosy burden, the NLCP must work hard to bring all the regions to low-
burdened, given that seven regions remain medium-leprosy-burdened.  
The leprosy burden analysis at the HD level in this study has led to the identification 
of specific hotspots within the regions (Fig 2.6) although there has also been a lot of 
improvement at this level. The number of high-leprosy-burdened HD has dropped from 68 in 
2000 to 18 in 2014 (Fig 2.6). The 18-remaining high-burdened HD are mainly concentrated 
in the Adamawa, East, North and South-west Regions of the country. These are areas where 
the NLCP should focus efforts in the coming years, to further optimize leprosy control in 
Cameroon.  
Despite the positive results registered in Cameroon in the post leprosy elimination era, 
further reduction of leprosy burden in the country is facing huge challenges.  After the 
achievement of leprosy elimination at national level in 2002, government and partner NGO 
commitments gradually faded away. There has been a reduction in financial and technical 
support from partners since 2005 to almost complete withdrawal in 2012. For this reason, the 
NLCP performance has been sub-optimal in essential components such as effective 
integration of MDT services into the primary health care, regular supervision, community-
based surveillance, capacity building and prevention of disability as required by the post 
elimination WHO strategies [29,30,31].  
The WHO lunched a roadmap for accelerating work to overcome the global impact of 
NTDs for the period 2012-2020 [32]. This roadmap was further endorsed in 2013 by the 66th 
WHA [33] and the 63rd WHO Regional Committee for Africa (WHO Afro) [34] respectively. 
Of the 17 NTDs considered in the roadmap, leprosy is being targeted for global elimination 
by 2020. The roadmap and subsequent WHA and WHO Afro resolutions urge national 
68 
 
Earnest Njih Tabah  Skin NTDs in Cameroon: the need for integrated control and elimination 
  
programmes, member states and support partners to more commitment so that NTD control 
efforts are sustained and set targets met by 2020. 
2.7 Conclusions: 
In Cameroon, the leprosy prevalence and detection rates have dropped significantly 
since 2000 but have been stagnating in the last years. Furthermore, the new concept of 
determining the leprosy burden by using the leprosy burden score, has unmasked problem 
areas that could not be determine by the prevalence rates alone and revealed alarming 
disparities of the total leprosy burden at sub-national levels. Thus, eighteen HDs of 
Cameroon have remained with a high leprosy burden in 2014 despite the long-acquired 
elimination status by the country. The NLCP should focus efforts on these HDs while 
monitoring the 20 medium burdened HDs as well. With improved government funding and 
more partner support, the NLCP objectives and the WHO targets can be met in all health 
districts of Cameroon by 2020. 
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Chapter 3 
Chapter 3 : Community knowledge, perceptions and attitudes regarding leprosy in rural Cameroon 
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3.1  Abstract 
Background 
 Although leprosy is one of the oldest diseases known to humanity, it remains largely 
misunderstood. Misconceptions about leprosy lead to stigma towards people with the disease. 
This study aimed at exploring the knowledge, perceptions and attitudes regarding leprosy in 
rural Cameroon. 
Methods 
We carried out a cross-sectional community survey of 233 respondents aged 15-75 years, free 
from leprosy, and living in two rural health districts of the South-west Region of Cameroon. 
A questionnaire designed to evaluate knowledge, perceptions and attitudes about leprosy was 
used. Binary logistic regression was used to determine independent predictors of negative 
attitudes. 
Results 
About 82% of respondents had heard about, and 64.4% knew someone with leprosy. 
Information on leprosy was mainly from community volunteers (40.6%), friends (38.0%), 
and the media (24%). Only 19.7% of respondents knew the cause of leprosy, and a 
considerable proportion linked it to a spell (25.3%), unclean blood (15.5%) and heredity 
(14.6%). About 72% knew that leprosy is curable and 86.3% would advise medical treatment. 
Attitudes towards leprosy patients were generally negative. Only 42% would shake hands, 
32.6% would share the same plate, and 28.3% and 27% respectively, would allow their child 
to play or marry a person with leprosy. Furthermore, only 33.9% approved of participation of 
leprosy patients, and 42.9% of their employment. Independent predictors of negative attitudes 
were: the belief that leprosy is a curse; is caused by a germ; and having seen a leprosy 
patient. The negative attitudes were dampened by: the beliefs that leprosy is a punishment, is 
hereditary and is due to poor personal hygiene. 
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Conclusion 
An awareness intervention using community volunteers and the media, with information 
on the cause of leprosy, its clinical manifestations and curability, and sensitization messages 
correcting the misconceptions and beliefs regarding leprosy, could improve the community 
knowledge and attitudes towards leprosy. This would ultimately contribute to the reduction of 
leprosy burden in the community. 
Key words: leprosy, knowledge, perceptions, attitudes, Cameroon. 
 
3.2 Author summary 
Leprosy is one of the oldest diseases known to humanity but remains largely 
misunderstood. This misunderstanding leads to stigma towards people with leprosy (PWL). 
We explored knowledge, perceptions and attitudes regarding leprosy among 233 community 
members in the South-west of Cameroon. Our respondents were very familiar with leprosy. 
Their information on leprosy was mainly from community volunteers, friends or from the 
media. Despite high familiarity, very few knew the cause of leprosy. A good proportion 
attributed it to curses, unclean blood, or heredity. However, most of them agreed that leprosy 
was curable and would advise medical treatment. Attitudes of community members towards 
PWL were generally negative. Very few of them would shake hands with, eat from the same 
plate, or allow their child to play with or marry a PWL. The main reasons for these negative 
attitudes were the beliefs that leprosy is a curse; is caused by a germ; and having seen a 
leprosy patient. An awareness campaign using community volunteers and the media, with 
information on the cause of leprosy, its clinical manifestations and curability could improve 
community knowledge and attitudes towards leprosy. This would ultimately contribute to the 
reduction of leprosy burden in the community. 
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3.3 Introduction 
Leprosy is one of the oldest diseases known to humanity and can be traced as far back 
as 100 000 years [1]. It is an infectious disease caused by Mycobacterium leprae. It affects 
peripheral nerves, the skin and the mucosa of the upper respiratory pathways [2]. Although 
the exact mode of transmission is not clear, it is believed to occur through nasal droplets or 
prolonged skin contact with an untreated patient [3; 4].  
For a long time, humans were believed to be the only reservoir of Mycobacterium 
leprae. However, since 2005 the 9-banded armadillos in southcentral [5] and south-eastern 
[6] United States of America were confirmed to harbour the bacilli and to transmit it amongst 
themselves [6]. Another rodent, the red squirrels in the British Isles has also been shown to 
harbour the bacilli [7]. These new findings have implications for zoonotic transmission of 
leprosy [5; 6] as well as for the eradication of this scourge [8].   
Untreated leprosy patients or those with late diagnosis usually develop irreversible 
and progressive disabilities and disfiguring complications. Physical deformities in addition to 
socio-cultural misconceptions about leprosy have led to intense social stigma and 
discrimination of people with leprosy (PWL) throughout history [9; 10; 11].  Social stigma 
related to leprosy is typically anticipated, felt or experienced by the victim [9] and is 
generally characterised by social exclusion, rejection, blame, and participation restriction 
among others [12; 13; 11].  Social stigma has been blamed for delay in seeking treatment by 
leprosy patients, who because of anticipated stigma, would rather prefer to conceal their 
condition [14; 15]. This has been an obstacle to early detection, prompt treatment and cure of 
leprosy patients. 
Despite the advances in treatment [16; 17] and political commitment at the global 
level [18] with attendant reduction in leprosy burden worldwide [19], further reduction of 
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leprosy burden meets with enormous challenges. These challenges are three-prong, including 
further reduction in the number of new cases, the registered prevalence, and the social stigma 
and exclusion through prevention and management of disabilities [20]. The full involvement 
of endemic communities as well as persons affected by leprosy is primordial in these efforts 
of leprosy burden reduction [20]. 
In Cameroon, leprosy elimination was achieved at the national level since 2000.The 
current prevalence and detection rates are below 0.20/10 000 and 1.46/100 000 population 
respectively [21]. By the end of 2014, the proportion of MB leprosy among new cases was 
87%, the proportion of child cases was 18%, and the female proportion was 43%. The grade-
2-disability proportion was 7% and the rate was 0.10/100 000 population [21]. In addition, 
ten health districts (HD) remained highly endemic for leprosy by the end of 2014 [21].  
In order to assist the national leprosy control programme (NLCP) to improve the 
strategies for further reduction of the leprosy burden, we carried out a community-based 
study to assess knowledge, perceptions and attitudes regarding leprosy in the Ekondotiti and 
Mbonge HDs in the South-west Region of Cameroon.  
3.4 Methods 
Study design 
We carried out a community-based cross-sectional descriptive and analytical study of 
knowledge, perceptions and attitudes regarding leprosy in rural Cameroon. The study was 
done within the framework of a screening campaign for leprosy and other skin diseases in 
Ekondotiti and Mbonge HDs of the South-west Region of Cameroon, organized by the NLCP 
(results presented elsewhere). 
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Survey setting 
This community-based survey was carried out in April and May 2015 in two 
neighbouring rural HDs of Ekondotiti and Mbonge of the South-west Region of Cameroon 
(Fig 3.1). These districts were among those with the highest leprosy-burden in the country 
between 2010 and 2014 [21]. Ekondotiti and Mbonge HDs comprise 78 and 65 villages 
respectively. Six villages from Ekondotiti and seven from Mbonge respectively, were 
selected for the survey, based on leprosy case-notification from 2010-2014. 
 
Fig 3.1: Map of Ekondotiti and Mbonge health districts showing number of participants by village surveyed (drawn using 
QGIS version 2.18.9 Las Palmas [22]). 
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The 2010-2014 trend in leprosy prevalence rate was constantly above 1 per 10000 
populations in Ekondotiti. For Mbonge, it fluctuated from 3.23 in 2010 down to 0.36 in 2012 
and back to 1.73 per 10000 population in 2014 (Fig 3.2A). Over the same period, the leprosy 
detection rate was stable at about 21 per 100,000 population in Ekondotiti from 2010-2011, 
then dropped to 6 in 2012 before rising again to 43.1 per 100,000 in 2014. In Mbonge, the 
detection rate was higher than in Ekondotiti but witnessed fluctuations from about 50 per 
100,000 populations between 2010 and 2011, down to 1.2 in 2012, then rose sharply to 145.5 
in 2013 before dropping again to 80 in 2014 (Fig 3.2B).   
 
Fig 3.2: Panel A shows the trend in the leprosy prevalence rate per 10,000 populations from 2010 to 2014, while panel B 
shows the leprosy detection rate per 100,000 populations over the same period in Mbonge and Ekondotiti health districts. 
The trend in leprosy prevalence rate was constantly above 1 per 10000 populations in Ekondotiti. For Mbonge, it fluctuated 
from 3.23 in 2010 down to 0.36 in 2012 and back to 1.73 per 10000 populations in 2014. Over the same period, the leprosy 
detection rate was stable at about 21 per 100,000 populations in Ekondotiti from 2010-2011, then dropped to 6 in 2012 
before rising again to 43.1 per 100,000 in 2014. In Mbonge, the detection witnessed fluctuations from about 50 per 100,000 
populations between 2010 and 2011, down to 1.2 in 2012, then rose sharply to 145.5 in 2013 before dropping again to 80 in 
2014. 
 
Three-quarters of the inhabitants of Ekondotiti and Mbonge HDs were of the Oroko tribe, 
sub-divided into ten clans [23], with each clan speaking their own dialect [24]. Despite the 
predominance of Oroko people, the two HDs are quite cosmopolitan, with inhabitants from 
diverse ethnic origins of Cameroon. With this mix, the use of Pidgin English language has 
been highly developed and is widespread in the area [25]. The two HDs fall within the cocoa 
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production basin of the South-west Region and majority of the inhabitants are farmers, 
involved mainly in cocoa farming.  
Participants, sampling and data collection 
Participants: Participants included in the study were individuals of both sexes aged 
15 years and older. Persons below 15 years of age, leprosy patients, health care personnel and 
those who did not give their consent were excluded from the study. 
Sampling: The survey team visited 13 villages selected for the survey according to a 
pre-established schedule. In each village, villagers were invited to gather at a central place for 
screening of leprosy and other skin conditions. We used a systematic random sampling 
whereby every fifth person screened, who fulfilled the inclusion criteria and who gave his/her 
consent to participate in the survey was selected for interview. 
Data collection: Data was collected using a closed ended questionnaire in English, 
designed to collect demographic variables and to evaluate knowledge, perceptions and 
attitudes regarding leprosy, adapted from the one used for KAP-epilepsy studies in Cameroon 
[26; 27; 28]. Four data collectors fluent in both English and the Pidgin-English languages 
were trained on the administration of the questionnaire by the lead author. The training 
included among other things, full understanding of, and appropriate translation of the 
questionnaire into Pidgin-English and back-translation into the English language by the data 
collectors. The questionnaire was field-tested in two villages which were not included for the 
survey. After field testing, questions 5 and 7 were modified for better comprehension. The 
data collectors then moved along with the leprosy screening team and conducted face-to-face 
interviews with the participants.  
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Operational definitions and outcome variables 
Operational definitions 
` High Knowledge of leprosy: Participants who answered “Yes” to ≥ 50% of 
knowledge questions were considered as having high knowledge. 
Positive attitudes: Participants who answered “Yes” to ≥ 50% of the attitude 
questions were considered having positive attitudes toward PWL. 
Erroneous perceptions: Participants who indicated any of the following (curse, bad 
blood, heredity, divine punishment, marrying from a family with history of leprosy) as being 
the cause of leprosy and/or who believed that leprosy is not curable was considered as having 
erroneous perceptions regarding leprosy. 
Outcome variables 
   The questionnaire designed for the survey included fifteen questions: 7 to assess 
knowledge and perceptions and 8 to assess attitudes regarding leprosy (Table 3.1).  
 
 
 
 
 
 
 
 
81 
 
Earnest Njih Tabah  Skin NTDs in Cameroon: the need for integrated control and elimination 
  
Table 3.1: List of study outcome variables  
 Variable 
number 
Variable (Question) 
Knowledge and 
perceptions 
regarding leprosy 
*Q1 Have you heard about leprosy? 
Q2 Have you ever seen someone with leprosy? 
Q3 Do you know someone with leprosy? 
Q4 Do you have a relative who has or had leprosy? 
Q5 What is the cause of leprosy according to you? (Yes = 
Germ/microbe, poor hygiene, living in close contact with a 
leprosy patient, No: any other cited cause) 
Q6 Do you think leprosy is curable? 
Q7 Where would you advise your relative or friend to seek 
treatment if he/she had leprosy? (Yes=health facility, medical 
doctor, nurse; No = Roadside medicine, No treatment, 
Traditional/spiritual healer) 
Attitudes 
regarding leprosy 
Q8 Would you shake hands with someone with leprosy? 
Q9 Would you eat from the same plate with someone with 
leprosy? 
Q10 Would you feel ashamed if you had leprosy? 
Q11 Would you reveal your status to someone if you had leprosy? 
Q12 Would you allow your child to play with another child who 
has/had leprosy? 
Q13 Would you accept your child to marry from a family with a 
history of leprosy? 
Q14 Do you think people who have/had leprosy should be allowed 
to participate in activities like anyone else? 
Q15 Do you think people who have/had leprosy should be given 
employment like anyone else? 
*Q = Question 
Sample size 
Based on an assumed proportion for negative attitudes towards lepers of 21.6% 
demonstrated in the northwest of Cameroon [13], and for a 95% confidence interval, and an 
acceptable error of 0.05, a sample size of 261 was determined for our study.  
Ethics statement 
Ethical approval was obtained from the National Ethics Committee for Research in 
Human Health, Yaounde, Cameroon (No 172/CNE/SE/2011). Participation in the study was 
voluntary and each participant gave an informed consent. All data were anonymized and 
confidentiality was strictly respected in the data handling and analysis. 
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Data management and statistical methods 
Data management consisted of checking whether questionnaires were filled completely 
and correctly using appropriate codes. This was done daily until all the data was collected. 
The data was stored in a safe place until analysed.     
Data was entered on Microsoft Excel spread sheets and exported to SPSS for Windows 
version 20 statistical software for analysis. Proportions were calculated and the Chi-square 
test was used to examine associations between responses and variables. The level of 
significance was set at p <0.05. After performing orienting univariate analyses, we carried out 
binary logistic regression analysis to determine predictors of negative attitudes. 
 
3.5 Results 
Characteristics of participants 
Two hundred and sixty-one (261) individuals were contacted and 233 accepted to 
participate in the survey, giving a response rate of 89.3%. Their ages ranged from 15 to 75 
years with a mean age of 33 ± 12 years. They were 118 (50.6%) males. Seventy-two percent 
were protestant Christians. The majority (65.7%) were from the Oroko tribe, while 34.3% of 
them originated from 21 other Cameroonian tribes. Most (59.7%) of the participants had only 
the primary level of education, 56.7% were married and 59.2% of them were farmers. 
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Knowledge, beliefs and perceptions regarding leprosy 
 The details of familiarity with and knowledge of leprosy are shown in Table 2. 
Generally, our respondents were very familiar with leprosy, as 82.4% had heard about it and 
64.4% had seen someone with the condition. About 75% of them declared that leprosy was 
curable however; only 19.7% knew the cause of the disease.  
The knowledge of leprosy and its cause were not influenced by demographic variables. 
Regarding familiarity with leprosy, respondents below 20 years of age (p<0.001), females 
(p=0.006), those with no level of formal education (p=0.041), and singles (p=0.028) were 
least likely to have seen someone with leprosy.  Those below 20 years of age (p=0.033), 
females (p=0.014), and singles (p=0.045) were least likely to know someone with the 
condition (Table 3.2). We found the highest proportion of respondents in the group aged 30-
39 years (p=0.005) who reported having a relative with leprosy. The unemployed (p=0.043) 
and those with no level of formal education (p=0.047) were the least likely to know that 
leprosy is curable (Table 3.2).
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For the 192 (82.4%) respondents who declared having heard about leprosy, their main 
sources of information on leprosy were from community volunteers (40.6%), friends (38.0%) 
and the media (24.0%) (Fig 3.3). 
 
Fig 3.3: Sources of information on leprosy. The major sources of information on leprosy to our participants were from 
community volunteers (41%), friends (38%), the media (24%), and health personnel (19%). 
 
The beliefs and perceptions held about leprosy in the Mbonge and Ekondotiti HDs are 
portrayed in the nature of causes cited by the respondents (Table 3.3). Although 29%, 27% 
and 10.3% of them respectively rightly linked leprosy to germs, poor personal hygiene, and 
living in close contact with an untreated leprosy patient, a considerable proportion cited 
erroneous causes. A considerable proportion of them believed that leprosy is a spell (25.3%), 
is caused by unclean blood (15.5%), is hereditary (14.6%), or results from marrying from a 
family that has/had leprosy (11.2%). A much lesser proportion of the respondents believed 
that leprosy is punishment for sins, is caused by natural forces, or results from eating some 
food types or from malnutrition. 
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Table 3.3: Causes of leprosy as cited by the respondents 
 Cited causes of leprosy N
o
 of respondents Proportion of 
‘Yes’ responses 
Poor personal hygiene 233 28.8% 
Germs or microbes 233 27.0% 
Curse or spell 233 25.3% 
Bad or unclean blood 233 15.5% 
Heredity 233 14.6% 
Marrying from a family that has/ had a leprosy 
patient 
233 11.2% 
Living in close contact with an untreated leprosy 
patient 
233 10.3% 
Spontaneous occurrence 233 8.6% 
Divine punishment for sin 233 8.2% 
Some natural forces 233 6.4% 
Malnutrition 233 6.4% 
Some types of food 233 4.3% 
 
Problems faced by people with leprosy or their families  
Between 43% and 71% of our respondents admitted that PWL and their families face a variety of 
problems, ranging from difficulties getting employment, admission in school, or getting 
married themselves; to bringing shame in the family and causing other problems to family 
members (Fig 3.4). 
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Fig 3.4: Cited problems faced by people with leprosy. The participants of our study admitted that PWL face a variety of 
problems in the society, ranging from difficulties getting employment, admission in school, or getting married themselves; to 
bringing shame in the family and causing other problems to family members.
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Relationship between attitudes regarding leprosy and demographic variables 
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Table 3.4 shows details of attitudes regarding leprosy among our respondents. A high 
proportion (86.3%) of them would advise a relative or friend with leprosy to consult a health 
professional, and 58.8% would be willing to tell someone if they had leprosy. Most of our 
respondents portrayed very negative attitudes with respect to leprosy, as only 42% would 
shake hands, and 32.6% would eat from the same plate with a leprosy patient. Only 28.3% 
and 27% would allow their child play with another child who had leprosy, or marry from a 
family with a history of leprosy, respectively. Only 33.9% of our respondent approved of 
leprosy patients participating in activities like anyone else, and 42.9% agree that they should 
be employed normally. Attitudes generally were not influenced by demographic variables, 
except for pupils/students, who were the least likely to reveal their leprosy status to anyone 
(p=0.019). 
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Relationship between knowledge, beliefs and perceptions regarding leprosy and attitudes towards PWL 
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The analysis of the effect of knowledge, beliefs and perceptions regarding leprosy of our 
respondents on their attitudes toward PWL is detailed in Table 3.5. The acceptance to refer a 
relative or friend with leprosy to a health facility was greater in respondents who knew or who 
had seen someone with leprosy (p=0.026), and who understood that leprosy is caused by a germ 
(p=0.014) and that it is curable (p<0.001). Only those who understood leprosy is curable 
declared they would shake hands with patients (p=0.002). Those who had heard about leprosy 
(p=0.041), and who understood that leprosy is curable (p=0.002) were more likely to eat from 
the same plate with a patient, but those who thought leprosy was due to poor personal hygiene 
were least likely to do so (p=0.042). Respondents who knew leprosy is curable were more likely 
to feel ashamed (p<0.001). Those who had heard about leprosy (p=0.039) and who knew leprosy 
is curable were more likely to conceal their status (p<0.001) if they had leprosy, but those who 
believed leprosy is a punishment for sins (p=0.005) or is caused by living in close contact with a 
patient (p=0.027) were least likely to conceal their status if they were affected. Those who had 
heard about leprosy (0.039) and who understood it is curable (p=0.014), or believed it was a 
punishment for sins (p=0.011), were least likely to allow their children play with one who had 
leprosy. Respondents who had heard about leprosy (p=0.026) were least likely to allow their 
children marry from a family with a history of leprosy, meanwhile those who knew leprosy is 
curable (p=0.016) were readier to let their children marry from such a family. Those who had 
heard about leprosy (p=0.034), who believed it was caused by living in close contact with an 
untreated patient (p=0.018) or due to poor personal hygiene (0.022) were least likely to accept 
that leprosy patients participate in activities like anyone else. However, those who knew leprosy 
is curable (p=0.005) had no problem with patients participating normally in activities. 
Concerning employment of PWL, those who had heard about the condition (p=0.004), or who 
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knew it was curable (p=0.002) were more likely to offer them employment, but those who 
believed leprosy was hereditary (p=0.033) or due to poor personal hygiene (p=0.007) would not 
do so. 
Independent predictors of attitudes towards PWL 
Table 3.6: Independent predictors of attitudes towards PWL 
Attitudes Independent Predictors 
 
95% CI 
 
OR Lower Upper P-value 
Would advise relative to seek 
treatment at a health facility 
or from a health worker 
− Think leprosy is caused by a 
germ 
3.86 1.11 13.48 0.034 
− Think leprosy is curable 4.93 2.24 10.87 <0.001 
Would not shake hands with 
someone with leprosy 
− Think leprosy is a curse 2.10 1.12 3.95 0.021 
− Think leprosy is a punishment 
for sin 
0.25 0.08 0.81 0.021 
Would not eat from the same 
plate with someone who has 
leprosy 
− Has seen a leprosy patient 2.09 1.12 3.87 0.02 
− Think leprosy is due to poor 
personal hygiene 
0.37 0.19 0.74 0.005 
Would feel ashamed if he/she 
had leprosy 
− Think leprosy is curable 2.64 1.34 5.21 0.005 
− Think leprosy is due to poor 
personal hygiene 
0.52 0.28 0.97 0.039 
Would not reveal status to 
anyone if he/she had leprosy 
− Think leprosy is a punishment 
for sin 
0.22 0.08 0.64 0.005 
Would not allow child to 
marry from a family with a 
history of leprosy 
− Has seen a leprosy patient 1.90 1.00 3.60 0.049 
Would not allow child to play 
with another child who has 
leprosy 
− Has seen a leprosy patient 2.63 1.34 5.13 0.005 
− Think leprosy is due to poor 
personal hygiene 
0.46 0.22 0.96 0.038 
Think that people with 
leprosy should not be allowed 
to participate in activities like 
anyone else 
− Has seen a leprosy patient 2.42 1.28 4.60 0.007 
− Think leprosy is caused by a 
germ 
2.78 1.38 5.61 0.004 
− Think leprosy is due to poor 
personal hygiene 
0.32 0.14 0.71 0.005 
Think that people with 
leprosy should not be given 
employment like anyone else 
− Has seen a leprosy patient 1.85 1.02 3.37 0.044 
− Think leprosy is caused by a 
germ 
3.38 1.65 6.93 0.001 
− Think leprosy is hereditary 0.31 0.12 0.79 0.014 
− Think leprosy is due to poor 
personal hygiene 
0.27 0.13 0.56 <0.001 
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In a binary logistic regression inputting community perceptions and knowledge that 
influenced attitudes with respect to leprosy, seven independent predictors were identified (Table 
3.6). The positive attitude of advising a relative or friend to seek treatment from a health facility 
was enhanced by two predictors: the understanding that leprosy is caused by a germ, and that it is 
curable. 
The eight negative attitudes studied (Table 3.6) were driven by three independent 
predictors, namely: having seen a leprosy patient, the belief that leprosy is a curse, and the 
knowledge that it is caused by a germ. However, the effect of these negative attitudes was 
dampened by three predictors namely: the knowledge that leprosy is due to poor personal 
hygiene or the belief that it is a punishment or that it is hereditary, which were found to be 
protective. 
3.6 Discussion 
Although the WHO enhanced global strategy for further reducing the burden of leprosy for 
the period 2011-2015 [20] has been implemented in Cameroon, over 300 new cases of leprosy 
continue to be reported in the country each year [21]. A new WHO global leprosy strategy 2016-
2020 has been launched and has as main focus: the reduction of leprosy transmission and of 
leprosy related disabilities, stigma and discrimination [29]. The implementation of this strategy 
could face the hurdle of lack of community knowledge, and erroneous perceptions about leprosy 
[15]. The success of any intervention to improve upon the outcomes of leprosy control would 
depend on a good understanding of these community knowledge and perceptions [15]. 
In the current study, 82.4% of respondents had heard about leprosy. Though relatively high, 
this figure is less than the 100% reported in an Ethiopian study [30]. The sources of community 
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information on leprosy in our study were varied (Fig 3.3). The most important sources of 
information were from community volunteers, friends and the media and only to a lesser extent 
from health personnel and schools. In Cameroon, community relay agents (volunteers) are 
important stake-holders in community health programmes like vaccination, community 
distribution of ivermectine against onchocerciasis and distribution of treated bed nets in the fight 
against malaria, and Buruli ulcer control [31; 32]. From our findings, an intervention to address 
community awareness on leprosy through the community relay agents, and local community 
radios could be the most effective approach. 
Only 19.7% of our participants knew the cause of leprosy. This is comparable to the 19.26% 
reported in Ethiopia [30], but better than the 0% reported in a community in Pakistan [33]. The 
majority of our participants wrongly cited as causes of leprosy: curse, bad blood, heredity, 
punishment for sins, and eating some types of food (Table 3.3). Similar misconceptions have 
been reported in the northwest of Cameroon [13]. In Ethiopia it is believed that leprosy is linked 
to curse/punishment by god, heredity, bad blood, and immoral conduct [30], while in eastern 
Sudan it has been linked mainly to some food types [34]. These misconceptions are clearly 
grounded in the customs and beliefs of the communities concerned, and are common to cultures 
in Africa, Asia and South America [15]. 
Seventy-five percent of our participants knew that leprosy is curable. This is higher than the 
67.9% reported in Mezam division in the northwest of Cameroon [35], 60% in Mangalore-India 
[36] and 18.3% in Pakistan [33], but less than the 92.5% reported in Ethiopia [30]. In our sample, 
business men (P=0.043) and those with a high school or university education (P=0.047), were 
most likely to know that leprosy is curable. Furthermore, 86.3% would refer a relative or friend 
with leprosy to a health facility for treatment. A comparable finding was reported in India [36]. 
95 
 
Earnest Njih Tabah  Skin NTDs in Cameroon: the need for integrated control and elimination 
  
This practice was strongly influenced by the knowledge that leprosy is curable (P<0.001), the 
understanding that leprosy is caused by a germ (P=0.014) or knowing someone with leprosy 
(P=0.026).  A considerable proportion (43% to 71%) of our respondents acknowledged that PWL 
face various and varied challenges in the society. At the individual patient level, the challenges 
range from difficulties in getting employment, getting admission in schools, interacting with 
other people, to getting married. The challenges went beyond the individual patient to affect the 
patient’s family like bringing shame to the family, and problems in marriage. The challenges 
faced by PWL are certainly a reflection of the society’s attitudes towards them. 
Attitudes were generally negative in our sample (Tables 3.4 and 3.5). The negative attitudes 
were not influenced by demographic variables in our study but were strongly influenced by lack 
of knowledge about leprosy and socio-cultural perceptions of the diseases (Table 3.5). Similarly, 
negative attitudes towards PWL have been reported in Ethiopia [30], and Secunderabad, India 
[37]. 
One positive and eight negative attitudes were found in our study. The lone positive attitude 
of advising a relative or friend with leprosy to seek medical treatment was independently driven 
by the knowledge that leprosy is caused by a germ, and that it is curable. This finding has 
important public health implications. The ultimate goal of any leprosy control programme is to 
break the transmission chain in endemic communities. This can only happen if all detected 
leprosy patients are treated adequately with multi-drug-therapy against leprosy. Increasing 
community knowledge on these two aspects regarding leprosy is therefore paramount. 
The independent predictors of negative attitudes were: having seen a leprosy patient, the 
knowledge that leprosy is caused by a germ and the belief by some that it is a curse. In the Oroko 
language, the name for leprosy is “diangi” signifying a disease that cuts off fingers, toes and 
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destroys the face. With this kind of perception about leprosy, community members develop fear 
of being infected and becoming a leper, if they associated with PWL. The common tendency is 
therefore to avoid PWL in all circumstances.  
The knowledge that leprosy is due to poor personal hygiene or the beliefs that it is a 
punishment for sins or is hereditary, were found to be independently protective against some 
negative attitudes in this study. Some community members tend to pity PWL and would not 
support some of the negative attitudes like refusing to shake hands with PWL; not allowing their 
child to play with PWL; or their relative to marry from a family with history of leprosy, on the 
basis that leprosy is due to poor personal hygiene. In rural communities of Cameroon, 
environmental and personal hygiene are generally poor, with very poor housing conditions and 
limited access to potable water [38] which is not limited only to PWL. In our study, some 
community members also did not see why PWL should not be employed, on the basis of the 
belief that leprosy is hereditary. 
We conclude that familiarity with leprosy was very high, with the major sources of 
information being from community volunteers and the media. However, knowledge on the cause 
of leprosy was very low, with a considerable proportion having erroneous perceptions about its 
cause. Quite a high proportion of our participants understood that leprosy is curable and would 
refer their relatives or friends with leprosy for medical treatment.  
Attitudes toward PWL were very negative in our sample. These negative attitudes were 
independently driven by the perception that leprosy is a curse, the knowledge that leprosy is 
caused by a germ, and having seen a leprosy patient. The negative attitudes were however 
dampened by the beliefs that leprosy is a punishment, is hereditary or is due to poor personal 
hygiene.  
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We recommend that, a leprosy awareness intervention, through the channel of community 
volunteers and the media, with information on the correct cause of leprosy, its curable nature, 
and messages discouraging the erroneous perceptions regarding it, could improve upon the 
community knowledge of leprosy, as well as attitudes towards PWL. This could ultimately lead 
to the reduction of leprosy burden in this community. 
3.7 Supporting information 
S1 Data: Compressed shapefiles of Cameroon health district, used for drawing up the map of 
Ekondotiti and Mbonge health districts, highlighting the villages visited and number of 
participants in each village (Fig 3.1).  
(rar) 
 
S1 Text: STROBE checklist for this cross-sectional study 
(doc) 
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Chapter 4 
Chapter 4 : Buruli ulcer in Cameroon 
Buruli ulcer in Cameroon: The Development and Impact of 
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4.1 Abstract 
Background: Cameroon is endemic for Buruli ulcer (BU) and organized institutional BU 
control began in 2002. The objective was to describe the evolution, achievements and challenges 
of the national BU control programme (NBUCP) and to make suggestions for scaling up the 
programme. 
Methods: We analysed collated data on BU from 2001 to 2014 and reviewed activity reports 
NBUCP in Cameroon. Case-detection rates and key BU control indicators were calculated and 
plotted on a time scale to determine trends in performance. A linear regression analysis of BU 
detection rate from 2005 – 2014 was done. The regression coefficient was tested statistically for 
the significance in variation of BU detection rate. 
Principal findings: In 14 years of BU control, 3700 cases were notified. The BU detection 
rate dropped significantly from 3.89 to 1.45 per 100 000 inhabitants. The number of BU endemic 
health districts rose from two to 64. Five BU diagnostic and treatment centres are functional and 
two more are planned for 2015. The health system has been strengthened and BU research and 
education has gained more interest in Cameroon.  
Conclusion/Significance:  Although institutional BU control Cameroon only began 30 years 
after the first cases were reported in 1969, a number of milestones have been attained. These 
would serve as stepping stones for charting the way forward and improving upon control 
activities in the country if the major challenge of resource allocation is dealt with. 
Key words: Buruli ulcer, Cameroon, National Control Programme, diagnosis, antibiotic 
treatment, surveillance, impact. 
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4.2  Author Summary 
Organized control of Buruli ulcer (BU), the third most common mycobacterial disease, began 
in Cameroon in 2002.  We used 2001-2014 data and activity reports from the National BU 
Control Programme, to describe the onset, evolution, achievements and challenges of BU control 
in Cameroon, and make suggestions for improvement and expansion of programme activities. A 
cumulative number of 3700 BU cases have been detected and treated free-of-charge in five 
functional BU diagnostic and treatment centres. Sixty-four BU-endemic districts are now 
confirmed in Cameroon. Furthermore, Cameroon has actively participated in several BU 
research activities. However major challenges regarding demanding and costly surveillance, 
education, diagnostic and treatment activities remain to be addressed. Capitalizing on 
experiences and lessons learned in the past 14 years of activities, the National BU control 
programme should however be prepared to move forward.  
4.3 Introduction 
Buruli ulcer (BU), caused by Mycobacterium ulcerans, is the third most common 
mycobacterial infection, after tuberculosis and leprosy. M. ulcerans infection leads to chronic 
necrotizing ulcers [1], resulting in deformities, functional limitation and social stigma, if left 
untreated [2; 3].  
BU occurs in tropical and sub-tropical regions near stagnant or slow flowing water bodies 
and marshlands [4; 5], and worldwide, this association has been shown to be a risk factor for the 
infection. The mode of transmission however is unclear, although some studies have suggested 
the involvement of an animal reservoir or of insect vectors [6]. 
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BU affects people of all ages and both sexes, but mostly children below 15 years of age. 
However, children below five years seem to be underrepresented among patients [7] and less 
exposed to M. ulcerans than older children [8]. Although all body parts may be involved, about 
90% of lesions occur on the limbs [7], which may reflect the mode of transmission.  Since M. 
ulcerans is thermosensitive, it is primarily causing skin lesions. 
BU presents in two major clinical forms: non-ulcerative (papule, nodule, plaque, and 
oedema) and ulcerative lesions (Fig 4.1). The WHO has defined three categories of lesions based 
on their sizes and location on the body [9]. BU can be diagnosed clinically by experienced and 
skilled health workers in endemic areas [10]. Four standard laboratory methods can be used to 
confirm BU [11], however, polymerase chain reaction (PCR) targeting the multi-copy insertion 
segment (IS) 2404 of M. ulcerans is the most commonly used because it has the highest 
sensitivity and results can be available within 48 hours [12]. The treatment of BU has evolved 
from exclusively surgical [13] to the use of specific antibiotics [10; 14] in association with, 
simple surgery for controlled wound healing, physiotherapy, nutritional and psychosocial support 
if required. Today, major surgery is reserved only for treatment of BU complications.  
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Fig 4.1: Clinical manifestations of BU cases seen in Cameroon. 
A. Papule: a swollen and non painful cutanous lesion of <1cm in diameter;  
B. Nodule: a swollen and non painful lesion extending from the skin to the sub-cutanous tissue, with a diameter of 1–2cm;  
C. Plaque: a firm and non painful induration of the skin with well delimited borders, usually with desqamation of the affected 
skin surface;  
D. Oedema: a diffuse and extended and non pitting swelling which is firm, non painful and has no clearly defined borders;  
E. Category I ulcer: a small ulcerated and mildly painful lesion of  <5cm of diameter with undermined borders;  
F. Category II ulcer: an ulcerated lesion with undermined borders and a diameter of  5–15cm; 
G. Category III ulcer: a large ulcerated lesion of >15cm of diameter with indurated undermined borders, commonly has 
necrotic tissue on the ulcer bed; 
H. Disseminated BU lesions;  
I. Sequelae of BU: a viscious healing of a poorly treated BU lesion with complete retraction of the hand in an extesion 
position. 
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Effective BU control began in Cameroon in 2002. In this article, we describe the national BU 
control programme (NBUCP) in Cameroon from its creation to 2014, based on a review of 
reports and data from 2001 to 2014 compiled at the NBUCP. The objective is to describe the 
evolution, achievements, and challenges of the NBUCP, and make suggestions for improvement 
and expansion of BU programme activities. The paper shall be useful for advocacy to mobilize 
resources for implementation of BU control programme activities worldwide. 
4.4 Methods 
We analyzed collated data on BU from 2001 to 2014 and reviewed activity reports 
available NBUCP office.  In Cameroon, BU is diagnosed and treated at BU diagnostic and 
treatment centres (BU-DTCs). Within the framework of national BU surveillance, all BU-DTCs 
are provided with BU case-definition, diagnostic and treatment guidelines and other 
documentation on the disease for use by the staff. Standard WHO patient case record files and 
registers are used at BU-DTCs to document information on each BU patient. The data recording 
and reporting process at BU-DTCs is regularly monitored and supervised by the NBUCP to 
ensure correctness and completeness. The data is compiled and transmitted together with activity 
reports monthly to the NBUCP where it is captured electronically.  
The data on BU cases was classified by year and health district of origin. The health 
districts that registered at least a case of BU between 2001 and 2014 were considered as districts 
at risk of BU and their annual populations for 2005 were obtained from the report of the 3rd 
general population and housing census of Cameroon [15]. The populations of these districts for 
the periods 2001-2004 and 2006-2014 were estimated on the bases of a population growth rate of 
2.8% and 2.6% respectively [15].  Aggregates of the district populations were used to calculate 
annual BU detection rates per 100 000 inhabitants. The annual number of BU cases, the 
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cumulative number of cases and the annual detection rates were plotted on a time scale to 
determine trends. Key BU control performance indicators [16] were calculated as proportions 
and plotted on a time scale to determine trends in the performance of the NBUCP. The 
performance indicators considered were the proportions of ulcerative lesions, category 3 lesions, 
cases confirmed by PCR, cases below 15 years of age and lesions located on limbs. A linear 
regression analysis of BU detection rate from 2005 – 2014 was done. The regression coefficient 
was tested statistically for the significance in variation of BU detection rate. Shape files of the 
Cameroon health district map obtained from the Sub-department for epidemiological 
surveillance in the Ministry of Public Health was used to produce the various BU maps of 
Cameroon, using the ArcGIS version 9 mapping software, to further illustrate trends.  
Ethics Statement 
This study was instructed by the Cameroon Ministry of Public Health Decision No 
0486/D/MINSANTE/CAB and was approved the National Ethics Committee of Cameroon 
through the authorisation No 041/CNE/DNM/09. All data were anonymized and confidentiality 
was strictly respected in the data handling and analysis. 
4.5 Results and discussions 
4.5.1 BU control in Cameroon: the creation and the evolution of the NBUCP 
Although BU was first reported in Cameroon in 1969 [17], control activities only began 
effectively 33 years later, in 2002. The triggers for control activities in Cameroon were the new 
momentum to BU control following the 1998 Yamoussoukro Declaration [18] and the 
reconfirmation of the Nyong Basin in Central Cameroon as a BU endemic area by Noeske and 
colleagues in 2001, when they identified 436 clinical cases of BU, 162 of whom were sampled 
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and 135 confirmed by IS2404 PCR [19]. Noeske’s findings led to the creation of the first two 
BU-DTCs in the country in 2002, in Ayos and Akonolinga both of which are located within the 
Nyong basin. These BU-DTCs were set-up with the support of two NGOs: FAIRMED (former 
Aide aux Lépreux Emmaüs Suisse) and Médecins Sans Frontières Suisse (MSF-CH), 
respectively. The effectiveness of the treatment of BU in these pioneer centres quickly led 
Cameroon’s Ministry of Public Health to create the NBUCP in 2004, underlying the important 
role of research in health development policy.  
The initial goals and objectives of the NBUCP largely reflected those of the WHO GBUI 
as stated in the Yamoussoukro Declaration” [18]. The NBUCP objectives have however evolved 
over time, to suit new developments and orientations in the domain as charted by the 2004 WHA 
resolution on BU and the 2009 Cotonou Declaration on BU.  
The current goal of the NBUCP is to reduce the suffering of the population due to BU. 
The global objective is to ensure accessibility to quality health services in endemic areas in order 
to reduce morbidity and disability linked to BU in Cameroon. Specifically, the NBUCP aims to 
detect cases of BU early, preferentially as non-ulcerative forms and category 1 lesions; to 
confirm 70% of clinical BU cases by PCR; to treat all active cases of BU according to standard 
guidelines; and to heal at least 95% of BU patients without limitation of joint movement. 
4.5.2 Major achievements of BU control in Cameroon 
Health system strengthening through case finding, management, and public-private 
partnerships 
The pivot of BU control in Cameroon has been the BU-DTCs situated in major endemic 
foci. The BU-DTC facilities were built or rehabilitated and equipped by support partners to 
provide adequate infrastructure for BU diagnosis and treatment, including surgical theatres, 
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wound dressing rooms, laboratories, physiotherapy units and admission wards. Health staff of 
the BU-DTCs received on-the-job training through workshops facilitated by experts, using the 
WHO training modules and guidelines on BU care. These training sessions included aspects such 
as wound management, which are also useful for general patient care. Health staff also received 
regular refresher training and supportive supervision from the NBUCP and partner NGOs.  
Initially case-finding was active, with medical teams from BU-DTCs carrying out mass 
screening for BU, sensitization and awareness campaigns in communities and schools. 
Gradually, health committees were activated in the intervention areas, and they became 
responsible for community sensitization and awareness campaigns about BU. Community 
participation increased as many volunteers were trained to recognize BU in their communities 
and refer suspected cases to the BU-DTC for confirmation and treatment. As communities 
became more aware of BU, the active case-finding gradually gave way to passive case-finding 
with cases coming on their own or being referred to BU-DTCs.  
BU case detection and management 
Fig 4.2 shows the trend in BU case notification between 2001 and 2014 at BU-DTCs in 
Cameroon. A cumulative total of 3700 clinically confirmed BU patients have been diagnosed 
and treated. The annual average case detection was 264 over the 14-year period. The peak in 
2004 is attributed to the national survey in that year [20]. This peak may imply that a proportion 
of cases remain unnoticed by the public health system and that the real annual case detection rate 
of BU in Cameroon is much higher than the annual average of 3.69 per 100 000 inhabitants over 
this 14-year period.  
The annual BU detection rate increased from 0.99 in 2001 to 3.89 per 100 000 inhabitants 
in 2005, and then dropped progressively to reach 1.45 per 100 000 inhabitants cases in 2014. The 
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reduction was significant (regression coefficient: -0.29 (95%CI: -0.45 to -0.12), P=0.004). This 
decreasing trend is comparable to the worldwide trend, with a 52.6% reduction in BU cases 
between 2005 and 2014 [21] (Fig 4.3).  
 
Fig 4.2: Trend in BU case notification between 2001 and 2014 in Cameroon. A cumulative number of 3700 BU cases were 
notified between 2001 and 2014, with an annual average case notification of 264 cases. The peak in 2004 is attributed to the 
national BU survey in that year. There is a progressive reduction in case notification since 2005. The annual BU detection rate 
increased from 0.99 in 2001 to 3.89 per 100 000 inhabitants in 2005 and dropped progressively to reach 1.45 per 100 000 
inhabitants cases in 2014.  
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Fig 4.3: Comparison between Cameroon national and the global trend in BU cases from 2002 to 2014. The trend in the 
global BU cases was similar to that of Cameroon with a rise from 3245 cases in 2002 to a peak at 5937 in 2004, followed by a 
progressive reduction to reach 2250 in 2014. The global BU data was downloaded from the WHO website at 
http://apps.who.int/gho/indicatorregistry/App_Main/view_indicator.aspx?iid=2448  
 
The exact reasons for the reduction in BU cases in the world are not known [12]. 
Although in Cameroon active BU case finding in the Nyong basin has greatly decreased, we 
cannot attribute the reduction in BU cases only to this, given that in the Bankim endemic area 
where activities are sustained; there has been a 46% reduction in BU cases between 2008 and 
2014. Could it be that the continuous case finding and treatment of BU for over one decade has 
led to the reduction in its incidence, or does BU has a cyclical pattern of occurrence and that we 
are coming to the end of a cycle? We suggest that, under the auspices of the WHO, the scientific 
community should carry out a multicentre study to determine the reasons for the reduction of BU 
cases worldwide.  
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A nine-year trend in key BU control indicators (Fig 4.4) reveals that the ulcerative form 
of BU constituted about 83% of lesions and 90% of all lesions were located on the limbs. On 
average, children below 15 years of age constituted 45% of cases. The proportion of category III 
lesions rose from 9% in 2008 to 52% in 2014, two-fold the new WHO target of ≤ 25% [22]. The 
proportion of BU cases confirmed by PCR dropped from 57% in 2010 to 20% in 2014, far below 
the new WHO target of 70% [22].  
 
Fig 4.4: Trends in key BU control indicators from 2006 to 2014. Notice that during this period, the ulcerative form of BU 
constituted about 83% of lesions and 90% of all lesions were located on the limbs. On average, children below 15 years of age 
constituted 45% of cases. The proportion of category 3 lesions rose from 9% in 2008 to 52% in 2014 and the proportion of BU 
cases confirmed by PCR dropped from 57% in 2010 to 20% in 2014. 
 
 
The NBUCP has depended largely on external partner funding from inception in 2002 for the 
implementation of its activities. This partner funds have dwindled rapidly since 2010. The 
consequences have been the decrease in BU surveillance and confirmation of cases by PCR, 
explaining the progressive rise in Category III lesions and drop in the proportion of cases 
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confirmed by PCR. To remedy this situation, the NBUCP has embarked on an aggressive 
advocacy with hierarchy of the Ministry of Health and non-governmental organizations (NGOs) 
to source additional funding for BU activities in general and the improvement of BU surveillance 
and PCR confirmation in particular. The Ministry of Health has begun to respond by instituting a 
budgetary line for BU activities since 2014, and one NGO has opted to pay for all confirmation 
by PCR in 2015. The challenge of the NBUCP shall be to sustain these offers.  
Expansion of BU control programme coverage 
Upon creation in 2004, the NBUCP developed its first national BU control strategic plan. 
Within the framework of the plan, the first national BU survey conducted in 2004 revealed the 
presence of BU in 19 health districts [20] in addition to the Ayos and Akonolinga Districts in the 
Nyong basin (Fig 4.5A & B).  In 2006, programme activities were extended, through the creation 
of BU-DTCs in three most endemic of the newly identified health districts namely: Bankim, 
Ngoantet-Mbalmayo and Mbonge, bringing to five the total number of BU-DTCs nationwide. 
They are located in the Adamaoua, South-West and Centre regions of the country respectively.  
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A B C 
 
Fig 4.5: Evolution of confirmed BU endemic health districts between 2001 and 2014. During the period 2001-
2002 (A), the only known BU endemic health districts were Ayos and Akonolinga in the Nyong basin of central 
Cameroon [19]. The first 2 BU-DTCs were created in these districts in 2002 to begin BU care in Cameroon. The 
national BU survey in 2004 following the creation of the NBUCP revealed the presence of BU in 19 other health 
districts (B). Three new BU-DTCs were created in 2006 in the 3 most endemic of the 19 health districts namely 
Bankim in the Adamawa region, Mbonge in the Southwest Region and Ngoantet-Mbalmayo in the Centre Region. 
From 2006-2014, the 5 BU-DTCs in the country have treated BU cases originating from sixty-four health districts 
(C). 
 
A study of origins of BU cases notified at the five BU-DTCs from 2006 to 2014 revealed that 
cases came from sixty-four health districts around the country (Fig 4.5C). The endemic health 
districts confirmed between 2000 and 2004 have remained the hot spots of BU all along. 
However, neighbouring health districts have consistently notified BU during this period. The 
need for further expansion of BU activities to these new foci is clear. The NBUCP plans to create 
two more BU-DTCs in 2015. Furthermore, there is need for another national survey on BU. Such 
a survey may confirm the presence of BU in the northern part of the country, given that in 2008 a 
case from a district in the North region was confirmed and treated at the Akonolinga BU-DTC. 
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Research accompanying BU control in Cameroon 
Cameroon has participated in research on BU since the launching of the GBUI in 1998. 
Indigenous research projects have been carried out in the country and Cameroonian researchers 
have participated in research consortia organized by international research institutes. Results 
from these research ventures have contributed to shape the knowledge pool available on BU 
today and has influenced health policy in the country. 
BU transmission studies in Cameroon have identified water bug families that harbour M. 
ulcerans in their salivary glands [23; 24]. Three of them are good flyers, are attracted by light 
sources, and do bite humans. The authors suggested that these bugs could play a role in 
disseminating M. ulcerans as hosts and vectors [24]. There is however no consensus on this 
within the scientific community [25].  
Persistence of M. ulcerans specific DNA sequences over a period of more than two years 
has been observed at a water contact location of BU patients in a village of the Bankim endemic 
area, after successful treatment of all local patients [26]. At defined positions in a shallow water 
hole used by the villagers for washing and bathing, detritus remained consistently positive for M. 
ulcerans DNA. Underwater decaying organic matter may thus represent a reservoir of M. 
ulcerans for direct infection of skin lesions or vector-associated transmission.  
A seroepidemiological study, also carried out in the Bankim area demonstrated that sera 
collected from children below the age of four do not contain antibodies against the 18KDa small 
heat shock protein of M. ulcerans [8]. These data suggest that exposure to M. ulcerans increases 
at an age which coincides with the children moving further away from their homes and having 
more intense environmental contact, including exposure to water bodies at the periphery of their 
villages [7]. 
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A study in Ayos and Akonolinga [27] revealed that in a context of free medical treatment 
of BU, the cost burden constituted 25% of the annual household earnings of affected families, far 
above the acceptable 10% recommended by the WHO for health expenditure. Further studies on 
innovative and more cost-effective interventions with greater involvement of the communities 
are required in order to deal with the high cost burden on affected families.  
The Ayos BU-DTC hosted the thermotherapy trial as an alternative treatment for BU 
[28]. This proof-of-principle trial demonstrated that heat application alone was effective in 
treating six category I BU lesions with no relapses after 1½ years of follow-up. The authors 
suggested that heat application device used could be suitable to treat BU in resource-poor 
settings like in Cameroon. 
Milestones in BU control in Cameroon  
A number of important milestones have been attained in fourteen years of BU control in 
Cameroon (Fig 4.6).  
 
Fig 4.6. Milestones in the evolution of BU control activities in Cameroon, 1969-2014. Although institutional BU control 
Cameroon only began 30 years after the first cases were reported in 1969, a number of milestones have been attained. These 
will serve as stepping stones for charting the way forward and improving upon control activities in the country. 
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4.6 Challenges in BU control 
BU is an expensive condition to treat and occurs primarily in poor and remote parts of 
Cameroon. Partner resources, upon which NBUCP activities largely depended, are becoming 
rarer leading to cutting down on activities and consequent drop in performance indicators. The 
Government of Cameroon funding for recurrent costs of programme activities is very limited and 
cannot cover the gap. This situation does not allow for rapid expansion of BU activities to new 
endemic districts. 
There is a lack of diagnostic and management skills for BU among the health personnel. 
BU care is not taught in all faculties of medicine and training schools for health personnel. 
Consequently, health personnel may only learn about BU on the job, if they get posted to a BU-
DTC, through workshops and refresher courses organized by the NBUCP and partners. A series 
of workshops on the management of chronic wounds and BU are being organized since 2013 in 
collaboration with MSF-CH, Hôpitaux Universitaires de Genève and the Faculty of Medicine 
and Biomedical Sciences of the University of Yaounde 1 (FMBS-UY1).  
Many unanswered questions about BU still prevail. The mode of transmission, the exact 
prevalence and incidence, the relationship between BU and HIV/AIDS, the role of beliefs and 
customs surrounding BU, economic costs of BU treatment and the effect of M. ulcerans infection 
on nerve conduction are a few of the concerns. These questions call for well planned and 
executed research projects. Most research projects in Cameroon so far were championed by 
expatriates. However, this trend is changing as more Cameroonian researchers are now involved, 
and the FMBS-UY1 has now introduced a course on BU in its curriculum. Furthermore, some 
Cameroonian researchers and care providers have recently founded the Cameroon Wound 
Management Society with the aim, among others, of promoting BU research.  
117 
 
Earnest Njih Tabah  Skin NTDs in Cameroon: the need for integrated control and elimination 
  
4.7 The way forward 
 Much experience has been acquired in 12 years of BU control in Cameroon. Capitalizing 
on these experiences and lessons learned should prepare the NBUCP to be more effective and 
efficient. This will require dealing with the identified challenges. The NBUCP is intensifying 
advocacy to get more partners on board as well as secure more resources from traditional 
partners of the programme. The Cameroon’s Ministry of Public Health is aware of the dwindling 
partner resources and has begun to put in some additional resources for recurrent costs since 
2013.  
The remaining faculties of medicines of the various state universities as well as the 
training schools for health personnel in Cameroon should follow the example of FMBS-UY1 to 
include courses on BU in their training programmes and be more involved in research activities 
on the disease. 
4.8 Conclusion 
This review shows that significant progress has been made in BU case detection and 
management, health system reinforcement, capacity building and research in Cameroon, 
although institutional BU control Cameroon only began 30 years after the first cases were 
reported. However, the reduction in programme resources and activities by the major support 
partners has led to a steady drop in performance indicators since 2010. More effort needs to be 
made in resource mobilization for expansion and scaling up of the programme activities. 
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4.10 Supporting information 
S1. Dataset for Fig 4.2 and 4.3: Trends in BU case notification between 2001 and 2014 in 
Cameroon and globally. In Cameroon, a cumulative number of 3700 BU cases were notified 
between 2001 and 2014, with an annual average case notification of 264 cases. The peak in 2004 
is attributed to the national BU survey in that year. There is a general drop in case notification 
since 2010. The trend in the global BU cases was similar to that of Cameroon with a rise from 
3245 cases in 2002 to a peak at 5937 in 2004, followed by a progressive reduction to reach 2250 
in 2014 [21]. 
 
S2. Dataset for Fig 4.4: Trend in key BU control indicators from 2006 to 2014. During this 
period, the ulcerative form of BU constituted about 83% of lesions and 90% of all lesions were 
located on the limbs. On average, children below 15 years of age constituted 45% of cases. The 
proportion of category 3 lesions rose from 9% in 2008 to 52% in 2014 and the proportion of BU 
cases confirmed by PCR dropped from 57% in 2010 to 20% in 2014. 
 
S3. Dataset for Fig 4.5: Evolution of confirmed BU endemic health districts between 2001 
and 2014. During the period 2001-2002 there were only two known BU endemic health districts 
in the Nyong basin of central Cameroon [19]. The national BU survey in 2004 revealed the 
presence of BU in 19 other health districts [20]. From 2006-2014, treated BU cases originated 
from sixty-four health districts. 
 
S1. Compressed shape files _Cameroon health district: The Cameroon health district shape 
files used for drawing up of the maps in this article were obtained from the Sub Department for 
epidemiological surveillance in the Ministry of Public Health, Cameroon. 
S1 Survey. Report of the preliminary survey on the situation of Buruli ulcer in Cameroon carried 
out by Um Boock and collaborators in 2004. 
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Chapter 5 
Chapter 5 : A case of cutaneous TB in a BU endemic area 
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5.1 Presentation of Case 
A 27-year old male farmer presented himself to an integrated health centre in the Bankim 
Health District of the Adamaoua Region of Cameroon with two ulcerative lesions with undermined 
edges on the upper chest and neck as well as swollen lymph nodes on the neck (see Fig. 5.1). He 
had not sought any alternative treatment and indicated that the condition had been ongoing for one 
month. Given the known high prevalence of Mycobacterium ulcerans disease (Buruli ulcer; BU) 
in the Bankim Health District [1], ulcer exudates were examined for acid fast bacilli by Ziehl-
Neelsen (ZN) staining at the local health centre and tested positive. Based on the clinical 
presentation and the positive ZN stain, a diagnosis of Buruli ulcer was made and the treatment 
recommended for BU by the World Health Organization (WHO) [2], daily Rifampicin (600mg 
p.o.) and Streptomycin (1g i.m.) for 56 days, was administered to the patient. Additional swabs of 
ulcer exudates were analyzed using the M. ulcerans specific IS2404 quantitative polymerase chain 
reaction (qPCR) assay[3]. All 4 swabs obtained from the patient tested negative. Exudate swabs 
were also used for the initiation of a culture on Löwensein-Jensen medium after decontamination 
with 2.5% oxalic acid for 30 minutes at room temperature.  After 8.5 weeks of incubation at 31ºC, 
the optimal growth temperature of M. ulcerans, mycobacterial growth was observed.  The cultured 
mycobacteria were ZN positive, but negative in the M. ulcerans specific IS2404 qPCR.  PCR 
amplification [4] and DNA sequencing of the rifampicin resistance determining region (RRDR) of 
the rpoB gene identified the strain as belonging to the M. tuberculosis complex; no rifampicin 
resistance conferring mutation in the RRDR was found.  A qPCR analysis of the single-nucleotide 
(A to C) change at position 2’154’724 further characterized the cultivated strain as belonging to 
Lineage 4 (Euro-American) of M. tuberculosis [5].  Spoligotyping and analysis using the SpolDB4 
database, revealed that the M. tuberculosis strains belonged to the "T-family" [6]. 
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Based on this laboratory diagnosis of an M. tuberculosis infection, the patient was re-
examined 186 days after completion of the BU treatment.  At this point the ulcers had fully scarred 
(see Fig. 5.1).  However, the lymph nodes of the neck remained indurated.  A chest x-ray provided 
no evidence for pulmonary TB and the patient tested negative for human immunodeficiency virus 
(HIV) infection.  Given the laboratory results and the clinical presentation, the patient was 
retrospectively diagnosed as a case of cutaneous TB [7].  Given the insufficiency of the BU 
treatment to cure TB, the patient was started on the full regimen of the standard TB treatment 
recommended by the Cameroon National TB Control Program: 2 months of isoniazid, rifampicin, 
ethambutol and pyrazinamide followed by 4 months of isoniazid and rifampicin.   
5.2 Case Discussion 
Ethical approval (clearance No 041/CNE/DNM/09, 19/06/2009) to analyse patient 
specimen was obtained from the National Ethics Committee of Cameroon, registered under the No 
IRB00001954. Written informed consent from the patient was obtained before specimen were used 
for reconfirmation of clinical diagnosis and detailed laboratory analysis. 
BU disease presents with a variety of clinical manifestations including non-ulcerative 
forms, such as movable subcutaneous nodules, plaques and oedema, which may eventually 
progress to ulcerative lesions with characteristic undermined edges.  Without treatment, ulcers 
may enlarge considerably and involve entire limbs or large areas of the trunk [8]. It is believed that 
mycolactone, the macrolide toxin produced by M. ulcerans, largely contributes to the pathogenesis 
of BU disease [9]. The diversity in clinical presentation renders clinical diagnosis difficult. Of the 
four currently available methods for laboratory reconfirmation of BU [8], only one, ZN 
microscopy, is suitable as a point-of-care diagnostic test in the African endemic areas that are 
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usually remote and rural. However its sensitivity is limited [10,11]. Cultivation of the slow-
growing mycobacteria, histopathology and PCR-based detection of M. ulcerans DNA can only be 
performed in central reference laboratories. 
Given its wide range of clinical presentations, the differential diagnosis of cutaneous 
tuberculosis, which makes up 1%-2% of all TB cases worldwide [7,12], is also difficult. Both 
infectious and non-infectious diseases of the skin need to be considered when examining a 
potential case of cutaneous TB [13]. For a definite diagnosis, histological examination, PCR, or 
optimally isolation of M. tuberculosis is required. All of these diagnostic methods again requires 
sophisticated reference laboratories [7,12]. Once diagnosed, patients can be treated with regimen 
that is also used to treat pulmonary TB [7]. It is remarkable that a clinical manifestation very 
similar to that of BU disease was observed in the case presented here, though M. tuberculosis does 
not produce a potent macrolide toxin. 
For patients from BU endemic regions, ZN microscopy is usually accepted as 
reconfirmation of the clinical diagnosis and, to reduce costs, it has been suggested that only ZN 
negative swabs should be sent to a reference laboratory for analysis by PCR [11].  While the vast 
majority of ZN positive samples are also PCR positive, sensitivity of PCR is much higher than 
microscopy and many ZN negative samples still turn out PCR positive [11]. In BU endemic areas 
as remote as the Bankim Health District, clinical diagnosis by local medical staff is often 
considered sufficient for treatment decision. It has been shown, that if clinical diagnosis is 
performed by highly trained and experienced staff, more than 90% of the suspected cases can be 
reconfirmed by PCR [14].  However in regions where health care staff does not regularly encounter 
BU cases, a large proportion of suspected BU cases cannot be confirmed by laboratory tests [15].  
Clinical over diagnosis on one side and missing true BU cases by relying only on ZN microscopy 
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on the other side, can lead to over- or under treatment of patients, respectively.  It is therefore 
recommended that all BU cases should be laboratory confirmed [15].  If the decision is made to 
send only ZN negative swabs for confirmation to a reference laboratory, training of health care 
staff in BU differential diagnosis becomes even more important. Furthermore, such training should 
include the clinical presentation of other skin diseases including other mycobacterial diseases. As 
demonstrated by the case presented here, lymphadenopathy – not a typical sign of BU – should 
lead to more detailed clinical examination. 
Overall, the case of a misdiagnosed patient with cutaneous TB in a BU endemic area 
presented here further underscores the need for a simple, highly sensitive and specific point-of-
care diagnostic test for BU.  
 
Figure 5.1 Clinical Evolution of TB Patient Discovered in BU Endemic Area. A 27-year-old male presented to an integrated 
health centre in a BU endemic area in Cameroon with multiple lesions on the neck and upper chest. After observing acid fast bacilli 
in the wound exudates, the patient was diagnosed with BU and treated according to WHO guidelines. Figure 1A shows the patient 
on day 17 of BU treatment. The lesions healed following 8 weeks of Rifampicin / Streptomycin combination therapy. Figure 1B and 
C show the patient 86 and 178 days after completion of BU treatment, respectively. Further laboratory analysis on the original 
wound exudates showed that the patient was suffering from TB as opposed to BU, and the appropriate long-term TB treatment 
was administered. 
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5.3 Learning points 
➢ Clinical diagnosis of Buruli ulcer should be supplemented with laboratory examinations 
➢ Microscopy, the only point-of-care laboratory test currently available, does not 
differentiate between Buruli ulcer and infection by other mycobacteria. 
➢ Clinical presentation of other mycobacterial diseases should be included when training 
staff on the differential diagnosis of Buruli ulcer. 
➢ There is a pressing need for a sensitive and specific point-of-care laboratory test for Buruli 
ulcer. 
 
5.4 Acknowledgement 
We would like to thank Fidel Gaetan Wantong, Jacques Christian Minyem, and all the 
Bankim health care staff for their great support in the field. Thank you also to Marie-Thérèse Ruf 
and Katharina Röltgen for their valuable help in the laboratory. 
5.5 References 
1.  Marion E, Landier J, Boisier P, Marsollier L, Fontanet A, et al. (2011) Geographic 
expansion of Buruli ulcer disease, Cameroon. Emerging Infect Dis 17: 551–553. 
doi:10.3201/eid1703.091859. 
2.  World Health Organization (2004) Provisional guidance on the role of specific antibiotics in 
the management of Mycobacterium ulcerans disease (Buruli ulcer). 
3.  Fyfe JAM, Lavender CJ, Johnson PDR, Globan M, Sievers A, et al. (2007) Development 
and application of two multiplex real-time PCR assays for the detection of Mycobacterium 
ulcerans in clinical and environmental samples. Appl Environ Microbiol 73: 4733–4740. 
doi:10.1128/AEM.02971-06. 
4.  Kim BJ, Lee SH, Lyu MA, Kim SJ, Bai GH, et al. (1999) Identification of mycobacterial 
species by comparative sequence analysis of the RNA polymerase gene (rpoB). J Clin 
Microbiol 37: 1714–1720. 
128 
 
Earnest Njih Tabah  Skin NTDs in Cameroon: the need for integrated control and elimination 
  
5.  Gagneux S, DeRiemer K, Van T, Kato-Maeda M, de Jong BC, et al. (2006) Variable host-
pathogen compatibility in Mycobacterium tuberculosis. Proc Natl Acad Sci USA 103: 
2869–2873. doi:10.1073/pnas.0511240103. 
6.  Demay C, Liens B, Bruguière T, Hill V, Couvin D et al. (2012) SITVITWEB- A publicly 
available international multimarker database for studying Mycobacterium tuberculosis 
genetic diversity and molecular epidemiology. Infect Genet Evol 12: 755-766. 
doi:10.1016/j.meegid.2012.02.004  
7.  Bravo FG, Gotuzzo E (2007) Cutaneous tuberculosis. Clin Dermatol 25: 173–180. 
doi:10.1016/j.clindermatol.2006.05.005. 
8.  Asiedu K, Scherpbier R, Raviglione M (2000) Buruli ulcer. World Health Organization, 
Global Buruli Ulcer Initiative. p. 
9.  George KM, Chatterjee D, Gunawardana G, Welty D, Hayman J et al. (1999) Mycolactone: 
a polyketide toxin from Mycobacterium ulcerans required for virulence. Science 283: 854-
857 
10. Bretzel G, Siegmund V, Nitschke J, Herbinger KH, Thompson W, et al. (2007) A stepwise 
approach to the laboratory diagnosis of Buruli ulcer disease. Trop Med Int Health 12: 89–
96. doi:10.1111/j.1365-3156.2006.01761.x. 
11.  Yeboah-Manu D, Asante-Poku A, Asan-Ampah K, Ampadu EDE, Pluschke G (2011) 
Combining PCR with microscopy to reduce costs of laboratory diagnosis of buruli ulcer. 
Am J Trop Med Hyg 85: 900–904. doi:10.4269/ajtmh.2011.11-0362. 
12.  James WD (1994) Military Dermatology. Dept. of the Army. 617 p. 
13.  Frankel A, Penrose C, Emer J (2009). Cutaneous tuberculosis: a practical case report and 
review for the dermatologist. J Clin Aesthet Dermatol 2: 19-27 
14. Mensah-Quainoo E, Yeboah-Manu D, Asebi C, Patafuor F, Ofori-Adjei D, et al. (2008) 
Diagnosis of Mycobacterium ulcerans infection (Buruli ulcer) at a treatment centre in 
Ghana: a retrospective analysis of laboratory results of clinically diagnosed cases. Trop Med 
Int Health 13: 191–198. doi:10.1111/j.1365-3156.2007.01990.x. 
15.  Portaels F, Silva MT, Meyers WM (2009) Buruli ulcer. Clin Dermatol 27: 291–305. 
doi:10.1016/j.clindermatol.2008.09.021. 
 
 
 
 
 
129 
 
Earnest Njih Tabah  Skin NTDs in Cameroon: the need for integrated control and elimination 
  
Chapter 6 
Chapter 6 : Yaws in the Lomie Health District, East Region of Cameroon 
 
Yaws in the Lomié health district of the East Region of 
Cameroon 
  
 
 
Earnest Njih Tabah1, Alphonse Um Boock2 
  
1. National committee for leprosy, Buruli ulcer, leishmaniasis and yaws control;  
2. Regional Bureau for Africa of FAIRMED (former ALES)  
 
 
 
 
 
 
 
Published in French in: Bull. de l’ALLF 2010; 25:77 
https://www.leprosy-information.org/files/BALFF%20no%2025%20pages%2063_a_126.pdf  
 
Abstract, published in: 
WHO Annual Meeting on Buruli ulcer, 22-24 March 2010: abstracts. Page 121 
www.who.int/buruli/reources/Buruli_Meeting_abstracts_ENG_pdf?ua=1 
 
 
 
 
130 
 
Earnest Njih Tabah  Skin NTDs in Cameroon: the need for integrated control and elimination 
  
6.1 Introduction 
Yaws, a disease that was eradicated, is re-emerging in the Congo basin. It is thought to be 
endemic among the pygmy population who inhabit the dense equatorial rain forest of the Congo 
basin. Gerstl and collaborators (2009) reported a prevalence of 4.7% in the general population of 
the rural Wasolo health zone in the Equator Province of the north Democratic Republic of 
Congo. Damas Obvala (2010) reported 646 cases of yaws among the pygmies of the Likouala 
and Sangha divisions of Congo. The Sangha division of Congo shares a common border with the 
Upper Nyong and Bomba and Ngoko divisions of the East region of Cameroon. All of the 
divisions cited are located in the Congo Basin and are home to the pygmies. 
In 2008 and the first semester of 2009, cases of yaws were notified by health authorities of the 
Abong Mbang, Lomie and Mbang health districts of the East region of Cameroon, with Lomie 
notifying the highest number of cases. All of the cases notified were among the Baka pygmies. 
We carried out a mass screening of yaws and treatment of clinical cases of yaws among the Baka 
pygmies in the Lomie health district from the 27th of October to the 2nd of November 2009. 
Lomie health district is one of the 14 health districts in the East Region of Cameroon. It has a 
population of 36581 inhabitants, of whom 5211 are the Baka Pygmies. These pygmies in this 
health district live in 35 villages (pygmy camps). 
6.2 Objectives and Methods 
The objectives of this screening activity were to determine the magnitude of yaws among the 
pygmies in the Lomie health district and to gather information favoring its propagation in this 
population, in view of establishing a proper control strategy. 
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In collaboration with the Lomie health district authorities, the pygmy villages were identified and 
a programme of visit was drawn and communicated to the villages in advance. Two teams were 
constituted and trained on the clinical diagnosis and treatment of yaws. After the training, the 
teams went into the villages for mass screening and treatment. In each village, villagers were 
gathered at the village town-hall or school premises and each villager present was examined 
following a standardized checklist for clinical signs suggestive of yaws. Those with yaws were 
each given an injection of benzathine penicillin, and a blood sample taken from those who were 
6 months or older, for TPHA analysis.  
6.3 Results 
Thirty-five (35) pygmy villages were visited, where 822 persons were examined. 167 (20.3%) 
cases of yaws were detected in 22 of the 35 villages. For the 167 cases of yaws, 61% were males 
and 80% were children below 15 years of age. The mean age was 11.9 years (min= 3months, 
max=55 years). The average number of contacts was 6 (min=2, max17).  Early yaws constituted 
94% of the cases. Out of 143 blood samples collected, 40(28%) were positive for TPHA test. 
6.4 Follow-up  
The 167 patients screened and treated were followed-up by the district medical officer and his 
team. Within a period of 3 weeks, 149 (89.2%) of the treated cases had healed. 
6.5 Challenges 
The pygmy population of the Lomie health district lives in a very difficult geo-economic and 
socio-cultural environment. The unhygienic living conditions, abject poverty, high illiteracy rate, 
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lack of potable water, insufficient health infrastructure and the attachment of this population to 
the warm and humid equatorial rain forest favour the transmission of yaws. The expensive nature 
of organizing mass screening and treatment campaigns also poses a big challenge. 
6.6 In perspective 
There is need to survey the remaining health districts of the East Region where pygmies live. At 
the end of these surveys, the National Committee for Leprosy, Buruli ulcer, Leishmaniasis and 
Yaws Control in the Ministry of Public Health would have a clear picture of the situation of 
yaws, to be able to develop an effective and efficient strategy. 
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7.1 Abstract 
Yaws, a chronic skin, bone and cartilage treponemal infection of rural tropical 
communities, causes mostly painless but stigmatizing lesions some of which may become 
permanent, disfiguring crippling deformities. The palmar and plantar forms of yaws are, however, 
very painful. The clinical prevalence of yaws was up to 30% or more in some communities before 
the mid-1960s and caused considerable rural poverty1.  A global eradication effort led by WHO in 
1952 reduced the prevalence in endemic countries by over 95% towards 19652. But short of 
eradicating it and given the poor health systems of endemic countries then a resurgence of yaws 
began again in the 1970s and has since been fought successfully only by Ecuador and India3. Some 
sub-Saharan African (SSA) countries, Southeast Asian countries and Pacific Ocean Islands remain 
endemic for yaws4. There is evidence that children under 15 years who are the most affected by 
yaws continue to suffer stigma and deformities resulting in family and community neglect and 
high school “drop-out” rate. Country and global goals for poverty reduction and universal 
education cannot be achieved if diseases like yaws continue to be neglected despite the availability 
of effective tools to eradicate or at least eliminate them. 
7.2 Introduction:  
Yaws is a contagious disease of skin, cartilage and bones. It causes firm swellings (bumps), 
ulcers and rashes on the skin and can affect any part of the body. It may cause mild pain and 
tenderness, with or without swelling, in the bones and joints5.  Children in deprived communities 
in the tropics are mostly affected, but no age is spared. The infective agent is a bacterium called 
Treponema pallidum pertenue. It is transmitted by persons with yaws skin lesions to susceptible 
contacts who have breaches in the skin through which the organisms enter and set up new infection 
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and possibly disease. The infection stimulates some antibody production but no lasting immunity 
is attained. The disease is diagnosed mostly clinically and easily treated with an appropriate dose 
for age, using single injection of aqueous benzathine penicillin intramuscularly or oral 
azithromycin tablets or capsules5.  
Yaws is known and given local names in parts of SSA. In Ghana it is called “gyator” 
generally in the middle and southern belt, “ekli” in the eastern border with Togo and “jaga” 
generally in northern Ghana. Yaws was well known by endemic populations before eradication 
attempts wiped out a lot of the disease6. Of late though, it is less known, especially among the 
younger generations. However, it is still quite known in typically endemic communities even by 
children as for example primary school children in the Eastern Region of Ghana were able to 
describe the disease accurately. Anecdotes of local treatments of yaws in the past included rubbing 
the painless “bumps” with rough sponges till they were scaled down and using bluestone (copper 
sulphate) to shrink lesions. Many children with yaws today are still not sent to clinics for treatment 
and some of such children hide their lesions if possible, with clothing till they disappear or grind 
them away with rough tools. Such neglect has cost some children their education and deformed 
others with gangosa and other deformities permanently.   
7.3 Clinical features of yaws 
This section describes the forms of presentation of yaws, its signs and symptoms, diagnosis 
and treatment. There probably can be no more complete description of the clinical picture of yaws 
than that presented in Manson’s Tropical Diseases and by the papers of C. J. Hackett, a WHO 
yaws expert of the 1950s and 60s1. This section describes clinical yaws with focus on observations 
made particularly in Ghana and the black skin of SSA for that matter.   
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7.3.1 Yaws presentations  
 The following terminologies have been associated with the clinical presentations of yaws 
and are defined from the onset to clarify further discussions.  
Early yaws refer to lesions of the first two phases of yaws called primary and secondary 
yaws. Primary yaws, also called mother yaw, is the first lesion, usually a single raised bump called 
a papilloma, that appears in 2 to 6 weeks at the site of entry of yaws germs into a skin breach5. 
This papilloma may have other primary small satellite papules or papillomas near it (Fig 7.1). The 
primary papilloma may also be two at different positions depending on the sites initially inoculated 
with treponemal organisms. In one bad case of primary yaws affecting the left eyelids, the lesion 
had been present for about nine months before being seen because the child was hidden in a room 
away from the public (Fig 7.2).  
  
Fig 7.1. Primary yaws papilloma with satellite lesions (Picture courtesy 
of Nsiire A) 
 
Fig 7.2. Ulcerated primary yaws papilloma over left 
eye (Healed after treatment with no affection of eye 
sight) (Picture courtesy of Nsiire A) 
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Secondary yaws appear in other parts of the body, earliest 2 weeks after the primary 
papilloma, but may take as long as 16 weeks or longer to appear. These may present as uniform 
lesions of one kind or a mixt of papillomas, ulcers, macules or papules of various sizes. They may 
also present as pustules especially in the scalp, anhydrosis of the skin; cracks, pitting, erosions or 
thickenings of palms and soles; or painful bone and joint swellings1,5,7. Secondary lesions result 
from organisms that enter the blood stream from the primary papillomas to set up skin, bone or 
joint affections in other parts of the body than the site of initial entry.  Secondary yaws can 
therefore co-exist with a primary yaws papilloma or its ulcerated stage which can make their 
distinction difficult except by careful history taking5,7.  
 Late yaws also called Tertiary yaws, refers to a very small fraction of early yaws cases 
(less than 5%) which progress to late forms of yaws which are destructive of tissues leaving 
permanent scars, contractures or other bone and cartilage deformities (gangosa, gondou, sabre tibia 
and dactylitis)5.  
 
Fig 3. Gangosa in two 13-year-old boys (Picture courtesy of Nsiire A) 
Late yaws does not normally co-exist with early yaws lesions but two 13-year-old boys 
from the same community reported with yaws-like lesions on the noses which progressed to 
permanent gangosa deformities (Fig 3). This is consistent with reports which suggest that gangosa 
and gondou can occur early in yaws infection and can be stopped with appropriate treatment or 
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progress to permanent deformities5. This makes it imperative to pay particular attention to lesions 
on the face and nose in yaws endemic populations. Saber tibia and dactylitis may also be stopped 
and reversed if treated early or may progress to permanent deformities if left untreated. Late yaws 
is non-infectious because the body’s own defense mechanisms has eliminated the organism or 
greatly attenuated it, though no permanent immunity is generated. 
For practical purposes of yaws control, elimination and eventual eradication, primary, 
secondary and tertiary yaws have been simply regrouped into the: i) infectious Early yaws group; 
this group can be controlled with drug treatment and other measures like personal hygiene and 
avoiding close contact behaviour7; and the ii) non-infectious Late yaws (which are generally 
physical deformities) can be corrected surgically and/or through physiotherapy.  
7.3.2 Infectious yaws:  
This refers to all the skin lesions of early yaws with the potential to transmit yaws 
organisms to other persons. In order of infectiousness, the papilloma come first because they 
secrete many organisms, followed by all the other skin manifestations (macules, papules etc.) 
which secrete very few. Papilloma on the palms and soles are also infectious but the palmar and 
plantar forms like cracks, erosions and fissures which occur more on the soles than palms are least 
infectious5,7. This means children playing or sleeping together more easily get infected from 
papillomas than from the other skin forms for which closer contact (e.g. wrestling and sweating) 
is needed. 
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7.3.3 Non-infectious yaws:   
The early bone and joint forms as well as all the late forms of yaws are non-infectious as 
they secrete no treponemes on the surface. Technically, the early bone and joint forms are still in 
the infectious phase as organisms from them may later show as skin lesions after latency7. 
 
7.3.4 Overt and latent yaws:  
Overt yaws show signs on the skin, cartilage or bone. It is diagnosed clinically and treated. 
Latent yaws is a phase during early yaws infection when all skin, bone and joint manifestations 
have disappeared without treatment or with ineffective treatment. The organisms have however 
not all died out but persist in the blood to manifest later with signs of early yaws on the body7. 
Because of this, latent yaws cases are a crucial population in yaws eradication activities as not 
treating them allows transmission of the disease to persist in the population7. 
7.3.5 Contacts of yaws:  
Yaws contacts are those who are incubating the disease (i.e. between inoculation of germs 
and appearance of primary papilloma(s) which on average is 2 to 6 weeks but can be longer.  This 
means that one overt case can continue infecting many people and set up a continuum of new cases 
and incubators who will not show overt disease for weeks. These incubators will be missed out 
when looking for cases in facilities, schools or communities. Contacts are therefore a crucial 
population in disease elimination and eradication strategies because if they are not treated they 
will later show overt disease and continue the transmission of yaws. 
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7.3.6 Attenuated yaws:  
This term attempts to describe the current clinical and epidemiological picture of yaws due 
to widespread use of antibiotics and improving sanitation which are believed to reduce the 
manifestation of the disease. Thus, attenuation appears in four ways: i) reduced size of lesions (e.g. 
papilloma) on an individual, ii) reduced extent or numbers of lesions on an individual, iii) absence 
or near absence of late forms of yaws and iv) generally low prevalence in traditionally highly 
endemic countries. While the concept of attenuated yaws may generally be acceptable whatever 
its value to eradication efforts, it should be stated that very large papillomas have still been 
observed both in children and adults. Late yaws lesions including gangosa have also been observed 
in sub-Saharan Africa. A high prevalence of up to 17% has been reported among the pygmies by 
Medecins sans frontier staff piloting single dose oral azithromycin mass drug administration in 
20128. Sporadic outbreaks have also been reported in Cameroon9 and in Ghana (Outbreak Report, 
2009).  
7.3.7 Clinical features of yaws: Signs and symptoms 
Constitutional symptoms are very mild in yaws expressing as mild joint and bone pains in 
children at night with no obvious fever. This is easily complained of by guardians in some endemic 
communities where the disease is called by its local name.  
Early yaws lesions may appear on any part of the skin from the scalp to the sole of the foot. 
The majority of the lesions however are found in the lower limbs because of the greater exposure 
of those parts. The bone and joint forms affect mostly the face, forearms, wrists, hands, fingers, 
legs and the ankles. But nodular forms may also affect the skull. Early yaws lesions are 
characterized by the presence of one or more of the following5,10. 
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Papillomas are pale or yellowish, painless and firm to hard chancres usually with dark tips 
showing points of beginning necrosis. They vary in size from less than one to three centimeters 
typically with no inflammation of the skin around them. But papillomas may also have a pale halo 
of macula inflamation extending a centimeter or more around them. Those on the exposed parts 
especially the legs tend to have surrounding skin inflammation due to bacterial infection and there 
may be pigmented skin around the lighter yaws lesions or a mixture of pale and pigmented 
surroundings5,10. Because they are painless and stigmatizing, some children tend to hide them with 
their clothing or rub off those in accessible parts of their body with rough tools like sponges or 
even sand until they are flattened small yellowish blebs feeling rubbery soft rather than hard. 
Ulcers: These may occur as initial lesions or be ulcerated papilomas, they usually have 
raised edges, especially papillomas that necrose from the tip (Fig 7.4). The floor is dirty and crusty 
or yellowish and soggy. Some papillomas may not ulcerate from tip downwards but peel off the 
skin leaving a raw fungating surface5. Both papillomas and ulcer forms attract flies because of 
their secretions but there is no documented evidence of transmission by flies. 
  
Fig 7.4. Papillomata and papules of early yaws (Picture 
courtesy of Kwakye-Maclean C) 
Fig 7.5. Maculo-papular lesions of early yaws on elbow 
(Picture courtesy of Kwakye-Maclean C) 
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Papules are of the size of rice grains or smaller, pale, painless, firm and usually discrete5. 
The smaller forms may be patchy and itchy. 
Macules are small, pale discrete dots or patches5. They may be present mixed with other 
yaws lesions like papillomas and papules (Fig 7.5). The dorsum and margins of feet frequently 
show macula-papular rashes that may have atypical appearance due to the exposure of those parts 
to hazards of the physical environment. 
Palmar and plantar yaws are painful lesions of the palms and soles5 (Fig 7.6 and 7.7). The 
palmar lesions are less painful usually showing as yellowish hyperkeratosis. Plantar yaws 
especially are very painful showing as cracks or fissures, erosions, pitting or hyperkeratotic 
thickenings on the soles (Figs 6 and 7). Papillomas may also occur on palms and soles and are 
similarly painful.  
  
Fig 7.6. Plantar yaws: thickenings; (Picture by Kwakye-
Maclean C) 
Fig 7.7. Plantar yaws erosions (Picture by Kwakye-Maclean C) 
 
Bone and joint lesions: Moderate swelling and tenderness affect mostly the bones and 
joints of the forearm, wrist, fingers and legs5,10 (Fig 7.8 and 7.9). Usually one or two bones may 
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show obvious swelling with other bones having subclinical osteitis. Beginning of tibia bowing 
may be seen with or without ulcerated lesions on the leg (Fig 7.9). It is not uncommon to see a 
pale, contiguous patch on the dorsum of a hand with one of the fingers of the same hand swollen 
and tender (Fig 7.8).  The presence of bone and/or joint swellings together with suspicious skin 
rashes in a child in an endemic area should lead to a high suspicion of yaws.  
  
Fig 7.8. Yaws dactylitis (early yaws affection of 
bones) (Picture by Kwakye-Maclean C) 
Fig 7.9. Saber tibia (early yaws affection of 
bones)(Picture by Kwakye-Maclean C) 
 
Ganglia, nodules and enlarged lymph nodes: These have rarely been seen in Ghana 
attributed to yaws but can occur especially near the joints and in the head. Enlarged lymph nodes 
have been seen in few cases. 
Yaws may present as other atypical rashes including anhydrosis and other scaly dry or 
pigmented conditions with line markings especially on the lower limbs. Lesions on elbows and 
knees tend to be mixed papules, macules and small papillomas which usually ulcerate and look 
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soggy, but they may also be clean macules or papules or patches of them. Generally, all early yaws 
skin lesions are paler than the normal skin and painless except for those on the soles and palms or 
when secondarily infected with other bacteria. They are also frequently polymorphous – that is, 
many types of early lesions present together. 
Late yaws lesions are now rarely seen but have traditionally affected the face (Gangosa and 
Gondou), forearm and finger bones (polydactylitis), leg bones (sabre tibia) and the skin as ugly 
and permanent scars5,10. It should be noted that bending of long bones occurs in early yaws but can 
be corrected with treatment. Sabre tibia is therefore technically used to describe late yaws where 
the tibia deformity has become permanent. 
7.4 Diagnosis of yaws 
Yaws is mostly diagnosed clinically from the various lesions described above. For purposes 
of searching for overt and latent cases and contacts in control or eradication programs however, a 
case definition of yaws involves anyone with one or more of the following: papillomas, ulcers with 
raised edges, papules, macules, arthralgia especially in children, bone swellings with moderate 
tenderness especially in children, nodules or ganglia, plantar cracks, erosions or thickenings, or a 
history of any of these in the last five years. Gangosa, gondou, sabre tibia, deformed finger bones 
and joints and skin gummata, active or within the recent past or any skin condition not attributable 
to any known cause should be considered as yaws7. 
The laboratory diagnosis of yaws is based on both qualitative and quantitative serological 
tests. The two main types of serology used are treponemal and non-treponemal tests11,12,13. 
Treponemal tests detect Treponemal antibodies which are present for life once a person is infected 
with any of the Treponemes13. They are useful therefore in confirming a person’s previous 
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exposure to infection but do not confirm a current infection. Examples of treponemal tests are 
Treponema pallidum hemagglutination (TPHA) and Treponema pallidum passive particle 
agglutination (TPPA) tests11, 13. There are variants of these tests like Syphilis First Response used 
in antenatal clinics and on the field qualitatively as point of care tests (POCTs). Treponemal tests 
can also be used quantitatively to estimate the dose of antibodies in the individual. 
Non-treponemal tests like rapid plasma reagin (RPR) detect active disease by the presence 
of nonspecific antibodies that rise with infection but peter out in a month or two14. They may also 
be used qualitatively and quantitatively but have the drawback of cross reactivity in other 
conditions like malaria, typhoid and pregnancy. In community surveys they are probably more 
useful than treponemal tests in detecting latent cases and contacts who are harbouring active 
infection.  
Perhaps the best serological tests are the modern generation of dual path platform POCTs 
being developed for both treponemal and non-treponemal tests on one platform. New products like 
the Chembio Dual Path Platform tests for treponemal and non-treponemal antibodies at the same 
time. Some of these are being evaluated in Ghana, Papua New Guinea and Vanuatu and will be 
useful as point of care rapid diagnostic tests for surveys, confirmation of yaws in resistant lesions 
to treatment and for surveillance in the eradication phase of yaws if found of satisfactory 
sensitivity, specificity and are cost effective15,16. For routine diagnosis however and identifying 
endemic communities for total community treatment or total targeted treatment with Azithromycin 
or benzathine, clinical diagnosis with given case definitions will continue to be the preferred tool 
with highest sensitivity17.   
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Genetic tests like the polymerase chain reaction tests are being developed with primers 
specific for yaws11. These will be the only tests to differentiate the various Treponemes. Venereal 
diseases research laboratory (VDRL) tests and dark field microscopy12,18 are hardly being used 
nowadays for yaws diagnosis. They have been replaced by the dual path platform rapid diagnostic 
test for syphilis. 
7.5 Differential diagnoses of yaws 
These include similar skin, bone and cartilage lesions of the three related Treponemal 
diseases, namely, venereal syphilis, endemic syphilis and pinta. Pinta is however not found in SSA. 
Other differential diagnoses are leprosy, impetigo, eczema, fungal skin infections, cutaneous 
leishmaniasis, tropical ulcers, pressure niduses of the soles, plantar and venereal warts, weather-
cracked soles of Harmattan, moluscum contagiosum, scabies, lichen planus, psoriasis and 
congenital epidermiolytic hyperkeratosis5.  
7.6 Treatment of yaws 
Yaws, like syphilis, has fortunately remained sensitive to penicillin especially in SSA. 
Depot forms for single intramuscular injections to keep high blood levels for long periods have 
included penicillin aluminium monostearate in oil (PAM) which was used for yaws eradication 
purposes in the 1950s and 60s2,19,20. It had the undesirable effect of leaving scars at injection sites 
due to the oil base. PAM was therefore replaced by aqueous benzyl benzathine penicillin which 
can keep blood levels high for two to four weeks. The dose of depot penicillin for adult cases and 
children over 10 years is 1.2 mega units once intramuscularly while half of that is given to 
corresponding adult and child contacts. For children 10 years and below 0.6 mega units is used 
and half of that (0.3 mega units) for child contacts 10 years and below. Aqueous benzyl benzathine 
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penicillin is however very painful and cumbersome for mass field administration for control, 
elimination or eradication purposes7.  
The Ghana and Papua New Guinea drug trial studies of 2010/201121 have however caused 
the World Health Organization (WHO) to revamp and revise the policy for yaws eradication using 
single oral doses of tablet or capsule Azithromycin in mass drug administration17. The prescribed 
doses are as indicated in the Fig 7.10 below22.  
 
Fig 7.10: Azithromycin treatment chart for a yaws screening and treatment campaign. Source: adapted from the summary report 
of the WHO consultative meeting on yaws eradication22. 
7.7 Importance of yaws 
The importance of yaws derives from the direct physical effects as well as the social, 
cultural and economic effects on individuals, families and communities23. The burden of yaws may 
not necessarily be in terms of mortality but rather morbidity related to the discomforting and 
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sometimes painful or crippling lesions, which could be transient or permanent. Some yaws lesions 
leave stigmatizing sequelae negatively affecting social life and the education of some children. 
The painful and crippling yaws (crab yaws, dactylitis, sabre tibia) can also impact negatively on 
individual, family or community activities and incomes. Thus, the millennium development goals 
on poverty reduction, universal education and morbidity reduction are negatively impacted upon 
by yaws and the other neglected tropical diseases.  
7.8 Epidemiology of yaws  
Yaws affects persons of all ages but mostly children under 15 years of age. Young adults 
are next most affected especially by plantar yaws. Boys are more affected than girls. The reasons 
for this lie in behaviour, children, especially the boys, being usually more exposed and more 
contact and bruise prone which are necessary conditions for yaws transmission. Poor personal 
hygiene is a strong contributing factor7,10,. 
Between 1940 and 1950, 37 Sub Saharan African countries, reported yaws cases to WHO1. 
Since 46 countries were involved in the global campaign for yaws eradication2 it means Africa 
formed the bulk of yaws endemic countries then3. Today, yaws is still endemic in a number of 
SSA countries with wet, humid forest and/or dry, grassland areas (Fig 7.11). 
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Fig 7.11: Map of distribution of yaws in the word in 20123  
 Generally, these countries lie within the tropics with temperatures between 20oC and 40oC 
and exceptionally exceeding these limits especially in East and South Africa with considerable 
highlands and which may lie within the southern temperate belt. Yaws or its close relation bejel 
therefore probably thrives in all of Sub Saharan Africa but current WHO records indicate that only 
13 of about 50 such countries have any reports or post eradication period assessments suggesting 
that they are yaws endemic. These are Benin, Burkina Faso, Cameroon, Central African Republic, 
Chad, Congo, Democratic Republic of Congo, Ghana, Guinea, La Cote d’Ivoire, Liberia, Sierra 
Leone and Togo22,24. Report of a WHO Afro Regional Meeting on “Yaws and other endemic 
Treponematoses” held in 1986 also listed additional countries to the above that reported yaws cases 
in 1984, namely, Burundi (102), Chad (629), Equatorial Guinea (283), Gabon (257) and Rwanda 
(225)25. The same report mentions that yaws was being reported from states like Borneo and 
Bauchi in Nigeria which were previously not known to be endemic. The current yaws situation on 
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the African continent therefore really need a reassessment. The highest prevalence remains among 
the pygmies of central African countries (Cameroon, Central African Republic and the Congos)8,9. 
In Ghana and other West African countries however, the prevalence is generally low but the 
distribution is wide in isolated rural areas and some suburban poor communities. Surveys in Ghana 
suggest that yaws may be found more in children and young adults not in school than those in 
school26. 
Records compiled by C. J. Hackett for 37 SSA countries of the 1950s gave some 
information on the seasonality pattern to yaws though few countries (Angola, Cameroon, Congo, 
Mozambique and Sierra Leone) indicating higher numbers of yaws during the warm, humid, rainy 
seasons1. Current monthly returns to the national program in Ghana do not show clear seasonality. 
Some reports suggest however that yaws incidence may rise in the cold seasons as a behavioural 
outcome when children huddle together during sleep, as reported of the cold monsoons in parts of 
India27.  
Yaws is transmitted through skin contact between infectious yaws cases and others who 
sustain bruises or openings of any kind during the contact, or previously, allowing the organism 
(Treponeme) to enter and establish infection7,10. The Treponeme is a slow growing oxygen 
dependent intracellular organism with a doubling rate of about 30 hours28. This combined with a 
long incubation period of up to 90 days10 yaws a not too highly infectious disease. But the very 
existence of long incubating contacts and latent cases makes yaws transmission intractable unless 
effective interventions are put in place7. Apart from age and sex, other predisposing factors for 
yaws transmission are poor personal hygiene especially not bathing at least once a day and, in the 
evenings, poor water supply and overcrowding. 
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7.9 Public health importance of yaws 
   As a communicable disease yaws remains a public health hazard to all at risk populations 
which is the totality of Sub Saharan Africa living under predisposing conditions. The current 
clinical prevalence is probably below 5% in most endemic populations other than among the 
pygmies8,9. Clinical yaws surveys among school children in Ghana put yaws prevalence district-
wide at less than 2%26.  Thirteen percent to 19% have however been recorded in individual schools, 
but the quality of these surveys is questioned. The colonial office medical department annual 
reports (MDARs) 1938-39 of the Gold Coast Government (now Ghana) point to the high burden 
of yaws in those days and some documentations ranked yaws as highest cause of outpatient 
morbidity or at same level with malaria, guinea worm and onchocerciasis6.  Qualitative comments 
of the social and economic impact on rural populations are rampant in the literature but these have 
never been quantified and are absent in recent research works. Anecdotal evidence and personal 
experience of the authors and some field workers seem to indicate that stigma and morbidity affect 
children negatively in terms of their education and social life. Two children abandoned school 
permanently. One abandoned for severe morbidity and stigma on the eye but with support from a 
philanthropist, resumed school after treatment. A fourth girl of 12 years almost crippled with bone 
and joint conditions and socially cast out, resumed a vibrant life after treatment.    
Surveillance of yaws after the global eradication efforts seemed to have been stopped in 
most African countries apart from Ghana. A personal communication by Dr Earnest Njih Tabah 
indicates that in Cameroon, the eradication effort ended in 1970 and with it, surveillance on yaws. 
It took outbreaks of yaws in 5 districts in 2007 and 2008 for the Ministry of Public Health to 
include yaws again in the Buruli ulcer, Leprosy and Leishmaniasis Control Program in 2009 and 
in the national master plan of 2012 – 2014. Between 2010 and 2011, 23 out of the 181 health 
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districts had reported yaws cases through mass screening and passive notification22. La Cote 
d’Ivoire similarly had no program of yaws control though in 2010, according to routine data made 
available to WHO by Professor Henri Asseh of the Buruli Ulcer program, 67 out of the 90 districts 
reported yaws. Ghana’s eradication effort ended in 1969 but Eastern and Central Regions, now the 
most endemic in the country, had been excluded in the effort.  In the event passive surveillance 
and treatment have been continuously carried out with clinic based medical field unit (now disease 
control unit), staff. Between 1980 and 1983, WHO, the World Bank and other partners tried a 
combined yaws mass treatment with immunization against yellow fever and tetanus, but it was 
short-lived. The current resurgence of global interest in the neglected tropical diseases and new 
treatment and diagnostic tools have caused WHO to bring to the fore again the drive to eradicate 
yaws. In this respect globally, countries have been divided into three categories. i) Category C 
countries are traditionally non-endemic or have achieved and documented yaws elimination for 
which they will be so certified. ii) Category B countries are previously endemic countries with 
little or no knowledge of their current situation. They will have to carry out studies/surveys to 
establish their status and either join category A or C. iii) Category A countries, like Cameroon and 
Ghana who know that they are endemic will carry out pilot studies with the new tools and scale 
up elimination activities. The WHO target for global eradication of yaws is 2020, along with 
elimination of ten other NTDs. But this poses the frequently asked question should yaws or any 
other disease be eliminated or eradicated instead of just being controlled?  
7.10 Should yaws be controlled, eliminated or eradicated? 
This section is written purposefully to answer this recurrent question: should any disease 
be controlled, eliminated or eradicated? For the authors, the real consideration for eliminating or 
eradicating diseases is one: it is the logical and ultimate goal of public health practice. This is aptly 
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put by Cochi and Dowdle, editors of the book “Disease eradication in the 21st century: the 
implications for Global Health”,  in which they state: “Disease eradication represents the ultimate 
in global equity and the definitive outcome of good public health practice”29. As an individual 
desire to be completely cured of a disease, so communities desire to be completely rid of diseases. 
But faced with the reality of life as a whole and not just as a biological property, concepts and 
definitions of concepts like quality of life, disease burden, disease control, elimination and 
eradication become necessary tools to help manage our human limitation. An institutional 
arrangement “International Task Force for Disease Eradication (ITFDE)” even exists at the Carter 
Centre to help in some of these concepts30.  
Disease control is the reduction of disease burden from one level to another.  This requires 
persistent and innovative effort to achieve the reduction and to keep it at that level or bring it 
further down to yet another level. This continues till the disease is eliminated or eradicated. Disease 
control is thus only palliative since individuals and the community are still at risk and it exacts 
significant resources. 
Elimination is reduction of a disease to a level of no public health importance. This means 
the disease can no longer spread in the population if it is communicable. For many communicable 
diseases elimination may be achieved even though a few cases persist in the population. The 
number of such cases is below the threshold of the capacity of that disease to spread even though 
the agent causing it and sometimes the intermediary hosts are still in the environment. Examples 
are leprosy and filariasis. Surveillance is however maintained to make assurances double sure 
because we are dealing with nature. In theory any disease, communicable or non-communicable 
may be considered eliminated if the factors predisposing to it in the population are absent. Thus, 
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HIV and AIDS will be eliminated if all know their status and effective protective sex is practiced 
and only safe blood is transfused. 
Disease eradication is total reduction of the disease to zero (no cases at all) and removal of 
the causative agent from the wild where it is free to move within the population. If it is a biological 
agent it may be constrained to a laboratory but if this laboratory specimen is also destroyed then 
the disease is said to be extinct. For a disease like yaws that is known to exist also among other 
primates like chimpanzees and gorillas, it would seem more appropriate to talk of yaws elimination 
rather than eradication. In theory though eradication of the disease and not the germ from among 
the human population is still conceivable and may be so pronounced by politicians. Else, to 
eradicate yaws, the animal reservoirs must also be tackled. 
Considerations for eradication of a disease: The most exhaustive work on this subject is 
presented in the book edited by  Cochi and Dowdle29. Authors of varied backgrounds, experiences 
and from all over the globe consider all the possible and numerous factors and lessons relevant to 
disease eradication. Ideally all diseases should be scored and scaled based on a matrix of these 
factors for prioritization for elimination or eradication. If this is not done and a disease like yaws 
is picked and earmarked for eradication because of one or two considerations, two big problems 
arise: Where is the basis and what priority level does yaws occupy? And it is within such arguments 
that the true purpose of public health gets lost. If diseases with proven scientific tools to eliminate 
or eradicate them must be so targeted based on the harsh realities of economics, then the ultimate 
objective of public health must be redefined like man himself as a diogenes post script. In the 
authors’ view, any disease that is scientifically amenable to elimination or eradication from a 
population must be so targeted and the social effort of that population re-engineered to achieve it.  
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8.1 Abstract:  
Stigma which has been defined as an “attribute that is deeply discrediting, and that reduces the 
bearer from a whole and usual person to a tainted, discounted, and inferior one” (Goffman 1963), 
arises from various sources and occurs in different forms. Stigma can be internalised or anticipated 
by the stigmatised person who accepts perceived exclusionary views of the society fear of enacted 
stigma on behalf of a person with a stigmatizing condition. Lastly, stigma may be endorsed or 
accepted by the society (Weiss 2008).  
Stigma is associated with many neurological diseases globally, especially in the neglected 
tropical diseases. Stigma develops within the background of rich and diversified cultural beliefs 
and traditions, where the population’s knowledge on chronic neurological conditions is usually 
limited and therefore, attitudes practices are based largely on misconceptions and myths. 
Stigma has serious consequences on the people affected by neglected neurological conditions 
and their families. It may be considered as the weakest link in the chain of disease diagnosis, 
treatment, prevention and eventual control or elimination. Stigma therefore constitutes a limiting 
factor to an acceptable quality of life for the patients and the society. Various strategies have been 
suggested to fight stigma but this war is far from being won, although some battles have been 
successful.  
The brain mechanisms of stigma are largely unknown although some interesting data are now 
available. The growth of the young discipline of social neuroscience despite many challenges may 
provide leads on more effective strategies of stigma reduction in the future. 
Keywords: Stigma; Neurological disease; Tropics; Neuroscience; Determinants; Consequences 
and Control. 
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8.2 Introduction 
8.2.1 Stigma: from the historical concepts to a new formulation 
In his landmark treatise entitled Stigma: Notes on the Management of Spoiled Identity, the 
social scientist Erving Goffman (1963) noted that originally the term stigma is a Greek word that 
referred to a type of marking or tattooing that was cut or burned into the skin of criminals, slaves, 
or traitors in order to visibly identify them as blemished or morally corrupted persons. These 
individuals were to be avoided or shunned, particularly in public places. Goffman then defined 
stigma as an “attribute that is deeply discrediting, and that reduces the bearer from a whole and 
usual person to a tainted, discounted, and inferior one” (Goffman 1963). 
Stigmatizing traits occur in three forms: (i) Overt or external deformations, such as scars, 
physical manifestations of leprosy, or of a physical or social disability; (ii) Deviations in personal 
traits like behaviour change in mental illness, drug addiction, homosexual tendencies, alcoholism, 
and criminal background; (iii) "Tribal stigmas" are traits, imagined or real, of an ethnic group, a 
nationality or a religion that is deemed to be a deviation from the prevailing normative ethnicity, 
nationality or religion (Goffman, 1963).  
Studying the phenomenon further, Link and Phelan (2001) underscored the fact that stigma 
develops through a sequential process. This begins by distinguishing and labelling a trait or a 
human difference. The second step is to link the labelled person to undesirable characteristics-
referred to as negative stereotypes; the third, separating “them” (the labelled persons) from “us” 
(the normal ones). In the fourth step, the labelled persons experience loss of status and are 
considered inferior. Finally, the labelled persons are subjected to all forms of discrimination. The 
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stigma process has been schematized by The International Federation of Anti-Leprosy 
Associations (ILEP) (2011).  
The stigma process occurs in a context of social, economic and political power that permits 
the identification of differences and construction of negative stereotypes, labelling, separation of 
labelled persons and discrimination against them (Link and Phelan, 2001).  
 
 
Figure 8.1: The stigma process (adapted from ILEP 2011) model seen over time 
 As conceptualized above, the stigma process appears to be dynamic, with two of the 
components - status loss and discrimination -, growing in relevance and scope over time. 
Furthermore, both these components would appear to exert some influence one over the other in a 
“positive-feedback loop”. This occurs as the negative stereotypes gradually become accepted by 
the community and internalized by the stigmatized individuals (Yanos et al. 2012). We propose a 
“Stigma Process Dynamics” model, modified from the ILEP (2011) illustration of the stigma 
process, to show this dynamism (Fig. 8.1). 
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Building on Goffman’s initial conceptualization, Jones and colleagues (1984) have 
identified six dimensions of stigma namely concealability, course, disruptiveness, peril, origin, 
and aesthetics. Concealability is a condition which is obvious or can be hidden; course is the 
severity and pattern of the condition over time, and disruptiveness is the degree of interference 
with the usual patterns of social interaction. The term ‘aesthetic qualities’ is how much the 
condition upsets others by way of the five senses; origin is the perceived cause and degree of 
responsibility of a person for contracting the illness (or condition). Finally, peril is the amount of 
fear and danger associated with a person’s illness (Feldman and Crandall, 2007; Jones et al, 1984; 
Quinn and Chaudoir, 2009).  
Goffman (1984) and Scambler and Hopkins (1986) have developed two key concepts to 
distinguish between “enacted” and “felt” stigma. Enacted stigma are acts or instances of 
discrimination against people with a stigmatizing condition on grounds of their perceived 
unacceptability or inferiority by members of the society. This could include overt discrimination 
in the workplace or educational institution, neglect, hostility, abuse or what is termed “fair and 
legitimate” discrimination, such as banning, driving or operating heavy machinery for epilepsy. 
Felt stigma is the anticipation or fear (on the part of persons with a stigmatizing trait) of enacted 
stigma, or negative reactions to the disclosure of the stigmatizing condition, and this also 
encompasses feelings of “difference” and shame. Felt stigma does not need to be based on personal 
experiences of enacted stigma but is often built upon perceived social responses to the given 
stigmatizing condition and is as debilitating as enacted stigma itself. These concepts are known as 
“Scambler’s hidden distress model of stigma”, extended by Weiss (2008) to include the concepts 
of “internalized, endorsed, anticipated and accepted stigma” (Fig. 8.2). In particular: 
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• Internalized stigma is a process through which a person with a stigmatized condition 
accepts perceived exclusionary views of the society and self-stigmatizes himself or herself.  
• Anticipated stigma is fear of enacted stigma on behalf of a person with a stigmatizing 
condition. 
• Endorsed stigma is a situation whereby some members of the society support and 
encourage acts of discrimination or exclusion against persons with a stigmatized condition 
although they do not actively engage in those acts themselves. 
• Accepted stigma is the attitude of some members of the society who completely disagree 
with acts of discrimination or exclusion of persons with a stigmatized condition but do 
nothing to stop it.  
 
Hidden distress model of 
stigma 
Enacted Felt / perceived 
Those who are 
stigmatized 
Those who stigmatize 
Enacted 
Enacted 
Internalized Anticipated 
Endorsed Accepted 
Figure 8.2: Weiss Stigma Model: an extension of Scambler’s Hidden Distress Model of Stigma (Weiss, 
2008) 
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Since Goffman’s seminal treatise on stigma in 1963, the number of publications on social 
stigma has increased sharply in recent years (from 458 articles in 2006 to 1109 in 2011). 
In 2006, Weiss and collaborators proposed a new formulation to facilitate action-oriented 
research on health-related stigma:  
“Stigma is typically a social process, experienced or anticipated, characterized by exclusion, 
rejection, blame, or devaluation that results from experience or reasonable anticipation of an 
adverse social judgment about a person or group. This judgment is based on an enduring feature 
of identity conferred by a health problem or health-related condition, and the judgment is in some 
essential way medically unwarranted. In addition to its application to persons or a group, the 
discriminatory social judgment may also be applied to the disease or designated health problem 
itself with repercussions in social and health policy. Other forms of stigma, which result from 
adverse social judgments about enduring features of identity apart from health-related conditions 
(e.g., race, ethnicity, sexual preferences), may also affect health; these are also matters of interest 
that concern questions of health-related stigma”. 
8.2.2 Stigma and neglected tropical diseases (NTDs) 
The concept of NTDs emanated from the meetings convened in Berlin by the World Health 
Organization (WHO) and Deutsche Gesellschaft für Technische, now Internationale 
Zusammenarbeit in 2003 and 2004 (WHO, 2004; 2006). Following these developments, Weiss 
(2008) and Hotez (2009) recently reviewed the issues of stigma in NTDs. Historically leprosy has 
been a major focus of stigma studies and literature. Other NTDs that generate stigma overtones 
include onchocerciasis, lymphatic filariasis, plague, Buruli ulcer, leishmaniasis, African 
trypanosomiasis and Chagas’ disease. The numbers of existing cases of selected NTDs estimated 
by WHO (2010) and which cause stigma and disablement have increased sharply (Table 8.1). 
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Table 8.1. Estimated numbers of existing cases of selected NTDs which cause stigma and disablement 
Specific NTD Disabilities resulting from 
disease 
Numbers of cases/yr or with 
permanent chronic symptoms 
Buruli ulcer Disfigurement 5000/yr 
Onchocercosis/ mucocutaneous 
leishmaniasis 
Disfigurement 1.5 million/yr 
Onchocerciasis Blindness; Severe itching 265 000 existing cases 
746 000 existing cases 
Lymphatic filariasis Lymphoedema 
Hydrocele 
15 million existing cases 
25 million existing cases 
Trachoma Trichiasis 8.2 million 
Yaws Disfigurement 2.5 million (global prevalence 
estimates 1995) 
Leprosy Disfigurement 213 000/yr 
Human African 
trypanosomiasis 
Neuropsychiatric disorders Circa 10 000 new cases/yr 
 
In many NTDs stigma results from external deformations such as scars, physical 
manifestations of leprosy, or physical disabilities (Table 8.1). Furthermore, the impact of the 
meaning of the name of the disease may be as great, or even greater, source of suffering as 
symptoms of the disease. For example, paucibacillary leprosy may present at an early stage as a 
painless depigmented or anaesthetic patch. Receiving the announcement of the diagnosis is likely 
to be far more troubling than these symptoms per se (Weiss et al, 2006; Corrigan, 2007). The 
emotional impact of the social and cultural meanings of illness indicates another way by which 
stigma operates. For example, in settings where arranged marriages are a major concern of families 
for their children, the impact of a health problem on the ability to marry is troubling. For example, 
166 
 
Earnest Njih Tabah  Skin NTDs in Cameroon: the need for integrated control and elimination 
  
men with hydrocele suffer from embarrassment, ridicule and frustration due to their inability to 
perform sexual intercourse (Ahorlu et al, 2001). 
8.2.3 Neuroscience of stigma behaviour 
“We are, by nature, a highly affiliative species craving social contact. When social 
experience becomes a source of anxiety rather than a source of comfort, we have lost something 
fundamental – whatever we call it.” (Insel 2002). 
Thomas R. Insel, Editor of Biological Psychiatry concluded that findings from various 
neuroscience disciplines appear to suggest that the brain has a special way of processing social 
behavioural information (Yizhar et al., 2011; Greimel et al., 2012; Tate et al., 2006). It would even 
appear that special genes determine whether some animals that do not have brains exhibit solitary 
or social behaviour (Dreller and Page, 1999). We have attempted to summarize the current data in 
trying to answer to the following questions: 
1. What happens in the brain of a person who stigmatizes another individual or a group of 
persons? 
2. What happens in the brain of an individual who feels or is being stigmatised or simply 
afraid of being stigmatised? 
Is there any such neural ensemble as a stigma centre in the brain? How does the brain develop 
social norms and are these ‘programmes’ fixed in time and space and if not, what modulates them? 
These questions are clearly very difficult to answer. The young growing discipline of behavioural 
or social neuroscience is going to hopefully enable us to gain a better understanding of these issues. 
Derks and colleagues (2008) have reviewed data obtained with electroencephalography, event-
related potentials, or functional magnetic resonance imaging (fMRI) methods to examine neural 
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correlates of stereotype and social identity threat. The findings that brain activation is related to 
the experience of being stereotyped has shed light on the cognitive processes underlying the social 
identity processes (Derk et al 2008). Stereotype threat is a situational predicament in which 
individuals are at risk, by dint of their actions or behaviours, of confirming negative stereotypes 
about their group (Steele and Aronson, 1995). For example, data obtained using fMRI suggest that 
stereotype threat affects women’s mathematics performance in two ways: ﬁrst, it disrupts normal 
recruitment of cognitive areas required for high math performance (the inferior prefrontal cortex, 
left inferior parietal cortex, and bilateral angular gyrus) and, second, it increases the recruitment 
of areas which allow for the processing and regulation of emotions (ventral anterior cingulate 
cortex). This implicates that women perform more poorly under stereotype threat because valuable 
cognitive resources are spent on emotional regulation instead of on the task at hand (Derks et al 
2008). Although this approach has limitations, it has the merit of providing some leads to the 
understanding of the complex phenomenon of stigma, which may in future contribute to its 
reduction in the targeted populations. 
With regard to the second question, social neuroscience research has focused more on people 
who stereotype others rather than on the stigmatized individuals (see Bartholow and Dickter, 2007; 
Ito et al 2006, 2007). Brain imaging and electrophysiology has been applied to research on 
stereotyping from the perpetrator’s perspective and this approach has yielded some insights into 
the processes that underlie prejudice and racial bias. For example, race effects have been observed 
in two brain areas traditionally associated with face perception, the fusiform gyrus and the 
posterior cingulate cortex. While these brain areas are considered to be responsible for face 
encoding and person knowledge respectively, evaluation and behaviour regulation appears to 
occur in the amydala and anterior cingulate cortex, respectively (Ito and Bartholow, 2009). This 
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model, however, still has many unanswered questions such as the brain mechanisms of stereotype 
activation and regulation of stereotypic responses, and the psychological mechanisms involved.  
8.3 Neurological diseases associated with stigma in the Tropics 
 
Stigma is more likely to be associated with chronic, rather than acute neurological 
conditions and is one of the major limitations of care provision and control of these diseases. 
Among chronic neurological diseases we shall discuss leprosy, epilepsy, onchocerciasis, human 
African trypanosomiasis (HAT) and schistosomiasis.  
In the available published literature, amoebiasis, rabies, neurocysticercosis are only 
vaguely associated with stigma.  
8.3.1 Leprosy (Hansen’s disease) 
Leprosy, also known as Hansen’s disease or neurodermatitis, is arguably the most 
extraordinary and misunderstood of diseases. Leprosy is a dreaded disease caused by 
Mycobacterium leprae akin to causative agent of tuberculosis, affecting the skin, the nerves in and 
close to the skin, the anterior third of the eyes, the upper respiratory tract, and the testicles (Sabin 
and Swift, 1996). Although there is only one kind of leprosy bacillus, there are several varieties of 
leprosy because of the patient’s immunological reaction to the infection. Three major forms have 
been described: tuberculoid or paucibacillary form in patients with high immune resistance, 
borderline form, and lepromatous form in patients with little or no immune resistance leading to 
progressive debilitation and gross mutilation. Patients with borderline leprosy have less skin 
involvement than those with lepromatous disease and may have more circumscribed skin lesions. 
In these patients, skin lesions are more severe than in patients with tuberculoid disease. In the 
spectrum of borderline leprosy, immunity may change, with patients worsening and their disease 
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resembling lepromatous disease (downgrading reaction), or evolving toward the tuberculoid form 
(reversal reaction). Such shifts in the spectrum of disease may occur spontaneously or in response 
to drug treatment or inter-current medical conditions, such as underlying neoplasms or secondary 
infections (Sabin and Swift, 2008). 
Leprosy has been a major interest of health-related stigma studies from the outset. As cited 
by Hotez (2008), Berton Roueche observed that an ancient Egyptian pharaoh was known to banish 
people with leprosy to the edges of the Sahara Desert. He coined the term lepraphobia to describe 
how, at the peak of the leprosy epidemic in Europe in the 12th to 14th century, affected individuals 
were often subjected to their own mock funeral prior to banishment from their families and 
communities. In some cases, they endured torture and execution. Social constructions of leprosy 
are commonly guided by cultural, traditional and religious beliefs or myths about disease and 
illness (Wong, 2004; Waxler, 1981, Broek et al., 1998; Nsagha et al., 2001; Opala and Boillot, 
1996). Biblical teachings perpetuated by missionaries associated leprosy with sin and 
uncleanliness, and leprosy patients came to be considered outcasts as a consequence (Rod, 2006). 
Leprosy-infected people are frequently considered cursed or victims of witchcraft, or blameworthy 
or immoral, and their disease well deserved (Nsagha et al. 2011). In many countries, treatment 
policies require incarceration of people affected by leprosy at various leprosaria, sometimes due 
to the high rates of illiteracy and misinformation about the disease (Kazeem and Adegun, 2011). 
While people with enigmatic physical disfigurement (lepromatous form), and the distinctive ulcers 
consequent to untreated leprosy will face ridicule and rejection from society (Fig 8.3), the 
diagnosis of the tuberculoid or paucibacillary form will induce fear and ultimately anticipated 
stigma. 
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Fig. 8.3: Clawed and amputated fingers: muscle atrophy of the thenar and hypothenar hand regions in leprosy, Lepromatous 
lesions on the earlobe and back in same patient, foot ulceration (Courtesy EN Tabah). These severe disfigurements cause fear of 
contagion and lead to rejection of people with leprosy 
 
8.3.2 Epilepsy 
Although epilepsy is not a neglected disease, a chapter on stigma has to discuss the issue. 
According to the definition of ILAE, epilepsy is a transient occurrence of signs and/or symptoms 
due to abnormal, excessive, or synchronous neuronal activity in the brain (Engel and Pedley, 
2008). More than 60 million people worldwide suffer from epilepsy (Ngugi et al., 2010) and it is 
estimated that 80% of the burden of epilepsy worldwide is borne by resource poor countries 
(WHO, 2004; Birbeck and Kalichi, 2004; Kaiser et al., 1998; Longe and Osuntokun, 1989; 
Osuntokun et al., 1987; Jilek-Aall and Rwiza, 1992). Due to the treatment gap, the number of 
people with active epilepsy who have not accessed biomedical services or who are not on treatment 
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or are on inadequate treatment is between 62% and 75% in Sub-Saharan Africa (Mbuba et al., 
2012; Meyer et al., 2010). Traditional belief systems attribute epilepsy to demon possession, 
witchcraft, and/or seek to blame the victim (Baskind and Birbeck, 2005; Njamnshi et al., 2010). 
All this provides the ideal environment for stigma to flourish. Besides these beliefs, body 
disfigurement resulting from falls, burns or drug adverse effects also contribute to stigma 
development in epilepsy. For example, a Cameroonian epileptic patient sustained severe burns on 
the face and upper limbs, leading to the loss of her left hand. Because of the discrimination 
associated with epilepsy in this part of Cameroon, she was sent on exile from the city to live far 
away in a farmhouse, to avoid her associating with other people (Fig 8.4). 
 
Figures 8.4 Stigmatizing burn deformities in a Cameroonian epilepsy patient (Courtesy: Pastor Njamnshi JTN, 
Cameroon Baptist Seminary, Kumba) 
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8.3.3 Onchocerciasis (river blindness): 
Onchocerciasis results from infection with the nematode Onchocerca volvulus, for which 
man is the only reservoir. Adult worms live in sub-cutaneous nodules and have a reproductive life-
span of 9-11 years (Plaisier et al., 1991). The adult female worm produces microfilaria in millions, 
which migrate to the skin of the human host.  
 
Fig. 8.5 Stigmatizing onchocerciasis lesions: skin nodule, chronic onchodermatitis, skin atrophy and skin depigmentation 
(courtesy: AC Zoung-Kanyi Bissek) 
 
The microfilaria are responsible for the clinical manifestations of the disease which include 
dermatitis, with concurrent pruritus; lychenified skin lesions; skin depigmentation and atrophy; 
and lymphadenitis, which results in the hanging groin and elephantitis (Murdoch et al., 1993, cited 
in: Okoye et al., 2007). The most severe complication of onchocerciasis infection is irreversible 
blindness due to ocular lesions of both the anterior and the posterior chamber of the eye. 
The severe itching, depigmentation as well as lychenification of the skin as a result of 
onchocercal infection has been a source of discrimination and stigma (Awedoba, 2001). Skin 
nodules could also be a source of stigma depending on location (Fig. 8.5). Okoye and Onwuliri 
(2007) have found that the most worrisome consequence of onchocercal skin disease in 
Northeastern Nigeria included social isolation, feeling of shame and low esteem, skin blemish and 
marital problems. They recount the story of a 48-year-old female victim of onchocercal skin 
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disease as follows: “I am always afraid (anxious) that an attack of itching in a private part (buttock 
and groin) could occur at a public gathering; I therefore kept off; in fact, I hated myself”. In the 
same community, relating to stereotypes held with respect to marriage, a 26-year-old man said, 
“When a lady’s body has been spoilt by mbiba (popular rashes), only elderly widowers and 
already married men would seek her hand in marriage”. These pejorative attitudes are held across 
most onchocerciasis afflicted areas in Sub-Saharan Africa (Awedoba 2001, Tchounkeu et al. 
2012).  
8.3.4 Human African Trypanosomiasis (HAT; sleeping sickness) 
Stigma related to HAT is not clearly defined since the presenting symptoms resemble those 
of common conditions such as malaria in the early phase of the disease. However, in Malawi where 
transmission occurs around game reserves protected from human activity, individuals affected by 
HAT are stigmatized as deserving the condition, for having violated the band on infringing the 
game reserves (Chisi et al., 2011). 
8.3.5 Schistosomiasis 
Stigma in schistosomiasis is related to the post-micturation trickling of blood (Takoungang, 
2004). The female genital schistosomiasis, which is an advanced form in women, is usually more 
stigmatizing due to symptom similarity (lower abdominal pain, bleeding after sexual intercourse) 
to sexually transmissible infections (Ahlberg et al., 2003). These symptoms bring about shame and 
guilt, resulting in concealment and delay in seeking help among young girls and women. 
8.4 Measurement of stigma 
The full assessment of health-related stigma requires at least two levels of consideration 
that include: assessment in the community (general population as well as specific target groups 
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void of the stigmatized condition in question) to determine enacted and felt stigma and assessment 
among the affected persons, to determine anticipated, internalized and experienced stigma. The 
impact of stigma assessment would also target the affected persons, and will seek to measure the 
level of participation, quality of life, self-esteem and self-efficacy (van Brakel 2005; Rensen et al. 
2010). These approaches are very important as the study of people with a stigmatised health 
problem provides an account of self-perceived, experienced stigma as well as their consequences. 
Meanwhile the study of people without the stigmatised health problem in the community clarifies 
the social context of stigma targeting that condition (Weiss and Ramakrishna, 2006). 
Different methods could be employed within each approach. The most commonly used 
methods include: 
 Questionnaires: These are usually closed or open or interview guides, containing items 
that allow the collection of data on knowledge, attitudes and reported practices (KAP). 
This method has been widely used in the assessment epilepsy and leprosy related 
stigma (Njamnshi et al., 2009, 2010; Atadzhanov et al., 2010; Babikar and Abbas 2011; 
van Brakel 2003). 
 Qualitative methods: These are assessments based on such methods as key informant 
interviews, focus group discussions and observation by participants. 
 Indicators: These are often used in sets. They provide separate information for each 
indicator, and when pooled together, they may give a profile of stigma and 
discrimination. They cannot however be summarised in one measure, unless they have 
been developed as a scale. 
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 Scales: These are quantitative instruments intended to give a numerical result that 
indicates the severity or extent of the phenomenon measured. Examples of such stigma 
scales have been developed and validated recently for epilepsy in Kenya (Mbuba et al., 
2012) and for use across various neurological conditions in the USA (Molina et al. 
2012).  
Several instruments have been developed for measurement of health-related stigma. The 
majority of the instruments have however been disease-specific and the diseases of most interest 
to stigma research have been: epilepsy, leprosy, mental illness and HIV/AIDS. Two major reviews 
have sorted out the various instruments (scales, questionnaires, indicator sets) developed and used 
in the assessment of general and internalized health-related stigma (van Brakel, 2005; Stevelink et 
al. 2012).  
Attempts are being made to develop instruments that could be used to measure stigma across 
all stigmatizing conditions. For instance, the “Explanatory Model Interview Catalogue” (EMIC) 
developed by Weiss in 1992 for assessment of leprosy stigma has been adapted and used for the 
assessment of stigma in epilepsy (Rafael et al. 2010), depression (Raguram et al. 1996), 
schizophrenia (Raguram et al. 2004), Buruli ulcer (Stienstra Y et al. 2002). The stigma impact 
scale (SIS) and the stigma experience scale (SES) have both been used in Alzheimer’s dementia 
and Parkinson’s disease (Burgener and Berger, 2008). The “Internalized Stigma Mental Illness 
Scale” (ISMI) has been adapted and used for leprosy stigma (Resen et al. 2010). The “Child 
Attitude Toward Illness Scale” (CATIS) has been used to study stigma associated with epilepsy 
and asthma in children (Austin and Huberty, 1993) and adolescents (Heimlich et al. 2000). The 
most recently developed and validated scale, which seems to be the most federating, the Stigma 
Scale for Chronic Illnesses: 8-Item Version (SSCI-8), allows the measurement of stigma in five 
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neurological conditions: epilepsy, multiple sclerosis, Parkinson’s disease, stroke, and amyotrophic 
lateral sclerosis (Molina et al. 2012). However, the SSCI will still have to be tested and validated 
in the tropical context with a different neuroepidemiological picture from the temperate regions 
(Naeije et al. 2012). 
It should be underscored that many instruments have been developed to assess the intensity 
and qualities of stigma related to neurological disorders but often these have been condition-
specific. There are ongoing attempts to develop and validate more generic stigma assessment 
instruments that will cut across several stigmatizing neurological disorders. However, there is 
much still to be done, especially in the tropics, considering the huge socio-cultural variation in the 
expression and manifestation of health-related stigma. 
8.5 Determinants of stigma 
The measurement of stigma also allows the identification of possible determinants. In the 
tropics, factors associated with stigma seem to vary considerably from one culture to another and 
even between different communities within the same cultural setting. For instance, studies on 
epilepsy in different regions of Cameroon by Njamnshi et al. (2009a-e) revealed that the major 
determinants of negative attitudes towards people with epilepsy (PWE) included: advanced age; 
low level of education; the belief that epilepsy is insanity; hereditary, contagious, or caused by 
witchcraft. Anxiety, marital problems and social isolation were the major factor associated with 
epilepsy stigma in Benin (Rafael et al. 2010), while disclosure status, personal and community 
contagion beliefs are associated with epilepsy stigma in Zambia (Atadzhanov et al. 2010). In 
Mangalore, India stigmatization with respect to epilepsy was found to be related to the age and 
education of the respondent (Joseph et al., 2011). The factors associated with epilepsy stigma in 
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Cambodia were related to its curability, possibility of getting married, education, fear of seizure, 
convulsions (tonic-clonic seizure type), memory lapses, and the ability to speak about the condition 
(Bhalla et al. 2012). In Bolivia, the fear linked to loss of control, the feelings of sadness and pity 
toward people with epilepsy, the difficulties faced by people with epilepsy (PWE) in the 
professional and relationship fields, the level of education and type of seizure were factors 
associated with epilepsy stigma (Bruno et al. 2012). 
In Cameroon, enacted leprosy stigma is associated with fear of contagion, and cultural 
perceptions that attribute leprosy to punishment for wrong doing and witchcraft, while felt and 
experienced leprosy stigma is manifested by marital problems or being unable to marry, feeling of 
less self-esteem and shunning (Nsagha et al. 2011).  
8.6 Consequences and challenges of stigma reduction  
8.6.1 Consequences of stigma 
Stigma whether general or health-related brings about numerous negatives effects on its victims 
that may result in serious consequences.  
The first consequence is the discrimination against people with a stigmatizing condition. 
The discrimination may be overt, for instance banishment of persons affected by leprosy as 
reported in India (Jacob and Franco-Paredes 2008) and some tribal communities in Cameroon 
(Nsagha et al. 2011). Quarantining and segregation by sex to prevent reproduction among people 
with leprosy was practised in India during the colonial era (Jacob and Franco-Paredes 2008).   
Structural discrimination occurs, for example, when a treatment facility for a stigmatizing 
condition like leprosy is located in an isolated and remote neighbourhood. Another form of 
discrimination, which is more insidious, occurs when people with a stigmatizing condition accept 
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and internalize the negative label. They tend to have low self-esteem or may become aggressive 
or may just avoid contact with “normal individuals”. The outcome of this form of discrimination 
is usually low self-esteem, depression, participation restriction, unemployment and loss of income 
(Link and Phelan 2006). The fear of discrimination may lead to concealment in some individuals 
who become affected by a stigmatizing condition and shunning of those already labelled or 
stereotyped. The consequences of such an attitude are delays in seeking health care or 
abandonment or noncompliance with ongoing treatment. This leads to delay in diagnosis and 
treatment and worsening of the condition. This has been noted especially in leprosy and epilepsy. 
Stigma has been identified as source of chronic stress in people with a stigmatizing 
condition. Stress has been attributed to experienced stigma and the fear of being stigmatized and 
these have led to harmful health outcomes in the victims (James et al. 1984). Link and Phelan 
(2006) have remarked that in addition to stress from the illness itself, stress from stigma related to 
a health condition can lead to worsening clinical course of the illness and other outcomes such as 
lead a normal social life or ability to work. 
Stigma ultimately leads to poor quality of life in the affected persons and by extension, 
their families. 
8.6.2 Approaches to stigma reduction 
The domain of stigma reduction interventions is almost devoid of reliable evidence-based 
examples. For this reason, most of the literature in the area only tends to spell out broad guidelines, 
based on respected theories, upon which intervention programmes can be designed (Cross et al. 
2011).  
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Based on the study of stigma and the extension of the Scambler’s “hidden distress model”, 
Weiss et al. (2006) noted that stigma reduction interventions may vary from one health condition 
to another, and suggested a mitigating framework indicating the focus and approach for 
interventions to counter the effects of stigma. According to this framework, interventions may 
focus on support for affected persons, changing behaviour among the stigmatizers in the general 
population (or specific subgroups), and dealing with the stigmatizing condition.  
The guidelines by Weiss have generally been agreed upon by most investigators, but 
suggest that consideration of the process of stigmatization developed by Link and Phelan (2001) 
would make for more precise interventions (Cross et al. 2011).  
Motivated by the perceived need for multidimensional interventions and based on the 
observation that programmes that included counselling (at the individual level), education and 
contact (at both individual and community levels) appeared to be the most promising of the many 
interventions. (Heijnders and Van Der Meij 2006) suggested packages of strategies and 
interventions according to the social/ecological level under which each could be categorized (see 
Table 8.2).  
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Table 8.2. Stigma reduction strategies (adapted from Heijnders and Van Der Meij 2006) 
Level Strategies 
Intrapersonal Treatment 
Counselling  
Cognitive behavioural therapy  
Empowerment  
Group counselling  
Self-help, advocacy and support groups 
Interpersonal level Care and support  
Home care teams 
Community-based rehabilitation  
Organisational / institutional level  Training programmes 
Research for generating evidence*  
Policies, like patient-centred and integrated approaches 
Community level  Education 
Contact  
Advocacy  
Protest  
Governmental / structural level  Legal and evidence-informed* policy interventions 
Rights-based approaches 
Advocacy* 
 * our adaptations 
 
8.6.3 Challenges to stigma reduction  
The major challenge in stigma reduction is that there is no one-fit-all strategy, even for the 
same stigmatizing condition. Stigma is a complex issue, heavily influenced by cultural norms and 
beliefs. Therefore, developing any mitigating intervention adaptable to multi-cultural setting for 
any given stigmatizing condition remains a challenge. The need to consider several levels of 
interventions, each requiring multiple strategies, poses an additional challenge. These challenges 
are made even more difficult as the impact of stigma reduction interventions take quite long to be 
observed and are sometimes not very evident.  
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8.7 Conclusions and perspectives 
Stigma in neurological diseases (neglected or not) in the Tropics appears to be the weakest 
link in management and control or prevention as stigma has been shown to be a limiting factor to 
care-seeking behaviour. The young field of social neuroscience can hopefully develop, in spite of 
the current challenges, novel evidence for more effective, culturally sensitive and appropriate 
stigma reduction interventions. Success in this area may also pave the way for the removal of 
neglected neurological conditions from the neglected category. Otherwise, such conditions may 
become more neglected by this categorization, which may be discriminating in itself. 
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Chapter 9 
Chapter 9 : General Discussion and Conclusion 
 
 
Chapter 9: General discussion 
 
9.1 General remarks 
The control of some of the present-day Neglected Tropical Diseases (NTD) started in 
Cameroon in the early 1920s by the colonial authorities, as the burden of these diseases was high 
enough to preoccupy them 1. Between 1922 and 1930 for instance, 150 000 cases of sleeping 
sickness or Human African Trypanosomiasis (HAT) were recorded, and in 1956, 19 381 (41.2 
cases per 10 000) leprosy patients were registered 2 in Cameroon. 
Dr. Eugene Jamot, a French colonial military physician is credited for conquering sleeping 
sickness in Cameroon between 1922 and 1930. He applied a vertical intervention method 
whereby from his Ayos headquarters, he dispatched mobile teams to explore the villages, 
examine villagers, identify and treat HAT cases1. Even after he left in 1931, his control method 
was continued for decades and latter extended to the control of other great endemic diseases of 
the time including leprosy, malaria, syphilis and yaws3.  
In the post-independence Cameroon, the major communicable diseases affecting the 
population were malaria, measles, whooping cough, amoebic dysentery, yaws, pulmonary 
infections, bacillary dysentery, influenza, trachoma, leprosy, meningococcal infections and 
typhoid fever (Table 9.1)4. To deal with these diseases and other health problems, the 
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government of the newly independent Federal Republic of Cameroon, made an institutional 
organization of health services in 1965, under the Office of the Commissioner-General for Public 
Health and Population, with a deputy Commissioner for West Cameroon. The central services of 
this office had 3 directorates, including the Directorate of Public Health. The Directorate of 
Public Health had 8 departments dealing with various aspects of health, including endemic 
diseases and rural health 4, which was responsible for leprosy and yaws among others. 
Table 9.1: Situation of communicable diseases registered in main hospitals in 1965. 
Disease *Number of cases 
Malaria 214,338 
Measles 21,957 
Whooping cough 14,151 
Amoebic dysentery 13,411 
Yaws 13,312 
Pulmonary infections 10,067 
Bacillary dysentery 8,176 
Influenza 3,012 
Trachoma 1,239 
Leprosy 1,237 
Meningococcal infections 797 
Typhoid  422 
*Source: Third report of the World Health Situation 1961-1964, page 704.  
Through the department of endemic diseases and rural health, Cameroon has been involved 
under the auspices of the World Health Organization, and with the support of development 
partners, in fighting major endemic diseases affecting the country from independence to date. 
With these efforts, Yaws was eradicated in the country in the late 1960s5, before its resurgence in 
2007-2008. The burden of leprosy was considerably reduced6, and the emergent Mycobacterium 
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ulcer disease (Buruli ulcer) is being controlled. However, the number of health districts reporting 
new leprosy and Buruli ulcer cases has been on the rise in recent years, and the situation of yaws 
is unclear in more than two-thirds of health districts in the country. 
Within the scope of this PhD project, we have evaluated the burden of NTDs of cutaneous 
expression (skin-NTDs), established their trends in recent years (Chapter 2 and 4), and 
determined the challenges facing their control or elimination in Cameroon (Chapter 2,3,4, 5 and 
8). We have also confirmed the resurgence of yaws in the country (chapter 6). Based on the 
results, we have made recommendations for improving the control of these diseases in Cameroon 
(Chapter 2,3,4, 5 and 7). In the next few pages, we discuss the relevance of our findings and the 
pertinence of the recommendations for the way forward. 
9.2 Epidemiology 
9.2.1 The burden of skin-NTDs in Cameroon 
The WHO has recommended indicators for NTD burden measurement. For leprosy, the key 
indicators to measure leprosy burden are: 1. the prevalence rate per 10000 inhabitants and 2. the 
new case detection indicators which include the number new cases, detection rate, the proportion 
of MB, child and female cases as well as the rate of grade 2 disability7,8.  For Buruli ulcer, the 
key indicators are: 1. number of new cases 2. proportion of ulcerative forms, 3. proportion of 
category 3 lesions, 4. proportion of cases with limitation of movement and 5. proportion of case-
confirmation by PCR9. The current indicators for yaws are 1. the number of cases and 2. the 
number of health districts declaring them. Within the framework of this PhD project, we 
evaluated the burden of leprosy and Buruli ulcer in Cameroon, using the above stated indicators 
(Chapter 2 and 4) and confirmed the resurgence of yaws in Cameroon (Chapter 6).  
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i. Leprosy burden 
We confirmed the attainment by Cameroon of the elimination threshold of leprosy as a public 
health problem10, at the end of 2000 with a prevalence rate of 0.94/10 000 population, at the 
national level. We also showed that the prevalence rate continued to drop to reach 0.20/10 000 
population at the end of 2014 when we completed our study (Chapter 2). At the end of 2017, the 
prevalence rate was 0.13/10 000 population (Tabah EN, personal communication). We also 
showed that the leprosy new case detection underwent a similar trend, dropping from 4.88/100 
000 to 1.46/100 000 population over the same period. The trends in Cameroon were similar to 
those in other countries of the WHO African Region, with a sharp drop in both prevalence and 
new case detection between 2000 and 2007, followed by stagnation from 200811 for reasons  
discussed below. 
After achievement of elimination of leprosy as public health problem at national level in 
Cameroon, it was hoped that elimination at sub-national levels would be easier. This turned out 
not to be the case. The stagnation of leprosy new case detection and prevalence indicates that 
either the strategies implemented since the last decade have not been very effective in further 
reducing the burden of leprosy as expected, or the transmission chain remains strong or both. 
The stagnation in the WHO African Region has been blamed on a few number of countries that 
continue to the report high numbers of cases 11, likewise in Cameroon, four regions namely the 
North, Adamawa, East and Southwest account for over 70% of new cases (Chapter 2). 
The use of a new indicator, the Leprosy Burden Score (LBS) proposed by the WHO Africa 
Bureau in 201111, revealed that the traditional indicators of prevalence and detection rates were 
limited. The LBS was able to filter out more high-leprosy-burdened health districts (HD) than 
the traditional indicators did. In 2014 therefore, we identified 18 HDs as high-leprosy-burdened 
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by the LBS compared to 10 HDs using the traditional indicators (Chapter 2). The LBS has a 
peculiarity in that it is a composite indicator that includes all the previous leprosy elimination 
indicators, so that all aspects of a leprosy service in a given HD or region can be assessed at 
once. This indicator could be useful if it is further fine-tuned and adapted to local strategies that 
have to be applied in health districts, to achieve further reduction in leprosy burden.  
 Factors favouring persistent high numbers of new leprosy cases have not been sufficiently 
explored. In Cameroon the proportion of child cases, a proxy indicator for monitoring leprosy 
transmission, increased by 3 folds between 2007 and 2014 (Chapter 2). Multibacillary cases that 
constituted 62-87% of patients and sub-clinical cases which most of the time are persons in 
contact with MB patients, are thought to be perpetuators of transmission12,13. Animal reservoirs 
of M. leprae have been reported in armadillos,14 and recently in red squirrels,15,16 pointing to a 
possibility of zoonotic transmission.  
Leprosy-related stigma remains another huge burden in Cameroon. We have shown in 
Chapter 3 that erroneous perceptions regarding leprosy still prevail in rural Cameroon, and that 
they are responsible for negative attitudes manifested towards people with leprosy and their 
families. A review of stigma reveals that it is responsible for poor health-seeking behaviour and 
concealment in patients among other things (Chapter 8). There have been complaints by leprosy 
patients of being shunned at health facilities by health personnel because of their status. These 
are obstacles to the early case-detection strategy and integration of leprosy services into the 
general health-care system in Cameroon. 
The inability of the National Leprosy Programme to build and maintain a strong surveillance 
system is another major weakness mainly attributed to insufficient human, material and financial 
resources. The attainment of the leprosy elimination thresholds at the national level was 
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announced with a lot of enthusiasm and was an acclaimed public health victory in Cameroon just 
like in many countries. Elimination of leprosy to the lay-man, including the political class that 
have to decide on resource allocation, means complete removal (as defined by the Oxford 
English Dictionary) of leprosy from Cameroon. So, the politician does not understand why 
resources should continue to be allocated for leprosy that has already been dealt with, when there 
are more pressing and rampant conditions like HIV/AIDS, malaria, and vaccine preventable 
diseases that require the resources. This kind of attitude in Cameroon since 2000, has led to 
drastic reduction in government funding as well as partner funding for leprosy 
elimination/eradication activities. Furthermore, the infrastructure that was acquired for leprosy 
elimination has been gradually dismantled and/or reoriented for other use. Consequently, there is 
very little expertise in leprosy left in the country, with no leprosy training programmes, no 
services for management of severe leprosy reactions and other complications, irregular 
awareness and case-finding activities, no functional prevention of disability programme, just to 
list but a few gaps. Health professionals especially those concerned with leprosy, have decried 
this situation which is happening in almost all leprosy endemic countries to the point of 
wondering aloud whether it was leprosy, or the leprosy programme, that was being 
eliminated17,18. 
In as much we acknowledge that the burden of leprosy in Cameroon has reduced remarkably 
in the past years, some 200 to 300 new cases continue to be reported annually. Over 650 cases 
are followed up on treatment each year. Furthermore, there are over 2500 former leprosy patients 
living with disabilities in the country. For these patients, the country needs to maintain a 
minimum quality leprosy service: including but not limited to a quality multidrug therapy (MDT) 
service, a robust leprosy surveillance system, prevention of disability, and a reference-counter-
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reference system, integrated into the national health system. Such a service has to be monitored 
and supervised by a pool of experts including a scientific committee and a management board as 
part of the National Control Programme. 
ii. Buruli ulcer burden 
In this PhD project, we have shown in Chapter 4 that a cumulative number of 3700 cases of 
Buruli ulcer were registered and treated in Cameroun between 2001 and 2014. The number of 
reported endemic health districts increased from two to 64 over the same period of time. Despite 
many more health districts being confirmed endemic for BU, the annual number of cases 
witnessed a remarkable drop from 2008 to 2014, when our study ended. This downward trend 
has continued beyond 2014 (Tabah EN, personal communication). Although the number of new 
BU cases was reducing, the proportion of ulcerative and category-3 lesions, the main drivers of 
BU burden, were increasing. The National Control Programme in Cameroon has blamed the 
downward trend in the number of cases, and the late case-detection as manifested by high 
proportions of ulcerative and category-3 lesions, to reduced active-case finding activities in the 
endemic areas. There has been reduction and even stoppage of community awareness and case-
finding activities in the last half-decade, as the BU support-partners withdrew (the case of 
Médecins Sans Frontières Suisse [MSF-CH]) or reduced their support to three BU endemic areas 
(the case of FAIRMED Foundation). While the claim by the National Control Programme may 
be justified to some extent, the trend in the Bankim endemic focus, where activities have been 
sustained have also witnessed a drop of BU cases recently (Um-Boock A, personal 
communication), and this has been confirmed by data from Bankim from 2012 to 2016, retrieved 
from the National Control Programme (Fig 9.1). Comparing the Cameroon BU trend with the 
global trend, the patterns were very similar (Chapter 4). It has been suggested that the general 
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downward trend observed in BU could be attributed to effective BU control programmes in 
endemic countries, that have succeeded to reduce to mycobacterial load through detection and 
treatment of the human reservoir, therefore reducing bacterial shedding in the environment and 
consequently transmission19. If that is true, then efforts to sustain BU surveillance and control 
must be maintained and reinforced, to avoid resurgence like in the case of African Human 
Trypanosomiasis in the 1980s and 1990s after it was successfully controlled in the 1960s20, and 
most recently yaws that is resurfacing in many countries after near eradication in the 1960s21. 
Fig 9.1: Trend in BU case detection from 2012-2016 in Bankim-Cameroon. Source: PNLP2LUB-MINSANTE 
iii. Yaws burden 
The exact situation of the Yaws burden in Cameroon is not known. The epidemic outbreak 
amongst the pygmies in the East region of the country in 2007-2008 marked the resurgence of 
yaws since its eradication in the 1960s.  After the reorganization of the National leprosy and 
Buruli ulcer programme in June 2009 to include yaws control activities, efforts have been made 
to determine the burden of the condition in the country. The first step was to confirm the 
resurgence through a clinical and serological survey (Chapter 6). Between 2009 and 2012, 
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through surveys, we confirmed 22 health districts endemic for yaws22. A more recent survey we 
carried out in 2017 brought the number of confirmed yaws-endemic health districts to 37 out of 
52 already surveyed (Tabah EN et al. unpublished results). Between 2009 and 2017, a 
cumulative number of 4226 cases of yaws has been detected and treated in the country. 
9.2.2 Geo-ecological zones of Cameroon 
Cameroon has five geo-ecological zones, each of which may influence the occurrence of 
the skin-NTDs differently. The detail characteristics of the geo-ecological zones are given in 
Table 9.2 and the maps in Fig 9.x below. 
Table 9.2: characteristics of geo-ecological zones in Cameroon. 
Geo-ecological zone Rainfall (mm) Elevation (meters 
above sea level) 
Mean annual 
temperature (
o
C) 
Sudano-sahelian 500-900 250-500 28±7.7 
High Guinea Savanna  1500-1800 500-1500 23±6.4 
Western highlands 1800-2400 1500-2500 21±2.2 
Humid forest (monomodal rainfall 
regimen) 
2000-11000 0-2500 26±2.8 
Humid forest (bimodal rainfall 
regimen) 
1500-2000 400-1000 25±2.4 
Source :  Toukam GMS et al. 200923. 
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Fig. 9.2: Map of geo-ecological zones of Cameroon. Source : Shapiro D et al. 199224  
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9.2.3 Geographical distribution  
The geographical distribution of leprosy is wide spread across all the five geo-ecological 
zones of Cameroon, but with more concentration in the North, Adamawa, Centre, East, and 
Southwest regions of the country (Fig 9.3A). New leprosy cases have been reported from 96 
health districts within the past five years. These are the districts where leprosy transmission is 
still going on. The intensity of transmission is highest in 14 of the health districts where more 
than 20 new cases each have been reported. It should also be noted that in the 93 health districts 
where no cases were reported in the past five years, leprosy surveillance is low-key. So it will be 
prudent to consider them as silent districts rather than districts in which leprosy transmission has 
been stopped as per the orientations of the Global Leprosy Strategy 2016-20207.  In as much as 
the National Control Programme needs to focus attention on the 14 health districts with high 
transmission, it also has to reinforce and scale-up surveillance in all the districts. 
 The situation of yaws is not known for all the health districts. Available data however, shows 
a tendency to wide spread distribution but with a concentration in the North, Adamawa and East 
regions of the country (Fig 9.2B). Yaws is considered for eradication in the WHO 2020 
Roadmap for NTDs25. With the adoption of the Morges Strategy for the eradication of Yaws in 
2012 which has three major components (two or more rounds of total community treatment; 
interspaced with total targeted treatment with azithromycin; followed by post-zero sero-
surveillance) 26, the WHO has defined the tools needed by endemic countries to achieve the 2020 
target for yaws. One of the prerequisites to the implementation of the Morges Strategy is the 
determination of endemic status of all health districts within the country, for better planning and 
implementation. So far in Cameroon, the status of yaws is known only in 52 out of 189 districts. 
There is therefore a huge mapping gap for yaws in 137 health districts. 
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 Buruli ulcer is found mainly in the southern part of the country with concentration around the 
central-south (Fig 9.2C). About 64 health districts are endemic for Buruli ulcer in Cameroon, 
however, effective control activities have been implemented only in five of the districts, with the 
diagnostic and treatment centres (BU-DTC) as pivots. The National Programme has plans to 
expand activities to other endemic health districts, and this has been included into the integrated 
strategic plan 2018-2022 for the control of Case-Management NTDs. 
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Fig 9.2: The geographical distribution of Skin-NTDs in Cameroon. Panel A: Leprosy new cases from 2012-2017; Panel B: Yaws 
from 2009-2017; Panel C: Buruli ulcer from 2006-2016; Panel D: Leishmaniasis cases from 2010-2017. 
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Leishmaniasis on its part mainly occurs in the far north of the country (Fig 9.2D), which 
lies within the Sahelian belt where Cutaneous Leishmaniasis is common27. So far, cases have 
been reported only in 11 health districts, through passive case detection in some health facilities. 
Operationalization of leishmaniasis control has not begun on the field since its inclusion into the 
National Leprosy and Buruli ulcer control programme in 2009. This has been due mainly to two 
factors: the insecurity in the zone resulting from the Boko Haram terrorist insurgence; and 
secondly to the lack of resources. There is no funding for leishmaniasis yet, be it from the 
government or from support-partners.  
9.2.4 Co-endemicity  
There is a huge overlap in the geographical distribution of leprosy, Buruli ulcer, yaws and 
leishmaniasis in Cameroon (Fig 9.3). Out of the 122 health districts that are endemic for at least 
one of these NTDs, 40 are co-endemic for 2 and 12 are co-endemic for 3 of the NTDs. In the 
three northern regions, the co-endemicity is with leprosy and yaws or leprosy, yaws and 
leishmaniasis. In the southern part of the country, co-endemicity is with leprosy and yaws; or 
leprosy, yaws and Buruli ulcer. In addition to being NTDs of cutaneous expression, the overlap 
in their geographical distribution allow for integrated control interventions28. Although rarely 
mentioned, nearly all NTDs affect the nervous system, giving another reason for their integrated 
control. Leprosy and Buruli ulcer affect the peripheral29 and yaws probably the central nervous 
system30,31,32.  
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Fig 9.3: Co-endemic map of Skin NTDs in Cameron 
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9.3 Surveillance of Skin-NTDs in Cameroon 
Surveillance is an important element that cannot be dissociated from any disease control 
programme that meets international standards. In resolutions and declarations on the control of 
NTDs10,33,34,35, and other strategic documents and recommendations by the World Health 
Organization on NTDs26,36, surveillance has always been emphasized. In Cameroon, leprosy, 
Buruli ulcer, yaws and leishmaniasis are under one national control programme37. This 
arrangement was made because these four NTDs all manifest on the skin, offering therefore a 
great opportunity for integration of their surveillance and other control interventions, as has been 
recommended in several policy papers28,38,39. The goal for surveillance of Skin-NTDs in 
Cameroon is to provide the National Control Programme with information for monitoring of 
performance, and for strategic orientation and action. 
9.3.1 The current surveillance strategy for Skin-NTDs in Cameroon 
In Cameroon, surveillance is imbedded into the leprosy and Buruli ulcer control, as 
described in Chapter 2 and 4 of this thesis. It is also being instituted for yaws in the confirmed 
endemic health districts (Tabah EN, personal communication).  Data on leprosy and yaws is 
collected by health facilities that detect the cases, and that on Buruli ulcer is collected at 
specialized Buruli ulcer diagnostic and treatment centres (BU-DTCs). A monthly statistical 
report is transmitted by the health facilities to the health district service (HDS) territorially 
competent, that in turn registers the patients declared to it into a district leprosy, Buruli ulcer or 
yaws register, respectively. The HDS then aggregates data on patients detected and treated 
within the health district for the respective NTDs and transmit them to the regional delegation of 
public health (RDPH) on a quarterly basis. In addition to transmitting aggregated data to the 
regional level, the HDS is also supposed to analyse and interpret the data and give feedback to 
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the health facilities reporting cases to it immediately or during supervision visits to those 
facilities. The RDPH in turn, compiles and aggregates data on leprosy, Buruli ulcer and yaws 
from the health districts within the region and transmits them to the National Control Programme 
on a quarterly basis. The RDPH is also responsible for analysing, and interpreting the data, and 
providing feedback to the health districts during supervision visits or during regional evaluation 
meetings. In the course of this PhD project, we described the epidemiology and time trends of 
leprosy and Buruli ulcer in Cameroon in recent years (Chapter 2 and 4), thanks to the data 
transmitted to the National Control Programme from health districts through the RDPH for over 
the years. Until 2014, the data was about 97% complete for all the districts (Chapter 2). After this 
period there has been slackening in completeness and timeliness of data reporting in a good 
number of health districts.  
For the most part, leprosy, Buruli ulcer and yaws surveillance in Cameroon is passive. 
The option of passive surveillance has been adopted by the National Control Programme since 
the attainment of the leprosy elimination threshold in 2000 (Chapter 2) for a number of reasons. 
The passive method was cheaper and yet allowed for wide coverage40 of health districts in the 
country, but was also the recommended option in a situation of leprosy regression. On few 
occasions, active surveillance has been instituted for short periods of time in a few health 
districts reporting high numbers of new leprosy cases, or in major Buruli ulcer foci, or in districts 
declaring yaws epidemic outbreaks, like it was the case in 7 health districts in Cameroon in 2017 
(Tabah EN, personal communication). During such active surveillance activities, facility 
registers are checked and mass awareness and screening campaigns are organized in 
communities of primary schools of the targeted health districts to search for cases. Furthermore, 
during these occasions of active surveillance the capacity of local health personnel on diagnosis, 
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treatment and reporting of leprosy, Buruli ulcer and yaws is reinforced. The organization of 
active surveillance on the occasions just mentioned have proven very expensive for the National 
Control Programme, and mobilizing the required resources from the government and from 
support partners has been a difficult venture41. In the future active surveillance should therefore 
be reserved only for emergency situations like epidemic outbreaks. 
Active and passive community-based surveillance approaches, involving community 
health workers (CHW), school teachers, pupils and traditional healers have been evaluated in 
Cameroon for Skin NTDs with the outcome that the CHW represent an important potential for 
improvement of surveillance41,42. For optimal exploration of this potential, we have developed   
an integrated manual for use by the CHW for recognizing and referral of six NTDs namely: 
leprosy, Buruli ulcer, yaws, leishmaniasis, lymphoedema and hydrocele (Tabah EN, 
unpublished), that will be put at their disposal. 
9.3.2 Skin-NTDs surveillance tools in Cameroon 
The surveillance system for leprosy, Buruli ulcer and most recently yaws in Cameroon 
depends heavily on the health personnel at primary health care facilities including the Integrated 
Health Centres (IHC) and District Hospitals (DH). These facilities are supplied with diagnostic 
guides, posters on the diseases, and national policy documents on the conditions, to facilitate 
suspicion and clinical confirmation of cases. For Buruli ulcer diagnostic and treatment centres 
(BU-DTC), laboratory equipment, reagents and other consumables for Ziehl-Neelsen staining 
were supplied by support-partners and the National Control Programme is replenishing the 
stocks regularly.  
For recording and reporting of data on the patients, paper-based tools are in use at 
basically all levels. The health facilities that detect the patients keep patient treatment registers 
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and standardized patient forms. For leprosy data recording, the facility leprosy treatment register, 
the patient individual form/file, and the patient notification forms are kept. For Buruli ulcer, the 
standard BU 01 form for patient individual data and treatment record; the BU 02 register, and 
laboratory forms are kept. For yaws, a health facility register is kept. At the level of the district 
health service a district register is kept of each of leprosy, Buruli ulcer or yaws. In some health 
districts, all cases of leprosy notified in the district are treated at the HDS, and in this case, the 
district leprosy register is modified to also serve as a treatment register. 
For reporting, the health facility keeps a separate monthly reporting form for each of 
leprosy, Buruli ulcer or yaws cases, for reports to the district health service. For reporting from 
the HDS to the regional delegation of public health, the DHS has its own set of reporting forms, 
for quarterly reporting of leprosy information and yaws. For Buruli ulcer, it is a compilation on 
the same BU 02 form used by the health facility (BU-DTC). At the regional level, the National 
Control Programme had designed a separate Microsoft Excel Spreadsheet format for compilation 
of leprosy, Buruli ulcer and yaws information from the health district and reporting to the 
programme. The Regional NTD Focal Points who are responsible for the activity at the RDPH, 
transmit the filled Excel spreadsheets by email to the National Control Programme. These Excel 
spread sheets have further been adapted for health districts that have computers and have 
expressed the need. With the rapid evolution in the information and communication technology 
(ICT) sector and its increasing use for surveillance purpose, it is recommended for the National 
Control Programme to adapt its surveillance to these new technologies. The District Health 
Information System 2 (DHIS2) is currently being developed in Cameroon. This will be an 
opportunity for the National Control Programme to integrate the system for the surveillance of 
leprosy, Buruli ulcer, yaws and leishmaniasis through it. 
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9.3.3 Gaps in Skin-NTD surveillance in Cameroon  
The current surveillance system for Skin-NTDs present with a number of weaknesses. It 
is not effective in all the health districts of the country. The timeliness and completeness of 
reporting from the health districts to the regions is currently less than 70%. We have noted 
earlier that 93 out of 189 health districts were silent for leprosy in the past five, most probably 
because leprosy surveillance activities have become low-key in them. This situation does not 
augur well for Cameroon as gains made in leprosy elimination may be eroded in the near future, 
given that leprosy transmission has not been stopped. There are examples from India and Brazil 
from 2016 and 2017, where in India, a national survey of 14 725 525 individuals detected 2161 
new leprosy cases giving a detection rate of 14.68/100 000 population43; and a survey of 34 547 
school children in the Amazon, Brazil, detected 40 new leprosy cases giving a detection rate of 
115.9/100 000 population respectively44.  
The primary health care centres and the district hospitals on which the surveillance 
system depends is understaffed both in quantity and quality of health personnel. Most of the 
Integrated Health Centres in the rural areas are manned by a single staff member who most of the 
time is an assistant nurse by qualification. The staff member alone is responsible for curative, 
preventive and promotional health activities in the catchment area of between 5000 to about 
10000 inhabitants45, and has to report on all the activities at the end of the month to the district. 
The staffing situation at the DHS is not very different, where one may find only the District 
Medical Officer and his/her Chief of Bureau for Health (the district surveillance officer).  
Each Skin-NTDs has separate reporting forms with too many data variables, and this is in 
addition to similar forms for the other diseases or programmes like Malaria control, 
Reproductive health, and Enlarged Programme on Immunization, to name a few. This has 
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rendered the whole surveillance system cumbersome. The lone staff member at the IHC is often 
overwhelmed by the work load. Some surveillance tools like the leprosy treatment register, 
district leprosy register, and the monthly and quarterly reporting forms are now obsolete 
following new orientations in the 2016-2020 global leprosy strategy7.  There is dire need, at least 
for the surveillance of Skin-NTDs, for the tools to be rendered simpler, timely, sensitive, and 
most importantly acceptable and user-friendly for the primary health care staff on whom the 
system depends. The way forward shall be to develop an information and communication 
technology (ICT) based system employing smartphones and android-based applications usable 
by primary health care staff, linked directly to a server at the National Programme Office. Such 
systems have already proven their worth in similar situations46,47. 
Another major gap is the lack of updated cases-definitions for each of the Skin-NTDs at 
the health facilities. The National Control Programme is supposed to produce and disseminate 
these case-definitions to the facilities regularly, but this has not been done for over five years 
now for reasons of lack of financial resources. Furthermore, only an insignificant number of the 
primary health care level staff on whom the surveillance depends have been trained on the 
diagnosis, treatment and follow-up of cases of leprosy, Buruli ulcer, yaws and leishmaniasis, as 
well as how to report on them. This may explain the zero reporting or silence in many health 
districts where the health staff lacks the necessary diagnostic skills. 
9.3.4 Suggestions for improvement of Skin-NTDs surveillance in Cameroon 
The National Control Programme has an opportunity to improve upon and close some of the 
surveillance gaps identified above as it is currently finalizing an integrate strategic plan for the 
2018-2022 period. It will be important to consider the following in the plan for improvement of 
surveillance:  
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➢ Update, produce and disseminate case-definitions of the various Skin-NTDs to 
health facilities 
➢ Update and develop innovative integrated recording and reporting tools 
➢ Develop smartphone reporting formats of the reporting tools, linked to an 
electronic database at the National Control Programme Office.  
➢ Collaborate with the Health Information Unit at the Ministry of Public Health to 
integrate essential Skin-NTDs indicators into the DHIS2 currently being 
developed in the country. 
➢ Organize large-scale cascaded training for primary health care staff and other 
interveners in the Skin-NTDs surveillance system. 
➢ Set up a monitoring scheme for the system, as well as a real-time feedback to 
interveners in the system. 
9.4 Diagnosis 
9.4.1 Clinical diagnosis at primary health care level  
The accession that NTDs occur mainly in remote, rural and poor communities around the 
world, where there is limited access to good social amenities and health services and 
infrastructure25,48 is very true in the context of Cameroon. For this reason, simple diagnostic 
methods and tools are required to detect and management cases in their remote localities. Among 
the NTDs are diseases that have their clinical manifestations mainly on the skin now been code-
named Skin-NTDs, and include leprosy, Buruli ulcer, yaws and muco-cutaneous 
leishmaniaisis28. At the primary health care level where laboratory facilities are not always 
available, and for disease control purposes, the WHO recommended for well trained and 
experienced health personnel to diagnosed these skin-NTDs based on clinico-epidemiological 
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features and recommended case-definitions26,49,50 ; and initiate treatment without waiting for the 
results of laboratory tests, since high diagnostic accuracies  are often obtained51. As shown in 
Chapter 2 and 4, In Cameroon, case finding for leprosy, Buruli ulcer and recently yaws41, and the 
decision to treat cases has depended mainly on clinical diagnosis. Laboratory diagnosis being 
required for reconfirmation of clinical cases, and establishment of endemicity of a community 
particularly for Buruli ulcer and yaws.  
The simplified criteria for clinical diagnosis of leprosy based on the presence of one or 
more of the three cardinal signs and, the classification of clinically confirmed cases into two 
forms: PB and MB leprosy, based on the number of lesions49 greatly facilitated the 
implementation of the leprosy elimination programme. These criteria could easily be assimilated 
and applied at the periphery by low-level health personnel, and thus facilitated the 
rapprochement of multidrug therapy (MDT) services to the patients, who were mostly found in 
the remote areas. For Buruli ulcer, the painlessness of the lesions, the non-pitting nature of the 
oedematous form, and the characteristic undermined edges and the cotton wool-like appearance 
of the base of the ulcerated form allow for fairly easy clinical diagnosis. Though simple as this 
may look, successful application depends on substantial investments in large scale training of the 
primary health care level personnel, and supply to health facilities of clinical diagnostic memory 
aids in the form of printed case-definitions, diagnostic algorithms, brochures, flyers and posters. 
The need for regular supportive supervision to primary health care level from superior levels 
(health district and regional delegations of health) cannot be over emphasized.  
Simplified diagnostic criteria for a number of Skin-NTDs has facilitated task-shifting like 
in the case of epilepsy52, from medical doctors to nurses and assistant nurses, who are greater in 
numbers and more widely distributed in the national territory45. Even at the primary health-care 
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level, this task-shifting has been extended to the community health workers who are now being 
trained and involved in suspicion of cases in the communities and referral of suspected cases to 
the integrated health centre for confirmation by the nurse. Furthermore, the community health 
workers are being involved in sensitization and community mobilization as well as, in the 
follow-up of patients on treatment in communities to improve on treatment compliance and limit 
defaulter rate42,41. 
One of the targets for the global leprosy strategy 2016-2020 is to stop disability7. One of 
the major drivers of leprosy related disabilities is the leprosy reaction, that may occur before, 
during or even after MDT treatment53. Peripheral nerve involvement during these reactions is 
responsible for physical deformities in leprosy patients53,54. Detection of leprosy reaction is on 
clinical bases, requiring that health staff are skilled in neurological examination of the patient. In 
a rapid assessment of the skills of primary health care staff in the neurological evaluation of new 
leprosy patients (unpublished), we found out that over 85% of the staff were unable to do it. This 
implies that patients at risk of leprosy reactions and those in the early or mild stages of the 
reactions are missed out and may only be noticed in full-blown leprosy reactions. Another 
implication is that patients are not educated on early warning signs of leprosy reactions when 
they are first seen or during subsequent follow-up visits. The acute need for training of the 
peripheral health personnel is here again underpinned.  
In the context of co-existence of more than one Skin-NTD in the same locality and given 
that some clinical forms of the different Skin-NTDs may look alike, or resemble features of other 
disease conditions, specific clinical diagnosis can become challenging. An example of such a 
difficulty in a Buruli ulcer endemic district (Bankim) is illustrated in Chapter 5, where a case of 
cutaneous tuberculosis was mis-diagnosed for Buruli ulcer on the bases that ulcerative lesion had 
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undermined edges and supported by a positive Ziehl-Neelsen stain. We have also demonstrated 
that in the Buruli ulcer diagnostic and treatment centre of Akonolinga in Cameroon, Buruli ulcer 
constituted only 27% of all ulcers attending the centre (Fig 9.4) 55, and in this study, there was 
often lack of consensus in the clinical diagnosis of a number of cases, with a risk of over-
diagnosis of Buruli ulcer. In a recent evaluation of clinical diagnosis of Buruli ulcer in an another 
Buruli ulcer endemic area of Cameroon, we showed that only 56% of clinically suspected cases  
 
Fig 9.4: Differential diagnosis of ulcer cases received at Akonolinga BU-DTC. Buruli ulcer constitute 27% of all ulcers. Adapted 
from Trellu et al.55. 
were positive for PCR56. This situation underlines the need to emphasize on differential clinical 
diagnoses of mycobacterial infections but also of other skin-NTDs including yaws, leishmaniasis 
in particular and other ulcers in general, during training of health workers. The national Buruli 
ulcer control policy and guidelines document we developed in 201457, and the manual on the 
integrated management of five NTDs recently developed by the WHO Regional Office for 
Africa58 are resourceful documents for such training sessions. 
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9.4.2 Laboratory diagnosis for Skin-NTDs control 
i. Leprosy 
There are four paraclinical examinations that can be used for leprosy diagnosis including 
microscopy to detect acid fast bacilli (AFB) after Ziehl-Neelsen (ZN) staining59, histopathology 
to detect tissue alterations and AFB after staining of biopsy cuts from skin lesions using the 
Modified Fite-Faraco technique60, ELISA serology for detection of phenolic glycolipid 1(PLG-1) 
M. leprae antigen61, and finally PCR targeting the 36-kDA, 18-kDA, 65-kDA, antigens or the 
complex 16S rDNA genes62. Of the test, microscopy for AFB after ZN staining, and the PLG-1 
ELISA can be done at the primary health care level, on slit skin smears from the lesion or the 
earlobe for ZN, and from serum or whole blood sample for PLG-1. Although microscopy after 
ZN stain and PLG-1 are more feasible point-of-care (POC) test that allow for rapid results, their 
sensitivities are relatively low. Although AFB after ZN staining is still considered the standard 
test for leprosy confirmation, the bacillary index is positive only for MB, but negative for PB 
leprosy cases63,64 and the test cannot differentiate between different mycobacterial species . For 
PLG-1, in Cameroon we have seen a specificity of 70% and sensitivity ranging from 75% in 
leprosy patients through 52.3% among contacts of patients, to 44.2% among former leprosy 
patients treated and declared cured65. Another evaluation by Lobato and colleagues in Brazil has 
shown a specificity of 98% and a sensitivity of 68.68% for MB leprosy, 31.82% for PB leprosy 
and 25% for contacts of MB leprosy patients61.  Histopathology is done on biopsy samples 
acquired through invasive procedures and requires specialized laboratory facilities for the biopsy 
preparations and analysis. The histopathology analysis examines tissue cuts to look for presence 
of AFB and determination of the bacillary index (BI), and the granuloma fraction (GF). Based on 
the BI and GF, the histopathological index (HI) which is the amount of AFB in a given volume 
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of tissue is determined. The sensitivity of the test is moderate60. PCR techniques for leprosy are 
still undergoing development, but is already proving to be the future in the field of leprosy 
control,  as current PCR assays show 100% specificity, and sensitivity ranges from 34% to 80% 
in PB leprosy patients, and more than 90% in MB patients62. PCR for leprosy could therefore 
provide options for the confirmation of diagnosis, diagnosis of difficult cases like pure neural 
leprosy, follow-up of treatment, detection of resistant strains. For control purposes, POC tests 
with high specificity and sensitivity are more desirable for control programmes. In this regard, 
the PGL-1 could be a better candidate if is its sensitivity is improved upon, given that it is likely 
going to be more accessible compared to the PCR. However, the development of the GeneXpert 
technology for detection of multi-resistant TB and rifampicin resistance, qualified by some 
laboratory scientists as 100% specific and highly sensitive, and simple to operate by routine staff 
with minimal training66, gives hope for such advancement in the development of PCR 
technology for leprosy. 
ii. Buruli ulcer 
There are four methods currently available for Buruli ulcer laboratory diagnosis namely: 
microscopy to detect AFB after ZN staining, PCR based on the detection of the M. ulcerans 
specific insertion sequence IS2404, histopathology to put into evidence typical tissue alteration 
related to M. ulcerans infection and finally culture of M. ulcerans. The ZN staining, PCR and 
culture can be done on cotton swab samples of exudates collected from the undermined edges of 
the ulcerated forms or from fine-needle-aspiration samples from the non-ulcerative forms of 
Buruli ulcer. This is unlike histopathology that is done on biopsy or surgical samples obtained 
through invasive punch or through excision respectively. Out of the four methods, only 
microscopy following ZN staining can be carried out at the peripheral health facilities because it 
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is relatively simple, requiring low infrastructure and yields rapid results67. However, it is limited 
by its low sensitivity of between 40% to 78%51,68, 69, and its inability to differentiate between the 
mycobacterial species as we have indicated in Chapter 5, where a case of cutaneous tuberculosis 
was misdiagnosed as Buruli ulcer in the Bankim endemic area on the grounds that the ulcerated 
lesion with undermined edges was positive for AFB after ZN staining. The diagnosis would have 
been maintained as such if not for the curiosity raised by the negative IS2404 qPCR from 
specimen from the same lesion. A culture of specimen yielded mycobacterial growth that was 
ZN positive but again negative for M. ulcerans specific PCR. Further investigation revealed 
positivity for M. tuberculosis complex PCR so that the patient was retrospectively diagnosed for 
extra-pulmonary (cutaneous) tuberculosis. The IS2404 PCR is the gold standard for Buruli ulcer 
diagnosis due to its high sensitivity70. The method was first developed by Stienstra and 
colleagues71, but was improved upon to the IS2404 TaqMan Assay (Real-Time PCR (RT-PCR) 
by Rondini, which was 10 times more sensitive and results were yielded in a shorter time 
compared to the conventional PCR method72. Sensitivity of the RT-PCR could further be 
increased by collecting multiple samples per patient73, but also using moist transport media74 for 
transmitting the samples to the reference laboratory. Despite the advantage of RT-PCR over the 
other diagnostic methods in terms of high sensitivity and rapid yield in results from when the 
samples get to the reference laboratory, this advantage gets lost for a number of reasons. First, 
the reference laboratories with capacity for IS2404 RT-PCR are too far away from the endemic 
areas, and so the clinical diagnosis can only be confirmed retrospectively. Secondly, PCR 
analysis is costly, and cost gets swollen up by the transportation cost of samples from the 
endemic areas to the reference laboratory. In Cameroon, the cost burden may eventually be 
shifted to the patient as the partner resources that covered it is waning away. As a cost reduction 
216 
 
Earnest Njih Tabah  Skin NTDs in Cameroon: the need for integrated control and elimination 
  
measure, suggestions have been made to adopt a stepwise laboratory confirmation68 or combine 
microscopy and PCR in Buruli ulcer confirmation67. The culture of M. ulcerans from clinical 
specimen is the acceptable definitive diagnostic method for Buruli ulcer. However, in addition to 
the fact that it requires sophisticated laboratory setup which can only be available in a reference 
laboratory, it also has issues with lengthy time to yield results. Bratschi and colleagues have 
shown that M. ulcerans culture can take from 6 weeks to as long as 25 weeks to grow, as well as 
low sensitivity. For improvement of culture sensitivity, Bratschi and colleague have 
recommended that: samples should be transmitted to reference laboratories in moist transport 
media; multiple samples should be collected per case, and that the Lowenstein-Jensen culture 
medium be supplemented with antibiotics74.  Culture is therefore not very suitable for Buruli 
ulcer diagnosis but could be important in monitoring treatment outcomes, and useful for research 
purposes. Histopathology like culture also have limited diagnostic value. It has been shown that 
M. ulcerans is not uniformly distributed in affected tissue73. This may lead to false negatives just 
because the biopsy was taken from the wrong site. Collection of multiple samples per case has 
also been recommended as remedy for improvement of positivity rates in M. ulcerans 
histopathology. In as much as histopathology may not be useful for diagnosis, it very useful in 
research, for instance mycolactone extraction for development of a rapid diagnostic test. For 
Buruli ulcer control programmes in general and that of Cameroon in particular, having a rapid 
diagnostic test with high specificity and sensitivity, that is simple to perform, adapted for field 
conditions and of course affordable, is of utmost necessity. In this regard, there is a glimmer of 
hope as some research and development activities are ongoing to develop a mycolactone-based 
rapid diagnostic test for Buruli ulcer. A recent trial has been carried out with clinical Buruli ulcer 
samples from four African countries, to evaluate the fluorescence of mycolactone on thin layer 
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chromatography (f-TLC), and the outcome were quite encouraging, with a 73.2% sensitivity and 
85.7% specificity, and no significant difference in sensitivity by sample type75. While 
encouraging the search for alternative biomarkers that could also be candidates for development 
of point-of-care test for Buruli ulcer, we hope that the mycolactone-based f-TLC development 
goes rapidly and conclusively through a phase-3 trial, so that sooner than later, it can be available 
for use in endemic areas.  
iii. Yaws 
Yaws is caused by T. pallidum pertenue, a sub specie of T. pallidum responsible for syphilis. 
Diagnostic tools used for detection of syphilis are also good for the detection of yaws and other 
treponemes. The diagnostic tools include direct detection of treponemes in clinical specimens 
through dark-field microscopy, fluorescent techniques, or by molecular assays; and serological 
tests76,77. Historically, dark-field (DF) microscopy78 has been considered the best method for 
identification of treponemes. With a DF microscope, spirochetes from yaws lesion exudates can 
be visualized better compared to conventional light microscope as the spirochete’s cellular 
diameter is too small (0.2μm). DF microscopy is useful for the confirmation of active  early yaws 
lesions as in most patients with these lesions, immune response has not yet developed to 
detectable levels76,78. The limitations of DF microscopy are low sensitivity of <80%, inability to 
differentiate between the treponemal sub species, the requirement for performing it immediately 
after specimen collection, and the need for well-trained and skilled microscopist77,79. Direct 
fluorescent techniques can detect T. pallidum antigen, by use of fluorescein isothiocyanate-
labelled treponeme-specific antibody; or direct fluorescent antibody to detect T. pallidum in 
tissue. The major limitation of the direct fluorescent techniques is their inability to differentiate 
between the treponemal sub species77. A number of molecular assays based on PCR have been 
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developed for detection of T. pallidum in biological specimens76 which are highly specific and 
sensitive, being able to detect as low as less than 10 organisms per specimen77. Some of the PCR 
methods are able to differentiate between the T. pallidum sub-species80,81. Despite the advantages 
of PCR, the techniques have not been standardized, and are yet to be commercially available77. 
Serological tests are at the moment the most recommended for the diagnosis of T. pallidum 
although they too are unable to differentiate between sub species. There are two major groups: 
the non-treponemal and the treponemal serological tests. The non-treponemal serology test are 
based on the antigen formula for Venereal Disease Research Laboratory (VDRL) test, which 
contains cardiolipin, cholesterol and lecithin82. The most commonly used non-treponemal 
serology tests in Cameroon are the VDRL82 and the rapid plasma reagin (RPR)83. Non-
treponemal serology tests are simple to use, rapid and cheap, and can be used for diagnosis, 
monitoring of treatment and the detection of reinfection of treponemal infections77. However, 
they have reduced sensitivity and are susceptible to cross-reactivity with other antigens. 
Treponemal serology tests are used to detect the presence of antibodies against T. pallidum and 
the other pathogenic treponemal sub species like those causing yaws, bedjel and pinta in the 
serum or plasma samples. The treponemal serology tests are used as confirmatory tests after 
screening with the non-treponemal tests. The treponemal serology tests have relatively high 
specificity and sensitivity for T. pallidum, although cannot differentiate between the sub species. 
They may remain reactive for several years even after treatment, and therefore not suitable for 
monitoring of treatment response of detection of reinfection77. In sero-prevalence surveys for 
yaws targeting children under 15 years of age, a treponemal test could be used directly especially 
when the objective is not to dissociate active from latent yaws cases. We applied this method in a 
survey in Lomie health district in the east region of Cameroon (Chapter 6), using the Treponema 
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pallidum haemagglutination Assay (TPHA) test. Currently rapid diagnostic non-treponemal and 
treponemal tests exist and are being used at the point-of care. For the implementation of the 
Morges yaws eradication strategy, the WHO has recommended the use of a dual path platform 
(DPP) syphilis screen and confirm test, which combines both the non-treponemal and the 
treponemal test into one test platform. We have used DPP syphilis screen and confirm test 
satisfactorily for investigation of yaws outbreaks in Cameroon (Tabah EN, unpublished). A 
recent evaluation of the WHO- recommended DPP syphilis screen and confirm test in Papua 
New Guinea has shown sensitivities and specificities of 88.4% and 95.2% respectively for the 
treponemal component (DPP T1); and 87.9% and 92.5% respectively for the non-treponemal 
component (DPP T2)84. The bone of contention now remains the high cost of the DPP syphilis 
screen and confirm test and its limited availability in Cameroon. We recommend for the National 
programme to lobby for inclusion of the test into the Cameroon national list for essential drugs 
and medical consumables in order increase its availability nationally at a reduced cost.  
 
9.5 Treatment 
9.5.1 Leprosy: 
The treatment of leprosy has evolved from chaulmoogra and hydnocarpus oils before the 
1940s85 to promin refined to dapson86 that reigned as mono therapy for over 25 years87, through 
clofazimine and rifampicin monotherapies88,89, and finally to multidrug therapy (MDT) 
combining rifampicin, clofazimine and dapson from 1982 to date86,87,88. The advent of MDT 
alleviated and/or resolved the problems of dapson resistance, anarchical use of rifampicin 
monotherapy and fears of rifampicin resistance, toxicity, issues of late relapses due to persistent 
M. leprae or “persisters”, and finally issue of indefinite treatment87,88. The MDT regimen for PB 
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leprosy was to last for six months and that for MB leprosy for 12 to 24 months at the beginning, 
but as new evidence of effectiveness of the treatment became available, especially related to low 
relapse rates of <1% for MB and <2% for PB, the duration of MDT treatment was finally 
standardized at six months for PB and 12 months for MB leprosy respectively49,87. The 
implementation of MDT is widely accredited for the attainment of the 2000 target of leprosy 
elimination as a public health problem90, and the continuous reduction on prevalence after the 
year 200091. At the turn of 2000, the necessity to further shorten the duration of leprosy treatment 
was being felt and was discussed in the 3rd meeting of the WHO Technical Advisory Group 
(TAG) on Leprosy in 2002. A suggestion of a six-months uniform MDT for all forms of leprosy 
was put on the table, and following discussions, TAG members decided that trials would have to 
be conducted to gather enough evidence before making such a recommendation to leprosy 
control programmes92. At the time, some leprosy experts qualified uniform MDT regimen for 
leprosy patients as a wishful thinking, identifying a number of flaws in the trial protocol that was 
presented at the TAG meeting93. Outcome from the uniform MDT trial carried out in India and 
China where 2091 PB and 1298 MB newly detected patients were recruited, treated for six 
months each with a uniform MTD, and then followed-up for a period of five years for post-
treatment relapse were published in 2016. The PB group registered 2 (0.023/100 person-years), 
and the MB group 4(0.07/100 person-years) cases of relapse94. Another study carried out in 
Brazil between 2007-2015, randomizing newly detected MB leprosy cases into two treatment 
groups: one  with uniform MDT for six months and the other with regular MDT for 12 months 
reported a relapse rate of 2.6/1000 person-years in the uniform MDT group and 4.5/1000 person-
years in the regular MDT group95. Both studies concluded that uniform MDT was an acceptable 
option for adoption by leprosy control programmes94,95. The implementation of uniform MDT in 
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Cameroon will be a win-win situation for both the leprosy patients and the National Control 
Programme. On the patients’ side, the burden of attending the health facility every month for 
refill of MDT shall be cut by half for the MB cases who constitute over 75% (Chapter 2) and 
may also improve on compliance. Secondly more time will be devoted to early detection of cases 
and complications and their adequate management to prevent disabilities. For the National 
Control Programme, this will bring about cost reduction in logistics, training and 
surveillance92,96.Furthermore the burden on the health personnel in term of patient treatment 
monitoring, data recording and reporting shall be cut down.   In the past, the WHO has given 
treatment recommendations even before conclusive large-scale trials like in the case of drug 
treatment for Buruli ulcer in 200450, and for an all oral treatment for the same condition in 
201297. We think it is time a recommendation be given for a six-months uniform MDT for 
leprosy treatment. 
Monitoring and management of leprosy reactions and neuritis is a very important 
component of leprosy treatment, as they are the greatest threats to nerve damage in leprosy 
patients. Leprosy reactions and neuritis may occur before, during and up to two years after 
treatment53,98. In Cameroon, about 7% of newly diagnosed patients have nerve impairment 
(Chapter 2). MB leprosy patients have a higher risk of nerve impairment, and about 20-50% of 
them will develop nerve impairment within two years of follow-up99. Monthly evaluation of 
peripheral nerve function in leprosy patients on treatment is therefore very important and should 
be extended for one year after treatment for patients at high risk53. When established, leprosy 
reactions and/or neuritis should be treated early and adequately. The aim of early treatment is to 
control inflammation, reduce pain and stop and/or reverse nerve damage and reassure patients, 
bearing in mind that only 60-70% of nerve function could be recovered53. Prednisolone remains 
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the best treatment for leprosy reactions and neuritis, starting at 40-60mg daily and decreasing by 
5mg every 2-4 weeks depending on the clinical response of the patient53,100. Erythematous 
nodusum leprosum (ENL) or type 2 reaction is the more severe form of leprosy reaction, 
occurring in 10-20% of MB leprosy patients. It can begin during or after treatment, and can 
relapse repeatedly over a long period of time53. In addition to corticosteroid treatment, 
clofazimine 300mg daily can be used for its anti-inflammatory effects. Thalidomide 400mg daily 
dose have been recommended for treatment of ENL in young men, but not women for its risk of 
teratogenicity especially in the 1st trimester of pregnancy53. Given the complexities in the 
treatment and follow-up of cases of leprosy reactions, acquiring patient’s participation in 
prevention and management is key. Health personnel responsible for these patients must take 
every opportunity be it during first diagnostic examination or during follow-up visits to educate 
the patient on all aspects of the disease, reassuring him/her and refuting all erroneous perceptions 
regarding the disease (Chapter 3 and 8). The health personnel also need to make it clear to the 
patient that physical deformity already established are irreversible, but that its progression can 
stop, if the patient respects and applies prevention of disability (POD) measures taught 
him/her101. Some of the POD measures include wearing protective shoes with cushioned 
insole102, avoiding long treks (protecting soles from weight-bearing), wear protective gloves, use 
sun glasses, and other self-care activities like resting, soaking, and oiling of palms of the hands 
and soles of the feet103,104. 
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9.5.2 Buruli ulcer:  
Before 2004, the treatment of Buruli ulcer was exclusively surgical, involving large 
excisions of skin around lesions, with lengthy hospital stay and 16-28% risk of relapse105,106. 
There has been an evolution in the management of Buruli ulcer, and antibiotic treatment has now 
become the backbone of management, with the introduction of 8-weeks streptomycin and 
rifampicin combination therapy in 200450, and an all oral combination of 8-weeks rifampicin and 
clarithromycin in 201297. The advent of medical treatment has brought about flexibility in Buruli 
ulcer management. In Cameroon, the National Control Programme has now allowed treatment 
and follow-up cases with simple lesions: category 1 and some category 2 lesions at the integrated 
health centre level where antibiotics and wound dressing are sufficient for healing, under the 
supervision of the Buruli ulcer diagnostic and treatment centres (BU-DTC). The BU-DCT 
located at the district hospitals of endemic areas now take care of cases with category 3 lesions 
where in addition to antibiotics and wound dressing, other components of management like skin 
grafting, functional re-education and psychosocial support are necessary. The implementation of 
the all oral antibiotic treatment in Cameroon has been of great relief for Buruli ulcer patients 
from painful daily injections of streptomycin for 56 days of treatment. Furthermore, patients with 
category 1 and some category 2 lesions can be treated on ambulatory basis, at health centres 
closer to their homes. Consequently, the cost of transportation to far away BU-DTC at the 
district hospital and living expenses there during the period of treatment are curbed. In addition, 
patients or their care-takers are also able to carry on with their personal businesses during 
treatment. All of these factors have helped to reduce the financial and economic loss incurred to 
patients and/or family members during treatment for Buruli ulcer105,107. To improve upon 
treatment adherence for patients treated on ambulatory basis, community health workers (CHW) 
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are more and more being involved in the follow-up of these patients. The role of the CHW here 
is to ensure that patients take their antibiotics daily as required and respect their appointments for 
wound dressing at the health centre. Although not yet evaluated, the risk of decentralizing 
management of simple Buruli ulcer cases to the health centres could be a degradation in the 
quality of wound care. Some of the integrated health centres do not have adequate plateau 
techniques for wound dressing like a separate space with running water and autoclave for 
sterilization of dressing material. In such situations, the health centres are not authorized to 
manage Buruli ulcer until when the conditions are met. In authorized health centres, the practice 
of aseptic measures during wound dressing should be monitored closely by the BU-DTC and the 
National Control Programme during supervision visits.  
To date, no resistance of M. ulcerans to any of the three antibiotics in use namely 
rifampicin, clarithromycin and streptomycin has been notified. In as much as this is comforting, 
research into alternative and shorter courses of treatments for Buruli ulcer need to continue. In a 
review of drug treatment for Buruli ulcer, in addition to rifampicin/streptomycin and 
rifampicin/clarithromycin combinations that have been recommended by the WHO, the 
combination rifampicin/moxifloxacin have equal efficacy for 8 weeks of treatment108. Other 
candidate drugs include amikacin, ciprofloxacin and rifapentine that have bactericidal properties 
on M. ulcerans invitro and in vivo108,109. Furthermore, shorter courses of antibiotics (14-27 days) 
in association with surgery, with successful outcomes have been reported in Australia109. 
9.5.3 Yaws  
Penicillin, discovered by Alexander Fleming in the 2nd quarter of the 20th Century110, has 
been the drug of choice for the treatment of yaws and other treponematoses since its discovery, 
and continues to be very potent against this bacterium to date. It constituted the major tool for the 
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yaws eradication campaign by WHO and UNICEF between 1950 and 1970. 5,111,112. Recently, 
single-dose azithromycin was shown to have slightly greater efficacy than benzathine penicillin 
in the treatment of yaws113,114. With this new development and with the advantage of being an 
oral medication, there has been renewed hope of a yaws eradication by 202025. The Morges 
eradication strategy for yaws eradication developed in 2012, considers the single-dose 
azithromycin oral treatment as the central tool for its implementation26. The strategy has been 
piloted in the Lihir Island of Papua New Guinea, and within 42 months after total community 
treatment (TCT), followed by total targeted treatment (TTT), a re-emergence of yaws was 
reported, together with the detection of resistant strain of T. pallidum peternue to azithromycin in 
a village community in the island115. However, the re-emergence of yaws in the island was 
blamed on people who had been missed during the mass treatment campaign rather than on the 
resistant strain which at the time of the report was limited to one village community. The authors 
recommended multiple mass campaigns before total targeted treatment in the implementation of 
the eradication strategy115. This report of the first pilot of the Morges strategy underscores the 
need for high coverages in the initial mass azithromycin administration, when implementing the 
strategy. With the signal of azithromycin resistance, a second drug should be sought for, to be 
used in combination with azithromycin in order to reduce the risk of the emergence of resistant 
strains, as is the case in leprosy and Buruli ulcer. 
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9.6 Prevention 
9.6.1 Leprosy prevention  
Leprosy is a complex disease with a number of areas that still lack clear understanding. 
One of such areas is the transmission of M. leprae. It is believed to be shed in huge quantities 
from the nose, and to a lesser extent from the skin of an untreated multibacillary leprosy 
patients12, and to be transmitted mainly through the upper respiratory tract and minimally 
through breaks on the skin116. However, there is no robust evidence for mechanism of leprosy 
transmission yet117. Furthermore, the very long incubation period from time of contamination or 
exposure to time of early clinical manifestation, the inability to culture M. Leprae in vitro, and 
the difficulty to diagnosis sub-clinical cases and those with early clinical manifestations hampers 
development of a primary prevention strategy. With these limitations, we are currently left 
basically with secondary prevention, with the goal of preventing already infected individuals 
from developing leprosy related disability through early case detection, adequate treatment with 
MDT and appropriate management of complications96. In the current context when there is a 
general reduction in funding for leprosy activities, approaches like standalone active case finding 
are no longer cost-effective nor cost-efficient. With increasing evidence that close contacts of 
newly diagnosed patients have a high risk of developing leprosy12,116,118,119, preventive strategies 
are targeting contacts more and more, and have included chemoprophylaxis and immune-
prophylaxis120.  
Chemoprophylaxis in leprosy is an old idea dating back from the 1960s to 1970s, with 
dapson chemoprophylactic trials120. In India, randomized trials where child contacts of leprosy 
patients were given dapson or placebo on a weekly basis for two to three years.  The outcome 
was reduction in leprosy incidence of 40% among contacts in the dapson group compared to the 
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placebo group121. Since the late 1980s, after the introduction of MDT, a number of trials to test 
the efficacy of rifampicin chemoprophylaxis in leprosy have been carried out. Some 2751 people 
constituting 98.7% of the total population living in Southern Marquesas Island, and 3144 South 
Marquesans living elsewhere in French Polynesia were treated with a single dose rifampicin 
prophylaxis in January 1988, and after 10 years of follow-up, seven new cases of leprosy had 
developed: two of them within 21 months after chemoprophylaxis122,123,124. The authors felt that 
the first two were probably leprosy cases missed  out at the time of chemoprophylaxis and could 
not be considered as chemoprophylactic failure123,124. During the 10 years period of follow-up, 
17 new cases of leprosy were expected to occur if there had been no chemoprophylaxis, but only 
5 did, implying a 70% reduction. The authors further relativized by indicating that since case-
finding activities were reduced by 50% during the 10 years follow-up period, the actual 
effectiveness of the rifampicin chemoprophylaxis was about 35-40%124. A more recent and 
larger study was that carried out by the COLEP group in Bangladesh where 21711 close contacts 
of 1037 newly diagnosed leprosy patients were recruited and randomized into two groups of 
single dose rifampicin chemoprophylaxis and placebo respectively between June 2002 and 
December 2003125. After follow-up of 18869 (86.9%) of the participants for four years, 59 versus 
91 new leprosy cases had occurred in the rifampicin chemoprophylactic and placebo groups 
respectively. The authors noted an overall reduction of 57% in incidence of leprosy secondary to 
the single dose rifampicin chemoprophylaxis in the first two years, and with no difference in 
both groups thereafter up to the fourth year125. From the two trials cited, single dose rifampicin 
chemoprophylaxis should be recommended among close contacts of index leprosy cases, while 
treating the index cases adequately with multidrug therapy. The National Control Programme in 
Cameroon would be ready to implement such a strategy if the WHO gave the green light. 
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Vaccination is believed to be one of the greatest contributors to global health, leading to 
the eradication of smallpox, and near elimination of measles and poliomyelitis126. Historically, 
the BCG vaccine developed in the 1920s originally for vaccination against tuberculosis127 has 
been thought to confer limited protection against leprosy120. This has led to several vaccine trials 
using BCG either alone or in combination with killed M. leprae or other mycobacterium species. 
In 1991, a large scale trial involving 171,400 healthy volunteers was carried out in South East 
India to assess 4 different vaccines against leprosy namely: BCG; BCG + killed M. leprae; M. 
welchii; and the Indian Cancer Research Centre (ICRC) vaccine based on M. avium, each pitted 
against a normal saline placebo128. Seventy percent of the participants were resurveyed in 1998, 
and on the basis of incidence of leprosy across the different groups of the vaccine trials, the 
authors observed that: BCG + Killed M. leprae conferred a 64% protection, ICRC provided 
65.5% protection, M. welchii conferred 25.7% protection, and BCG alone gave 34.1% 
protection. The conclusion from the study was that the level of protection conferred by the ICRC 
vaccine and the BCG + killed M. leprae met international standards128. Other mycobacteria 
species-based vaccines: M. vaccae129 and M. Habana130 have subsequently been tried without an 
added value over the previous ones. Of all the vaccines assessed so far, only BCG has been 
recommended for routine use against leprosy, and in Brazil only120. In Cameroon, BCG 
vaccination against tuberculosis was introduced in 1968, and was being carried out as mass 
campaigns for individuals up to the age of 20 years until 1976 when the target group was limited 
to the newborn131. Records of BCG vaccination coverage in Cameroon are available beginning 
from 1981, when the Enlarged Programme on Immunization (EPI) was created in the Ministry of 
Public Health. The coverage increased steadily from 5% in 1981 to attain 78% in 1990, then 
dropped gradually to about 58% in 1998 before rising again to 78% in 2002132. The 
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implementation of EPI since 1981 in Cameroon coincided with the introduction of multidrug 
therapy against leprosy. Whether the vaccination of new-borns with BCG had a role in the 
reduction of leprosy incidence in Cameroon (Chapter 2) has never been evaluated. Maybe BCG 
has a share of the glory attributed to MDT for the reduction of leprosy incidence in Cameroon. A 
WHO position paper on BCG released February 2018 now recommends BCG for all new-borns 
in countries with high incidence of tuberculosis and/or leprosy for protection against tuberculosis 
and leprosy133. Since BCG is included into the EPI package in Cameroon, the implementation of 
the WHO recommendation requires simply improvement of BCG vaccination coverage. 
The inability to culture M. leprae invitro has been a challenge to vaccine development. 
The complete M. leprae genome sequencing134,135 has brought about new hopes for vaccine 
development against leprosy, as there has been discovery of enabling antigens that can be  
produced as recombinant proteins; and most importantly, the availability of adjuvants suitable 
for subunit vaccine design136. Antigens from M. leprae cell wall, cell membrane and the cytosol 
may provide protection and potential targets are the 35kD, 85B, hsp65137,138,139, as well as the 
10kD, 25kD and 65kD M. leprae proteins140. Regarding adjuvants, the most preferred for 
intracellular pathogens like M. leprae are those that can induce helper T-cell 1 (Th1) responses. 
Engaging macrophages and dendritic cells orchestrating suitable T-cell responses is prerequisite 
for developing new generation T-cell vaccine136. As an example, bagging on the safety and 
efficacy data monophosphory lipid (MPL), new generation ligands using the crystal structure of 
the myeloid differentiation protein-2 (MD2) molecule of the human tool-like receptor 4 (TLR4) 
have been designed and optimized 141. Of the new generation ligands synthesized, the 
glycopyranosyl lipid adjuvant (GLA) which is expected to be more potent and affordable 
compared to the previous MPL adjuvant136, is already being assessed in vaccine trials141,142. 
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9.6.2 Buruli ulcer prevention 
Similar to leprosy, there is no effective primary prevention strategy for Buruli ulcer as no 
clear mode of transmission has been identified. Efforts towards the search of the mode of M. 
ulcerans transmission have so far remained futile19. Consequently, Buruli ulcer control depends 
on early case detection and adequate treatment with rifampicin/clarithromycin or 
rifampicin/streptomycin anti-biotherapy, associated or not with excision and skin grafting and 
functional re-education to prevent disability97. No evidence of human to human transmission of 
Buruli ulcer has been found143. Furthermore, many people exposed to M. ulcerans do not 
develop the disease144,145, so chemoprophylaxis may not be a cost-effective option for prevention 
of the disease. There is evidence of the presence of M. ulcerans in water bugs (some of which 
can bite when provoked) in Cameroon146 and elsewhere, as well as in the guts of mosquitos in 
Australia147. Two studies carried out in Cameroon in two endemic foci of Akonolinga in the 
Nyong basin, and Bankim in the Mapé basin respectively to determine risks factors for Buruli 
ulcer have come out with similar findings: the use of mosquito bed nets, wearing of long sleeve 
clothing and trousers, and proper cleaning of small wounds are reducing the risk of developing 
Buruli ulcer148,149. 
Some studies showed that BCG could confer protection against Buruli ulcer150,151. 
However, a recent multi-country study including Ghana, DR Congo and Togo to assess the 
effectiveness of BCG vaccine in protecting against Buruli ulcer, found no influence of BCG on 
the development of Buruli ulcer, nor any correlation between BCG vaccination and the duration 
of BUD, or time to its healing152. Significant efforts for the identification of possible Buruli ulcer 
vaccine antigens have been made. The Hsp65 antigen of M. ulcerans provokes some limited 
immune protection in mice models, but a DNA vaccine encoding the homologous Hsp65 of M. 
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leprae did not prevent development of M. ulcerans disease in mice when vaccinated with it153. 
An M. bovis BCG protein-based vaccine candidate showed limited protective-efficacy in mice 
against progression of M. ulcerans disease and a DNA vaccine candidate encoding M. ulcerans 
Ag85A has shown a little better protection compared to an M. bovis Ag85A vaccine in mice. 
However, the protection was not sustained154. A M. ulcerans surface antigen-based subunit 
vaccine containing recombinant MUL_2232 and MUL_3720 elicited strong antibody response 
and little Th1 cellular response and showed limited protection against progression of M. ulcerans 
infection in the mouse footpad challenge model155. The BuruliVac project for the identification 
and development of vaccine candidates for Buruli ulcer identified 9 polyketides domains 
involved in mycolactone production and assessed their vaccine potentials. Of the 9 polyketide 
domains, two (acyltransferase – propionate (ATp) and enoylreductase (ER)) elicited strong 
antibody response and one (ATp) elicited a strong Th1-type cellular response. However, both 
ATp and ER conferred a weaker protection against Buruli ulcer compared to the Ag85A M. bovis 
BCG vaccine156.  In a most recent effort, a recombinant M. marinum strain expressing the M. 
ulcerans Ag85A was generated, and was shown to be more immunogenic and conferring a 
higher protection compared to the M. bovis Ag85A157. None of the candidate antigens tested so 
far in the mouse model showed sufficient efficacy to be considered for clinical testing. Buruli 
ulcer endemic countries thus may still have a long wait for a vaccine prevention against the 
disease. The finding that mycolactone specific antibodies have toxin neutralizing activity158  is 
raised hope that this macrolide toxin may be a suitable vaccine target. 
 Our recommendation for the scientific community is to intensify research to determine 
the exact mode of M. ulcerans transmission, and also continue the search for a potent vaccine 
against Buruli ulcer. While waiting, the National Control Programme in Cameroon has to 
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improve upon early case detection and adequate treatment of cases, as well as liaise with the 
Enlarge Programme on Immunization to improve upon the BCG vaccine coverage in Buruli 
ulcer endemic areas based on the WHO position paper on BCG133. 
9.6.3 Yaws prevention 
There is no vaccine against yaws. Since T. pallidum pertenue the causative agent for yaws is 
a sub species of the T. pallidum responsible for syphilis, we should think that any vaccine 
developed for syphilis should equally be effective against yaws. Vaccine development efforts for 
syphilis is facing a major challenge related to the fragile nature of the T. pallidum outer 
membrane, and the inability to cultivate and manipulate it genetically159. Current efforts are still 
at the level of identifying antigen targets for possible syphilis vaccine. So far, the γ-irradiated T. 
pallidum has exhibited some protection against homologous active T. pallidum in the rabbit 
challenge model, but not against the other treponemal species including T. pallidum pertenue 
responsible for yaws159. About 13 individual antigens have been identified as possible targets for 
syphilis vaccine, but none of them has conferred full protection. So any syphilis vaccine will 
most likely have to consist of a cocktail of a good number of different antigens159.  
With no vaccine in view in the nearer future, prevention of yaws will remain based on the 
interruption of transmission through early diagnosis and treatment of individual cases and mass 
or targeted treatment of affected populations or communities160. In addition to treatment, health 
education and improvement in personal hygiene, are essential components of yaws prevention160. 
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9.7 Control-elimination-eradication of NTDs in Cameroon 
9.7.1 The need for an integrated strategy 
Neglected Tropical Diseases (NTDs) are the most common infections of the poorest 
people of the world161, affecting 32.3% of the world’s population162. These diseases render 
affected individuals, families and communities even poorer through their effects of physical 
disabilities, lengthy periods of illness, impaired childhood growth and development, adverse 
outcome of pregnancy and reduced productivity48, with 15 to 38% of the burden being in Sub-
Saharan Africa163,164. The burden of NTDs in terms of disability-adjusted life-years (DALYs) put 
together is greater than that of malaria and tuberculosis and rivals that of HIV/AIDS38, for which 
donors, international agencies and governments have responded through the creation of 
organizations such as UNAIDS, Stop TB, Roll Back Malaria and the Global Fund to Fight AIDS, 
TB and Malaria164. NTDs have not received equal attention in terms of funding for control, 
research and development165,166, probably because they are diseases of poverty, affecting 
populations with low visibility and little or no political voice, and do not also travel widely to 
constitute a menace to the rich industrialized countries48.  
For a long time, separate disease-specific programmes and initiatives have been created 
at global and regional levels and implemented at national level in collaboration with ministries of 
health to combat the NTDs in a more or less vertical manner. These programmes included: the 
Leprosy Elimination programme, the Global Buruli ulcer Initiative, the Yaws Eradication 
Programme, the Leishmaniasis Control Programme, Human African Trypanosomiasis Control 
and Surveillance Programme, Programme for the control of Soil-Transmitted Helminth 
Infections, the Schistosomiasis Control Initiative, The African Programme for Onchocerciasis 
Control (APOC), Dracunculosis (Guinea Worm) Eradication Campaign, and the Global 
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Programme to Eliminate Lymphatic Filariasis167. For each disease-specific programme entity, the 
WHO provided technical guidance and developed partnerships with pharmaceutical companies 
for drug donation for free treatment of the affected populations164,168. Furthermore, public-private 
partnerships (PPP) between ministries of health of endemic countries and international non-
governmental organizations for the implementation of control, elimination or eradication of these 
NTDs were developed164,167. Undoubtedly, the implementation of these vertical programmes by 
ministries of health in collaboration with development partners through the guidance of the 
WHO has yielded a lot of achievements from near eradication of guinea worm169, to attainment 
of elimination targets for leprosy90, lymphatic filiariasis170, Human African Trypanosomiasis20, 
to interruption of transmission of onchocerciasis in a number of countries171.  
The implementation of disease-specific vertical programmes has been expensive, and not 
very cost-efficient. Furthermore, the resources harnessed through PPP for the implementation of 
the vertical programmes were not sustainable and have waned over the past one and half 
decades, following the attainment of elimination thresholds of some NTDs17,172. This situation 
puts to question the feasibility of meeting the WHO 2020 roadmap targets for NTDs25. 
To sustain implementation of control, elimination or eradication of NTDs in a context of 
decreasing interest by the donor agencies, the ministries of health of endemic countries have to 
adopt more cost-efficient strategies. The way forward at the moment is to transit from disease-
specific control programmes to integrated control interventions/activities for the fight against 
these NTDs. There is evidence that integration of interventions is more cost-effective and cost 
saving164. The idea of integrated control of NTDs is being supported by a number of policy 
papers28,164,170,172, WHO Afro Regional Strategy for NTDs173, and World Assembly 
Resolutions174,175. 
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9.7.2 The current situation of the control of NTDs in Cameroon 
Cameroon is endemic for at least 13 NTDs including: leprosy, Buruli ulcer, yaws, muco-
cutaneous leishmaniasis, human African trypanosomiasis, lymphatic filariasis, onchocerciasis, 
soil-transmitted helminthiasis, schistosomiasis, rabies, trachoma, scabies and snakebite 
envenoming. A revised National NTD Master Plan 2016-2020 was adopted in 2016, with all the 
different conditions included, except for scabies and snakebite envenoming that were just 
recently added to the list of NTDs in 2017176.  The control of the NTDs is carried out by separate 
vertical control programmes including the National Yaws, Leishmaniasis, Leprosy and Buruli 
ulcer control Committee (CNLP2LUB), the National Programme for Onchocerciasis and 
Lymphatic filariasis (LF) Control (PNLO), the National Programme for Schistosomiasis and Soil 
Transmitted Helminthiasis (STH) Control (PNLSHI), the National Programme for Human 
African Trypanosomiasis Control (PNLTHA), the National Programme for the Control of 
Blinding Trachoma (PNLCe). Some of these control programmes have one or more funding 
partners including the Helen Keller International (HKI), SightSavers, Lions Club International 
Foundation (LCIF), the FAIRMED Foundation, with the majority supporting mass drug 
administration against onchocerciasis, LF, STH, schistosomiasis, and Trachoma177. The major 
challenge with the partner funding is that they are strictly disease-specific, so that even if a 
control programme is in charge of more than one NTDs, it is not allowed to use funding 
allocated to a particular NTD for activities of the other NTD. Secondly government budgetary 
allocation to the control programmes is very insignificant with respect to the huge requirements. 
Amongst the Skin-NTDs, only leprosy and Buruli ulcer currently benefit from very limited 
support from the FAIRMED Foundation, which is restricted to five out of 122 endemic or co-
endemic health districts.    
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9.7.3 Why integrated control of Skin-NTDs is the best option for Cameroon 
i. The partner support to leprosy elimination and Buruli ulcer control in the country has 
waned drastically since 2010 (Chapters 2 and 4). Leishmaniasis and yaws control activities 
do not yet benefit from any partner funding, and there is no new committed partner funding 
in view. The government budgetary allocation to the control of leprosy, Buruli ulcer, yaws 
and leishmaniasis begun only five years ago and is still very limited with regard to the 
expressed needs. There is evidence that integrated control interventions/activities gives best 
value for money164. So, to optimize the little available resource, control interventions for 
these Skin-NTDs must be carried out in an integrated manner. 
ii. Skin-NTDs have a common ground for their clinical manifestations and that is the skin. 
This allows for integration of activities such as training of health personnel, training of 
community volunteers, case detection of the NTDs, surveillance, morbidity management 
and disability prevention related to the NTDs. Such activities could also have collateral 
benefits to other skin conditions like scabies, other fungal and bacterial infections of the 
skin as well as conditions like lymphatic filariasis morbidity (elephantiasis and hydrocele) 
and podoconiosis that has recently been shown to be endemic in Cameroon178. Common 
clinical manifestation of skin NTDs also facilitates optimization of health system 
strengthening through reinforcement of plateau techniques of fewer health facilities for 
integrated case management, as well as a referral-counter-referral system. Table 9.2 give 
details of those common features of Skin-NTDs and common intervention and activities 
involved in controlling them, that allows for an integrated control.  
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Table 9.2 Common features and control activities of Skin-NTDs 
Features and interventions/activities Leprosy Buruli 
ulcer 
Yaws Muco-
Cutaneous 
Leishmaniasis 
Organ/ site of 
affection  
Skin X X X X 
Nerves X X  X X  
Type of lesion 
  
  
  
  
  
  
  
  
Macules X   X   
Plaques X X   X 
Nodules X X X X 
Papules X X   X 
Skin infiltration X       
Oedema X X     
Ulcers X X X X 
papilloma     X   
Thickened nerves X       
Complications 
  
  
  
  
Auto-immune reactions X X     
Vicious scars with limb contractures   X     
Damage of nose X   X X 
Peripheral neuropathy X       
Involvement of bones X X X   
Goal 
  
  
Control   X   X 
Elimination X       
Eradication     X   
Mapping Mapping surveys X X X X 
Early case 
detection 
  
  
  
  
Training of Community volunteers, 
teachers, traditional healers 
X X X X 
Information, education and 
communication campaigns in 
communities and schools 
X X X X 
Early case detection in communities and 
schools using community health workers 
and teachers 
X X X X 
Household contacts tracing X   X   
Special actions towards hard-to-reach 
populations (Pygmies, Bororo, 
geographical inaccessibility) 
X X X X 
Health system 
strengthening 
  
  
  
Training of health personnel on 
diagnosis, treatment and follow-up of 
patients 
X X X X 
Standardized recording and reporting of 
case information 
X X X X 
Infrastructure, equipment   X   X 
Transport and logistics X X X X 
Case 
management  
  
  
  
  
Laboratory confirmation   X X X 
Rapid diagnostic test   X X   
Specific antibiotic treatment X X X X 
Wound care X X X X 
Surgery X X     
Prevention of disability/ rehabilitation X X X X 
Morges 
Strategy  
  
Total Community Treatment      X   
Total Targeted Treatment     X   
Post-zero sero-surveillance     X   
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Features and interventions/activities Leprosy Buruli 
ulcer 
Yaws Muco-
Cutaneous 
Leishmaniasis 
Stigma 
reduction 
  
  
Involvement of former patients in 
activities 
X X   X 
Animation of self-help groups X X   X 
Communication for behaviour change X X  X X 
Supportive 
activities 
  
  
Supervision, monitoring and evaluation 
of control activities 
X X X X 
Advocacy, social mobilization and 
partnerships 
X X X X 
Operational research X X X X 
 
iii. There is an overlap in the geographical distribution of leprosy, Buruli ulcer, yaws and 
leishmaniasis in Cameroon. We have mentioned earlier that 122 out the 189 health districts 
in Cameroon are endemic for at least one of the Skin-NTDs under consideration. Forty of 
the health districts are co-endemic for two and 12 are co-endemic for three of the NTDs. 
The co-endemicity is with leprosy and yaws or leprosy, yaws and leishmaniasis in the 
northern part of the country, and in the southern part, co-endemicity is with leprosy and 
yaws; or leprosy, yaws and Buruli ulcer. It is therefore very feasible to implement 
integrated packages of interventions/activities common to leprosy, yaws and Buruli ulcer, 
or leprosy, yaws and leishmaniasis at the same time and by the same team in health 
districts where these conditions co-exist. 
iv. An integrated control of Skin-NTDs shall offer an opportunity for linkages with other 
existing national programmes. The community directed distribution of ivermectine (CDTI) 
strategy used by the National Onchocerciasis and Lymphatic Filariasis Control Programme 
(PNLO) in Cameroon whereby community distributors are trained to carry out a door-to-
door census followed by a door-to-door distribution of mectizan to eligible individuals in 
households.  The opportunity for collaboration with the National Leprosy, Buruli ulcer, 
yaws and leishmaniasis Control programme (CNLP2LUB) here is that the community 
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distributors could be trained in Skin-NTDs case-suspicion and referral during their door-to-
door census and mectizan distribution. Furthermore, the PNLO is also in charge of 
lymphatic filariasis (LF) control through mass treatment with ivermectin and albendazole. 
However, the programme has not developed a strategy for management of LF morbidities 
which are hydrocele and lymphoedema. The CNLP2LUB that has experience in case 
management can collaborate with the PNLO to manage LF morbidities. Secondly, the fact 
that Buruli ulcer and yaws affect mostly children under 15 years of age, is an opportunity 
for collaboration with the National Programme for the control of Soil Transmitted 
Helminths and Schistosomiasis (PNLSHI), that targets school age children for deworming 
in schools. During this activity, pupils could also be screened for Skin-NTDs at the same 
time. Thirdly, the understanding that the BCG vaccine given to new-borns against 
tuberculosis by the Enlarged Programme on immunization (EPI) also confer a degree of 
protection against leprosy and perhaps Buruli ulcer133, provides a link for collaboration 
between the CNLP2LUB and EPI. Fourthly, the CNLP2LUB could collaborate with the 
National Roll Back Malaria Programme to reinforce the use of insecticide treated bed nets 
given that some studies have indicated could be protective against Buruli ulcer. Finally, 
there is the opportunity to integrate into the existing Buruli ulcer diagnostic and treatment 
centres the management of plantar ulcers and other complication of leprosy, diabetic foot, 
and other chronic ulcers. 
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9.7.4 Suggested intervention packages for an integrated control strategy of Skin-
NTDs in Cameroon 
We suggest six intervention packages for an integrated control of Skin-NTDs in 
Cameroon as shown in Fig. 9.4, which should build on the existing National Yaws, 
Leishmaniasis, Leprosy and Buruli ulcer control Committee. Briefly the content of each 
intervention package is as follows: 
i. Integrated mapping of Skin-NTDs and planning  
We have indicated earlier that the situation of each of the Skin-NTDs is not fully known in 
all the 189 health districts of the country. For instance, only 64 health districts are currently 
known to be endemic for Buruli ulcer, based on routine data from the five diagnostic and 
treatment centres in the country (chapter 4), that keep reporting new endemic health districts 
yearly. Yaws has only been mapped in 52 out of the 189 health districts and mapping needs to 
be completed in the remaining 137 health districts. For leprosy, 93 health districts have been 
silent in the past five years, and their leprosy status needs to be ascertained. Potentially, all the 
45 health districts of the Far North the North regions of Cameroon are endemic for cutaneous 
leishmaniasis, as they lie on the Sahelian belt179 but the situation is known only in 11 health 
districts. This intervention package will therefore contribute to the integrated mapping of Skin-
NTDs in order to determine the endemic and co-endemic status of each health district in the 
country. The availability of this information should provide guidance for strategic followed by 
operational planning of interventions adapted to the endemic or co-endemic situation of each 
health district. 
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Fig. 9.4: Proposed intervention packages for an integrated control of Skin-NTDs in Cameroon 
 
ii. Early case detection 
Cases of leprosy, Buruli ulcer, yaws and leishmaniasis need to be detected early and treated 
adequately to avoid development of complications and physical disability. Any opportunity to 
examine the skin should permit the detection of any of the above-mentioned diseases as well as 
scabies, hydrocele, lymphoedema at the same time in the same place by the same team or 
individual. The following strategies for early case detection should be employed: active case 
search in communities by primary health care personnel assisted by community volunteers, and 
in schools assisted by teachers; passive case detection in health facilities during routine 
consultation of patients who visit the facilities even for other motifs; contact tracing of cases of 
leprosy and yaws; organization of special actions for hard-to-reach populations including the 
pygmies of the equatorial rain forest of the Centre, East and South regions, the Bororos of the 
north-western highlands, the komas of the Atlantika mountains in the North of Cameroon, and 
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areas of geographical inaccessibility. The success of the early case detection intervention 
requires sound training of persons directly involved including primary health care personnel, 
community volunteers, school teachers, traditional healers and even former patients in the 
recognition of signs and symptoms of these different skin-NTDs. 
iii. Health system strengthening 
An integrated control of Skin-NTDs requires a strong component of health system 
strengthening. The capacities of health personnel must be reinforced in clinical diagnosis, correct 
treatment with specific antibiotics, wound care, surgery, prevention of disability techniques and 
health education/counselling of patients, through an integrated training. Personnel also needs to 
be trained on patient record keeping and reporting using standardized forms.  The plateau 
techniques of health facilities providing Skin-NTDs care services need to be optimal in terms of 
treatment space (wound dressing room, surgical theatre, admission wards), equipment, 
availability of specific antibiotics, wound care material, medical consumables. Means of 
transportation and other logistics like sound systems are also key for community outreach 
purposes.  
iv. Integrated Skin-NTDs case management 
In an integrated Skin-NTD control programme, the same team of health personnel in the 
same health facility are expected to be able to provide various care services related to the 
different Skin-NTDs to the patients. These include provision of specific antibiotic treatment, 
appropriate wound care, surgery, management of complications, prevention of disability, and 
health-education and counselling services.  Furthermore, the health facility should be able to 
conduct point of care laboratory diagnostic testing of cases, for example Ziehl-Neelsen staining 
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for diagnosis of Buruli ulcer and leprosy, rapid diagnostic testing in yaws etc., and also collect 
and transmit samples in required conditions to the reference laboratory.  
v. Stigma reduction 
Given that victims of most Skin-NTDs are subject to stigma and social exclusion (chapter 
3 and 8), an integrated control of Skin-NTDs should develop a package for stigma reduction. The 
content of the package should include but not be limited to: communication for behaviour 
change; involvement of former patients in IEC, and awareness activities; promotion and 
animation of self-help groups; and promotion of self-empowerment activities for victims of skin-
NTDs. 
vi. Supportive/cross-cutting activities. 
The life-wire for the achievement of an integrated control of Skin-NTDs shall reside in 
effective implementation of supportive and cross-cutting activities at all levels namely the 
national level, the regional level, the operational level which are the health districts and the 
implementing primary care facilities. The supportive activities include: integrated supervision, 
monitoring and evaluation; advocacy and social mobilization; partnership and resource 
mobilization; operational research and dissemination of results; and promotion of evidence-based 
decision making. 
9.7.5 Proposed model for collaboration of CNLP2LUB with other national control 
programmes 
There are other national control programmes in Cameroon with which the National Yaws, 
Leishmaniasis, Leprosy and Buruli ulcer control (CNLP2LUB) can collaborate for joint 
implementation of some activities in a way that will be beneficial to all. We propose here a 
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model for such collaboration between CNLP2LUB and four other national control programmes 
(Fig. 9.5).  
i. Collaboration between CNLP2LUB and the PNLO firstly for Skin-NTD case 
suspicion and referral by community distributors (CD) when they do two door-to-
door rounds to censor and then to distribute mectizan against onchocerciasis; and 
secondly utilization of CNLP2LUB structures and expertise to manage cases of 
hydrocele and lymphoedema which are complications of lymphatic filariasis. 
 
Fig. 9.5: Proposed model for collaboration of the integrated Skin-NTDs (CNLP2LUB) programme with other national control 
programmes in Cameroon. 
ii. Collaboration between CNLP2LUB and PNLSHI for detection of cases of skin-NTDs 
among school pupils during their activity of mass treatment of school age children 
against soil transmitted helminthiasis and schistosomiasis. 
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iii. Collaboration between CNLP2LUB and the Enlarged Programme on Immunization, 
to improve coverage of BCG vaccine through community sensitization, with the 
understanding that this may not only help EPI to meet up with the coverage target but 
will also boost the protection against leprosy and Buruli ulcer, thus reducing their 
incidences. 
iv. Collaboration between CNLP2LUB and the Roll Back Malaria Programme, to 
improve on the usage of insecticide treated mosquito bed nets. This will protect 
against mosquito bites and reduce malaria morbidity on the one hand but may also 
protect against transmission of Buruli ulcer in endemic areas on the other hand. 
 
9.8 What changes can we expect in skin-NTDs control in the near 
future in Cameroon 
 
With respect to the current state of disease burden, and surveillance, and research in 
diagnostics, therapies and vaccine development for leprosy, Buruli ulcer, yaws and other skin 
NTDs, the expectations of the National Control Programme are mixt.  
We do not expect to see any rapid increase in resource allocation for skin-NTDs control in 
the next five years from the government budget nor from donor partners. This implies that skin-
NTDs surveillance may not witness rapid improvement in terms of reinforcing the diagnostic, 
recording and reporting capacities of the primary level health care personnel and facilities. 
Secondly, case finding activities in communities and schools may not change much with the 
present dispensation. Consequently, disease transmission will continue and may even increase, 
leading the country into a situation of increased disease burden and reversal of gains made in the 
last three decades. Very recent studies in India and Brazil have shown an increase in new leprosy 
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case burden43, and an increase in leprosy transmission, with a prevalence 17 times higher than 
what is reported routinely44. However, if the integrated strategic plan 2018-2022 attracts some 
attention, and if an integrated skin-NTDs control strategy is implemented through the proposed 
intervention packages, the exploration of new communication technologies and most importantly 
collaboration with the other national control programmes, there could be some improvements in 
skin-NTDs surveillance, case detection and management and hopefully a reduction in the disease 
burden. 
As indicated earlier, one of the major challenges for skin-NTD control programmes is the 
lack of point-of-care (POC) diagnostic tests for most of the diseases. For yaws there exists the 
dual path platform syphilis screen and confirm rapid diagnostic test which is already in use by 
national programmes but needs to be rendered more accessible in terms of prize. Regarding 
leprosy, the phenolic glycolipid 1(PLG-1) based ELISA serology is the most promising POC test 
at the moment. However, it still has to undergo refinement to improve upon its sensitivity, and 
then made commercially available. There are hopes that this could happen within the next five 
years. For Buruli ulcer, the most advanced search for a POC diagnostic test is the mycolactone-
based fluorescent thin layer chromatography, which is already undergoing clinical testing, and 
could be available for used by national control programmes soon. However, the search for 
alternative biomarkers and the other mycolactone detection tests as candidates for Buruli ulcer 
POC test is continuing.  
In terms of treatment for the skin-NTDs, the expectation for the National Control Programme 
is to have shorter specific antibiotic treatment protocols for Buruli ulcer and leprosy. Some 
studies have suggested antibiotic courses of 14-27 days for Buruli ulcer, and a six-months 
uniform multidrug therapy regimen had been suggested for leprosy. We recommend that the 
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scientific community revisits these suggestions and proposes shorter and more efficacious 
treatment courses for the benefit of the patients. For yaws the single dose oral treatment with 
azithromycin is perfect, however it is threatened by the development of resistance. It is important 
that a second drug is sought for and added to azithromycin to constitute a combination therapy 
for yaws in order to limit the development of resistance. We cannot predict how long it will take 
to arrive at such a combination therapy for yaws. 
For the time being, the preventive strategy for the major skin-NTDs including leprosy, Buruli 
ulcer and yaws remains secondary prevention through early case detection and adequate 
treatment to avoid development of complications and limit transmission. Single dose rifampicin 
chemoprophylaxis of contacts of index leprosy cases has been suggested in a number of reports 
but is not yet recommended by the WHO. However, the WHO has published a position paper, 
recommending vaccination of new-borns with BCG for protection against leprosy and to an 
unknown extent against Buruli ulcer. The development of new generation vaccine against 
leprosy, Buruli ulcer and yaws is still farfetched and national control programmes should not 
expect such vaccines any time soon. 
With respect to the 2020 NTDs roadmap targets, Cameroon is very far behind the yaws target 
of eradication. The National Control Programme is still in the process of mapping yaws in the 
health districts and so far, only 27.5% of the health districts have been mapped. The Morges 
eradication strategy has not yet been piloted in the country. At this level, the country will 
certainly not be at the rendezvous in 2020. Regarding leprosy targeted for elimination, Cameroon 
achieved the target at the national level in 2000 and has consolidated the status to date. The 
objective for the National Control Programme shifted to elimination at the health district level. 
Considering the results from analysis of routine data, we can say the country is on target, 
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however, with the low-key status of leprosy surveillance and with currently 93(49%) of silent 
health districts, we are not quite sure what is the exact situation at the moment. The 2020 target 
for Buruli ulcer is control. Cameroon is certainly making efforts in this direction as 100% of 
clinically diagnosed Buruli ulcer cases are treated with specific antibiotics. The weakness 
however is with case finding and confirmation by PCR that has declined tremendously in recent 
years following reduced partner support.  
9.9 Conclusions 
Within the framework of this thesis project, we have evaluated the burden of two major 
skin-NTDs in Cameroon namely leprosy and Buruli ulcer and have confirmed the resurgence of 
yaws in the country. The basis of our evaluation were surveillance data from 2000 to 2014 for 
leprosy and Buruli ulcer available at the National Control Programme office, as well as 
community-based surveys and a literature review. From the evaluation, we have confirmed that 
Cameroon attained the threshold for elimination of leprosy as a public health problem in the year 
2000 and has consolidated the status to 2014 and beyond. We also showed that there was 
persistent but moderate transmission of leprosy, with an increasing trend from 2007on, and 
eighteen health districts remaining high leprosy-burdened at the end of 2014. The persistence of 
high leprosy-burdened districts and the increasing trend in leprosy transmission in Cameroon 
were attributed to community lack-of-knowledge and misconceptions about leprosy as well as 
reduction in key leprosy control activities including community sensitisation, awareness and case 
finding campaigns, surveillance, capacity building, and supportive supervision, secondary to 
waning of resource allocation by the government and support partners. For Buruli ulcer, we 
showed that a cumulative number of 3700, and an annual average of 264 cases were detected and 
treated in Cameroon between 2001 and 2014. Control activities started in two major endemic 
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foci of Ayos and Akonolinga along the Nyong basin in the centre region of the country and were 
later expanded to Ngoantet-Mbalmayo still in the centre region, Bankim in the Adamawa region 
and Mbonge in the southwest region following a national survey in 2004 that revealed new 
endemic foci in those areas. Analysis of case treatment data from Buruli ulcer diagnostic and 
treatment centres (BU-DTC) created at these foci, further revealed that 64 health districts mainly 
from around the southern part of the country were Buruli ulcer endemic. Trend analysis of Buruli 
ulcer case-detection first showed an increasing trendbetween 2001 and 2005, and then a 
progressive decline until 2014 and beyond, comparable to the worldwide trend. Analysis of key 
Buruli ulcer control indicators showed high proportions (83%) of ulcerative lesions, with 90% of 
lesions located on the limbs. Children below 15 years of age constituted 45% of cases. We 
noticed a degradation in BU care activities from 2010 to 2014 and beyond indicated by an 
increase in the proportion of category 3 lesions and a drop in the proportion of case-confirmation 
by PCR. In addition to evaluating the BU burden, we also highlighted the importance of 
differential diagnosis in a context of co-endemicity of mycobacterial diseases, through a case-
report of cutaneous tuberculosis misdiagnosed as Buruli ulcer. Over the period under evaluation, 
Buruli ulcer activities in Cameroon were supported mainly by two partners, who from 2010 
began to reduce their support. One of the partners completely pulled out in 2014 and the other 
one restricted its support to one endemic health district. Currently there is little funding from the 
government budget, which is insignificant compared to the needs. We also confirmed the 
resurgence of yaws in Cameroon through a survey among the pygmy population in the east 
region, where we registered a 20.3% clinical and 5% sero-prevalence of yaws. Building on this, 
follow-up activities consisted in advocacy to the national and international community as well as 
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surveying health districts to determine their yaws status. So far, 53 out of 189 health districts 
have been surveyed and 37 of them confirmed endemic for yaws. 
Research conducted within the framework of this thesis, has increased our understanding 
of skin-NTDs, the efforts made in their control, and the challenges faced by the control activities 
in Cameroon. We have also understood the common features of these skin-NTDs in terms of the 
common ground of their clinical manifestations, the common interventions and activities 
applicable to the control of each of the NTDs as well as the overlapping nature in the 
geographical distribution of these NTDs in the country. Based on these, we have suggested the 
recommendations for improvement of skin-NTDs control in the following section.   
9.10 Major recommendations for improvement of skin-NTDs 
control 
9.10.1 To the National Control Programme 
⎯ Map skin-NTDs in all health districts 
⎯ Integrate and reinforce surveillance of skin-NTDs 
⎯ Implement the integrated control strategy through the six intervention packages proposed 
and intensify operational research to support decision making for implementation. 
⎯ Create collaboration links with the other national control programmes using the model 
proposed 
⎯ Lobby for increase in government budgetary allocation to skin-NTD control 
⎯ Advocate for new support partners to skin-NTD control in Cameroon 
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9.10.2 To the scientific community 
⎯ Accelerate development of point of care diagnostic tests for leprosy and Buruli ulcer 
⎯ Search for alternative and shorter treatment regimens for leprosy and Buruli ulcer 
⎯ Search for an oral combination therapy for yaws to limit development of azithromycin 
resistance 
⎯ Continue development of vaccine candidates against leprosy, Buruli ulcer and yaws and 
proceed to clinical trials for identified potent candidates. 
 
9.10.3 To the World Health Organization 
⎯ Continue support to the National Control Programme in terms of provision of specific 
antibiotics, technical guidance and otherwise 
⎯ Support research and development of point-of-care diagnostic tests, alternative and 
shorter treatment regimens as well as vaccine development. 
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